
<html lang="en"     class="pb-page"  data-request-id="ba6eed70-8eb2-4d75-a4eb-1c4bb6734c83"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2013.56.issue-17;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm400926x;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats" /></meta><meta name="dc.Creator" content="J. Jean  Cui" /></meta><meta name="dc.Creator" content="Hong  Shen" /></meta><meta name="dc.Creator" content="Michelle  Tran-Dubé" /></meta><meta name="dc.Creator" content="Mitchell  Nambu" /></meta><meta name="dc.Creator" content="Michele  McTigue" /></meta><meta name="dc.Creator" content="Neil  Grodsky" /></meta><meta name="dc.Creator" content="Kevin  Ryan" /></meta><meta name="dc.Creator" content="Shinji  Yamazaki" /></meta><meta name="dc.Creator" content="Shirley  Aguirre" /></meta><meta name="dc.Creator" content="Max  Parker" /></meta><meta name="dc.Creator" content="Qiuhua  Li" /></meta><meta name="dc.Creator" content="Helen  Zou" /></meta><meta name="dc.Creator" content="James  Christensen" /></meta><meta name="dc.Description" content="The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An exclusively selective c-Met inhibitor (S..." /></meta><meta name="Description" content="The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An exclusively selective c-Met inhibitor (S..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 29, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400926x" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400926x" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400926x" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400926x" /></link>
        
    
    

<title>Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400926x" /></meta><meta property="og:title" content="Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0017.jpeg" /></meta><meta property="og:description" content="The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An exclusively selective c-Met inhibitor (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (8) was discovered from a highly selective high-throughput screening hit via structure-based drug design and medicinal chemistry lead optimization. Compound 8 had many attractive properties meriting preclinical evaluation. Broad off-target screens identified 8 as a pan-phosphodiesterase (PDE) family inhibitor, which was implicated in a sustained increase in heart rate, increased cardiac output, and decreased contractility indices, as well as myocardial degeneration in in vivo safety evaluations in rats. Compound 8 was terminated as a preclinical candidate because of a narrow therapeutic window in cardio-related safety. The learning from multiparameter lead optimization and strategies to avoid the toxicity attrition at the late stage of drug discovery are discussed." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400926x"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400926x">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400926x&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400926x&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400926x&amp;href=/doi/10.1021/jm400926x" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 6651-6665</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400294w" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm400947b" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Lessons from (<i>S</i>)-6-(1-(6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Jean++Cui">J. Jean Cui</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shen">Hong Shen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Tran-Dub%C3%A9">Michelle Tran-Dubé</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mitchell++Nambu">Mitchell Nambu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michele++McTigue">Michele McTigue</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neil++Grodsky">Neil Grodsky</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Ryan">Kevin Ryan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shinji++Yamazaki">Shinji Yamazaki</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shirley++Aguirre">Shirley Aguirre</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Max++Parker">Max Parker</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qiuhua++Li">Qiuhua Li</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helen++Zou">Helen Zou</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Christensen">James Christensen</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 858-638-6333. E-mail: <a href="/cdn-cgi/l/email-protection#99f3fcf8f7b7faecf0d9e9fff0e3fcebb7faf6f4"><span class="__cf_email__" data-cfemail="3c56595d52125f49557c4c5a5546594e125f5351">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400926x&amp;href=/doi/10.1021%2Fjm400926x" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 6651–6665</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 14, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 March 2013</li><li><span class="item_label"><b>Published</b> online</span>29 August 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 September 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400926x" title="DOI URL">https://doi.org/10.1021/jm400926x</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6651%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJ.%2BJean%2BCui%252C%2BHong%2BShen%252C%2BMichelle%2BTran-Dub%25C3%25A9%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D17%26contentID%3Djm400926x%26title%3DLessons%2Bfrom%2B%2528S%2529-6-%25281-%25286-%25281-Methyl-1H-pyrazol-4-yl%2529-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-b%255Dpyridazin-3-yl%2529ethyl%2529quinoline%2B%2528PF-04254644%2529%252C%2Ban%2BInhibitor%2Bof%2BReceptor%2BTyrosine%2BKinase%2Bc-Met%2Bwith%2BHigh%2BProtein%2BKinase%2BSelectivity%2Bbut%2BBroad%2BPhosphodiesterase%2BFamily%2BInhibition%2BLeading%2Bto%2BMyocardial%2BDegeneration%2Bin%2BRats%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6665%26publicationDate%3DSeptember%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400926x"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2648</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">21</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400926x" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Jean Cui&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Tran-Dubé&quot;},{&quot;first_name&quot;:&quot;Mitchell&quot;,&quot;last_name&quot;:&quot;Nambu&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;McTigue&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;Grodsky&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Ryan&quot;},{&quot;first_name&quot;:&quot;Shinji&quot;,&quot;last_name&quot;:&quot;Yamazaki&quot;},{&quot;first_name&quot;:&quot;Shirley&quot;,&quot;last_name&quot;:&quot;Aguirre&quot;},{&quot;first_name&quot;:&quot;Max&quot;,&quot;last_name&quot;:&quot;Parker&quot;},{&quot;first_name&quot;:&quot;Qiuhua&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Christensen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;6651-6665&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400926x&quot;},&quot;abstract&quot;:&quot;The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An exclusively selective c-Met inhibitor (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (8) was discovered from a highly selective high-throughput screening hit via structure-based drug design and medicinal chemistry lead optimization. Compound 8 had many attractive properties meriting preclinical evaluation. Broad off-target screens identified 8 as a pan-phosphodiesterase (PDE) family inhibitor, which was implicated in a sustained increase in heart rate, increased cardiac output, and decreased contractility indices, as well as myocardial degeneration in in vivo safety evaluations in rats. Compound 8 was terminated as a preclinical candidate because of a narrow therapeutic window in cardio-related safety. The learning from multiparameter lead optimization and strategies to avoid the toxicity attrition at the late &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400926x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400926x" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400926x&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400926x" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400926x&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400926x" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400926x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400926x&amp;href=/doi/10.1021/jm400926x" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400926x" /></input><a href="/doi/pdf/10.1021/jm400926x" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400926x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400926x%26sid%3Dliteratum%253Aachs%26pmid%3D23944843%26genre%3Darticle%26aulast%3DCui%26date%3D2013%26atitle%3DLessons%2Bfrom%2B%2528S%2529-6-%25281-%25286-%25281-Methyl-1H-pyrazol-4-yl%2529-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-b%255Dpyridazin-3-yl%2529ethyl%2529quinoline%2B%2528PF-04254644%2529%252C%2Ban%2BInhibitor%2Bof%2BReceptor%2BTyrosine%2BKinase%2Bc-Met%2Bwith%2BHigh%2BProtein%2BKinase%2BSelectivity%2Bbut%2BBroad%2BPhosphodiesterase%2BFamily%2BInhibition%2BLeading%2Bto%2BMyocardial%2BDegeneration%2Bin%2BRats%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D17%26spage%3D6651%26epage%3D6665%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jmcmar.2013.56.issue-17/production/jmcmar.2013.56.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The hepatocyte growth factor (HGF)/c-Met signaling axis is deregulated in many cancers and plays important roles in tumor invasive growth and metastasis. An exclusively selective c-Met inhibitor (<i>S</i>)-6-(1-(6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>8</b>) was discovered from a highly selective high-throughput screening hit via structure-based drug design and medicinal chemistry lead optimization. Compound <b>8</b> had many attractive properties meriting preclinical evaluation. Broad off-target screens identified <b>8</b> as a pan-phosphodiesterase (PDE) family inhibitor, which was implicated in a sustained increase in heart rate, increased cardiac output, and decreased contractility indices, as well as myocardial degeneration in <i>in vivo</i> safety evaluations in rats. Compound <b>8</b> was terminated as a preclinical candidate because of a narrow therapeutic window in cardio-related safety. The learning from multiparameter lead optimization and strategies to avoid the toxicity attrition at the late stage of drug discovery are discussed.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">c-Met, also called hepatocyte growth factor receptor (HGFR), belongs to a unique subfamily of receptor tyrosine kinases including macrophage stimulating 1 receptor RON. Hepatocyte growth factor (HGF), also known as scatter factor (SF), is the high-affinity natural ligand of c-Met. The HGF/c-Met signaling pathway plays important roles in invasive growth during embryo development and postnatal organ regeneration and is only fully active in adults for wound healing and tissue regeneration processes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> However, the HGF/c-Met axis is frequently hijacked by cancer cells for tumorigenesis, invasive growth, and metastasis.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> HGF and c-Met are expressed at abnormally high levels in a large variety of solid tumors including liver, breast, pancreas, lung, kidney, bladder, ovary, brain, prostate, gallbladder myeloma, and many others that are frequently associated with a metastatic phenotype and poor prognosis.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Various c-Met mutations have been identified in many tumors, including hereditary and sporadic human papillary renal carcinomas, ovarian cancer, childhood hepatocellular carcinomas, gastric cancer, and lung cancer.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The activation of HGF/c-Met signaling plays important roles in resistance to EGFR and BRAF kinase inhibitors. <i>MET</i> amplification has been detected in up to 20% of NSCLC patients with EGFR mutations who acquired resistance to gefitinib or erlotinib treatment.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Growth factor-driven resistance from the tumor microenvironment represents another potential mechanism to anticancer kinase inhibitors.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> HGF is present in melanoma patient’s stromal cells and correlates with a poor response to the BRAF inhibitor vemurafenib.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The upregulation of stromal HGF confers resistance to vemurafenib in BRAF mutant melanoma cells.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Because of the role of aberrant HGF/c-Met signaling in human oncogenesis, invasion and metastasis, and resistance, the inhibition of this pathway has great potential in cancer therapy.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> There are three approaches in modulating HGF/c-Met signaling currently in human clinical studies for oncology applications including the anti-HGF antibody (e.g., AMG 102, rilotumumab<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a>), c-Met monoclonal antibody (e.g., MetMab<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>), and small molecule c-Met inhibitors (e.g., crizotinib,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> cabozantinib,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and tivantinib<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a>). Preliminary clinical benefits from the inhibition of HGF/c-Met signaling have been reported.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The c-Met monoclonal antibody MetMab in combination with erlotinib for non-small-cell lung cancer significantly improved progression-free survival and overall survival, resulting in a near 3-fold reduction in the risk of death.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> One patient with a <i>de novo</i> highly <i>MET</i>-amplified NSCLC achieved confirmed partial response with crizotinib.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> While existing data have shown the potential of inhibiting the HGF/c-Met pathway, challenges remain in identifying specific patient populations as well as developing the right combination strategies (targeted agents, classic chemotherapy, or radiotherapy).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Potent and specific kinase inhibitors are highly desired to validate the pharmacology of the proposed target and allow for effective combination with other agents for the maximum efficacy of cancer treatment. A highly specific c-Met HTS hit <b>1</b> (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) was discovered at legacy SUGEN/Pharmacia.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Compound <b>1</b> was a highly selective and ATP competitive c-Met inhibitor with high biochemical ligand efficiency (LE = (−<i>RT</i> log <i>K</i><sub>i</sub>)/(the number of heavy atoms) = 0.42) and lipophilic efficiency (lipE = −log <i>K</i><sub>i</sub> – cLogD = 4.80). Optimization of <b>1</b> by Koenig et al. afforded analogs with improved enzymatic and cellular potencies, as illustrated with compound <b>2</b>, which has an enzymatic <i>K</i><sub>i</sub> of 1.3 nM and an IC<sub>50</sub> of 7 nM for the inhibition of c-Met autophosphorylation in the A549 cell line.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The cocrystal structure of <b>2</b> with unphosphorylated c-Met kinase domain (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zze">3zze</a>) revealed an unexpected binding mode, having the phenol residue as a hinge binder and oxindole hydrazide interacting with the A-loop to stabilize the c-Met protein in an autoinhibitory inactive conformation.<a onclick="showRef(event, 'ref16 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref18">(16, 18)</a> Vojkovsky et al. designed the tetracyclic aromatic scaffold, exemplified by <b>3</b>, which proved to be an effective mimic of the original oxindole hydrazide series.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The electron-deficient tetracyclic ring retained the strong π–π stacking interaction with electron-rich Tyr-1230 and could form hydrogen bonds with the N–H of Asp-1226 and the C═O of Arg-1208. Zhang et al. further chopped the nondruggable tetracyclic scaffold to the bicyclic triazolotriazine scaffold, exemplified by <b>4</b>, which revealed an even better ligand efficiency against c-Met than the tetracyclic scaffold despite the loss of the hydrogen bond with the carbonyl group of Arg-1208.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The electron deficiency of the bicyclic aromatic ring governs the strength of the interaction with Tyr-1230 at the A-loop and is a determining factor for the potency and selectivity. Therefore, the triazolopyrazine scaffold, exemplified by <b>5</b>,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and the triazolopyridazine scaffold, exemplified by <b>6</b>, are less potent in general.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. The Discovery of Highly Selective c-Met Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The initial chemistry efforts on discovering the unique c-Met binding mode and the critical chemical scaffolds for exclusively selective and highly potent c-Met inhibitors (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>) play an important role for the discovery and development of a class of exquisitely selective c-Met inhibitors into human clinical trials. The phenol hinge binder in the original chemistry series was successfully replaced with the conventional kinase hinge binder quinoline leading to <b>7</b> (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> However, the triazolotriazine scaffold suffered with high non-P450 hepatocyte clearance.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Optimization of the less potent triazolopyrazine series produced the clinical compound <b>9</b> (PF-04217903).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The cocrystal structure of <b>9</b> with unphosphorylated c-Met kinase domain revealed a similar binding environment as <b>2</b>, and <b>9</b> was exquisitely selective over 208 kinases.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In addition, the highly potent and selective c-Met inhibitors <b>10</b> (SGX-523),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a><b>11</b> (JNJ-38877605),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>12</b> (INCB-28060),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and <b>13</b> (AMG-208)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> were reported and have entered human clinical trials for potential oncology indications (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>).</div><figure id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Exquisitely Selective c-Met Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Herein, we report the medicinal chemistry lead optimization of the less potent triazolopyridazine series leading to the discovery of (<i>S</i>)-6-(1-(6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>8</b>). The effort was conducted in parallel with the optimization of the triazolopyrazine series leading to the discovery of the clinical candidate <b>9</b>.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Compounds <b>8</b> and <b>9</b> were potent and exquisitely selective ATP competitive c-Met inhibitors and demonstrated low nanomolar potency against c-Met in both <i>in vitro</i> cell assays and <i>in vivo</i> target modulation studies. Both compounds showed effective tumor growth inhibition with good oral PK properties. However, <b>8</b> was also a potent phosphodiesterase family inhibitor, which proved to be responsible for a sustained increase in heart rate, increased cardiac output, and decreased contractility indices, as well as myocardial degeneration in rats. Compound <b>8</b> was terminated as a preclinical candidate because of a narrow therapeutic window in cardio-related safety. Compound <b>9</b>, which has a higher LipE value for c-Met than <b>8</b>, has a clean kinase selectivity profile and also has a cleaner profile in a broad off-target screen. This favorable profile supported a large therapeutic window in <i>in vivo</i> animal tolerance studies. Compound <b>9</b> was selected as a preclinical candidate and entered human clinical evaluations for cancer treatment.</div><div class="NLM_p last">Toxicity and serious adverse events in late stage drug development are the major causes of drug failure. The adverse toxicologic effects are further classified as on-target, and off-target effects. The on-target toxicity reflects the exaggerated and adverse pharmacologic effects of the interested target, which may lead to the termination of a drug development based on the target. The off-target adverse effects are a result of modulation of biologically unrelated targets, which should be avoided at the early drug discovery stage. Although kinase selectivity has been a major challenge in kinase drug development because of the conservation of the ATP binding pocket among kinases, the off-targets outside the protein kinase family deserve equal attention at the early drug discovery stage. Both <b>8</b> and <b>9</b> are highly selective c-Met RTK inhibitors. However, the off-target effects from the inhibition of PDE family leading to a narrow therapeutic window in cardio-related safety resulted in the termination of <b>8</b> as a preclinical candidate. The learning from multiparameter lead optimization and strategies to avoid the late stage toxicity attrition will be discussed here.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The triazolotriazine chemical series, represented with <b>7</b> (Chart <a class="ref internalNav" href="#cht2" aria-label="2">2</a>), was successfully designed as a class of potent and kinase-selective c-Met inhibitors evolving from the HTS hit <b>1</b>.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The quinoline group functions as a hinge binder and the triazolotriazine group plays an important role in both c-Met cellular potency and kinase selectivity via the unique interaction with the A-loop residue Tyr-1230 (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The unique autoinhibitory position of the A-loop in unphosphorylated c-Met has been documented in c-Met crystal structures, including apo-c-Met.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In particular, many c-Met inhibitors form interactions with Tyr-1230, and the interactions vary in strength and contribute to different affinities and selectivity.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Although it had an attractive potency and selectivity profile, the triazolotriazine series suffered high clearance in human hepatocyte, and was deprioritized.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Alternatively, the less potent triazolopyrazine (represented with <b>5</b>) and triazolopyridazine (represented with <b>6</b>) series were explored. The detailed medicinal chemistry lead optimization of the triazolopyrazine series leading to the clinic candidate <b>9</b> was reported previously,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and some of the data are cited here as direct comparisons with the triazolopyridazine series for illustration of the learning. We previously reported the selection of quinoline as a suitable hinge binder with good potency and metabolic stability in the triazolopyrazine series in the replacement of phenol hinge binder in <b>1</b>.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Here, the quinoline group was directly used as the desired hinge binder in the triazolopyridazine series for the further lead optimization at the 6-position. With the replacement of N-7 in the triazolotriazine core with a carbon atom, the triazolopyridazine bicyclic aromatic ring is more electron rich, resulting in a less effective interaction with Tyr-1230. As a result, weaker potencies were generally observed in the triazolopyridazine series (A-series) as demonstrated with <b>14A</b>. <b>14A</b> was about 10-fold less potent in both enzymatic and cellular assays than <b>7</b>. The structure–activity relationship at the 6-position of the [1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-ylmethyl-quinoline series was investigated (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) for the potential improvement of potency and ADME properties. Overall, 6-substituted [1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-ylmethyl-quinolines were metabolically stable and had good permeability. However, a flat SAR in potency was observed for 6-aryl compounds <b>14A</b>–<b>16A</b> and <b>8A</b>. In general, the A-series was about 10-fold less potent than the B-series (the B-series was reported previously<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and cited here for the comparison), as demonstrated with <b>8A</b> and <b>8B</b>. The electron-donating amino and dimethylamino groups in <b>17A</b> and <b>18A</b> provided even weaker potencies. Consistently, <b>17A</b> was much less potent than the triazolopyrazine analogue <b>17B</b>.</div><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cocrystal structure of <b>7</b> with the unphosphorylated c-Met kinase domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zbx">3zbx</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure Activity Relationship of 6-Substituted [1,2,4]Triazolo[4,3-<i>b</i>]pyridazin-3-ylmethyl-quinolines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat version 9.3.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>) and cell IC<sub>50</sub> were determined as described under <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-Met.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">LipE (IC<sub>50</sub>) = pIC<sub>50</sub> – cLogD.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Human liver microsomal intrinsic clearance (μL/(min·mg)).</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Kinetic solubility at pH 6.5. ND, not determined.</p></div></div><div></div></div><div class="NLM_p">The triazolopyridazine series has a cLogD value more than one log unit higher than the triazolopyrazine series, and coupled with the weaker inhibition, this leads to lipE values more than three log units lower than the triazolopyrazine series. Considering LipE, there is little advantage to continue working on the triazolopyridazine series. However, comprehensive analyses of the ADME properties of both series indicated that the triazolopyridazine series has much higher intrinsic human liver microsome metabolic stability relative to the triazolopyrazine series (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>, log scale of human liver microsomal intrinsic clearance HLM CL<sub>int.,app</sub> vs cLogD). Overall, triazolopyridazines (blue square) were more metabolically stable than triazolopyrazines (red square) at higher cLogD value. Therefore, the triazolopyridazines could potentially provide a better chemistry space for multiparameter optimizations on metabolic stability, permeability, and potency.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Metabolic clearance in human liver microsomes vs cLogD (red color for the triazolopyrazine series, and blue color for the triazolopyridazine series).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because of the attractive ADME properties, the triazolopyridazine series was explored further to improve the c-Met potency. The cocrystal structure of <b>7</b> with the unphosphorylated c-Met kinase domain revealed a small hydrophobic pocket for the potential improvement of the c-Met potency (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The hinge binding quinoline substituent was linked with the triazolotriazine group via a methylene linker. The methylene group was adjacent to a hydrophobic pocket surrounded with the side hydrophobic chains of Lys-1110, Val-1092, Leu-1157 and Ala-1226. The modeling indicated that an (<i>S</i>)-methyl group could fit into the pocket well and potentially boost the potency. A series of compounds with an α-methyl group having the <i>S</i>-configuration were synthesized and screened for the potency against c-Met (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_p">Indeed, the (<i>S</i>)-methyl group improved potency significantly as demonstrated with <b>14A</b> and <b>14C</b> (10-fold improvement for the enzymatic activity and 4-fold for the cellular potency). Although the introduction of a methyl group increased the lipophilicity (cLogD) by 0.35 unit, the dramatic improvement on potency caused the cell LipE of <b>14C</b> to increase by 1.25 unit relative to <b>14A</b>, which justified the introduction of a hydrophobic group and also implied that the methyl group had a strong van der Waals interaction with the protein as originally designed. A broad set of R groups were investigated at the 6-position in C-series and D-series (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) in order to identify the potential candidates with comprehensively acceptable properties. Overall, 6-aryl substituents provided good potency against c-Met. The substituents at <i>ortho</i>, <i>meta</i>, and <i>para</i>-positions of the 6-phenyl group were well tolerated as demonstrated with compounds <b>14C</b>–<b>26C</b>. The R group in both the C- and D<b>-</b>series extended into the solvent-exposed area, and as expected, the substituents of both polar and hydrophobic groups did not change the potency significantly; however, the LipE and metabolic stability varied significantly according to the nature of the R groups. The <i>N</i>- or <i>O</i>-alkyl substituents on the 6-aryl group are highly cleared in human liver microsomes as demonstrated with compounds <b>19C</b>, <b>20C</b>, <b>23C</b>, and <b>27C</b>. Compound <b>21C</b> with a methyl group also showed a high metabolic clearance. The polar substituents including cyano group in <b>15C</b>, <b>16C</b>, and <b>22C</b>, amide group in <b>24C</b>, and sulfonyl group in <b>25C</b> and <b>26C</b> made the compounds potent and metabolically stable. In general, the 6-phenyl compounds in the C-series had low solubility. Compound <b>8</b> with the <i>N</i>-methyl pyrazol-4-yl group had a lower cLogD of 2.07 and comparable potency in comparison with 6-phenyl compounds, which led to a much improved LipE (6.15), good metabolic stability, and solubility. Consistently, the D-series was about 10-fold more potent than the C-series as shown with <b>8</b> and <b>8D</b>. Again, the (<i>S</i>)-methyl group improved the potency of 6-<i>N</i>-substituted compounds as exemplified by <b>28C</b>, which demonstrated an overall good profile, especially in solubility (433 μM). The contribution of the magic (<i>S</i>)-methyl group to the potency was further observed with the direct comparison of <b>9</b> and <b>9D</b>. Although the D-series was much more potent, the C-series had better solubility as illustrated with <b>8</b> (60.4 μM) and <b>8D</b> (16.3 μM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationship of 6-Substituted (<i>S</i>)-6-(1-[1,2,4]Triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinolines and (<i>S</i>)-6-(1-1<i>H</i>-[1,2,3]Triazolo[4,5-<i>b</i>]pyrazin-1-yl)ethyl)quinolines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0014.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat version 9.3.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>) and cell IC<sub>50</sub> were determined as described under <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-Met.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">LipE (IC<sub>50</sub>) = pIC<sub>50</sub> – cLogD.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Human liver microsomal intrinsic clearance (μL/(min·mg)).</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Kinetic solubility at pH 6.5.</p></div></div><div></div></div><div class="NLM_p">To test whether the effect of the α-methyl group is universal for the different hinge binders, a subseries with azaindole hinge binder was investigated (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). As a direct comparison, <b>8F</b> with (<i>S</i>)-methyl group was 10-fold more potent than <b>8E</b>. Compounds <b>8F</b>–<b>29F</b> with the azaindole hinge binder had a similar potency as the analogues in the C-series having the quinoline hinge binder; however, <b>8F</b>–<b>29F</b> provided better solubility profiles. The metabolite identification study of <b>8F</b> indicated the presence of the GSH-adducts at azaindole and methylene positions (Figure S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), and the F-series was deprioritized.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure–Activity Relationship of 6-Substituted 3-(1-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)ethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0015.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0016.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat version 9.3.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Inhibition constants (<i>K</i><sub>i</sub>) and cell IC<sub>50</sub> were determined as described under <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. The coefficients of variance were typically less than 20% (<i>n</i> = 2). A549 human lung carcinoma cell line was used for the evaluation of the inhibition of autophosphorylation of c-Met.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">LipE (IC<sub>50</sub>) = pIC<sub>50</sub> – cLogD.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Human liver microsomal intrinsic clearance (μL/(min·mg)).</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">Kinetic solubility at pH 6.5. ND, not determined.</p></div></div><div></div></div><div class="NLM_p">Collectively, a number of compounds achieved good potency and <i>in vitro</i> ADME profiles and were selected for <i>in vivo</i> rat PK studies (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>) and <i>in vitro</i> toxicity evaluations. The rat <i>in vivo</i> PK data of <b>9</b> was cited as a reference for the comparison.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Compounds <b>8</b>, <b>14C</b>, and <b>15C</b> demonstrated moderate plasma clearance and volume distribution. Compounds <b>8</b> and <b>14C</b> showed good oral bioavailability, and <b>14C</b> and <b>15C</b> have good half-life.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vivo</i> Rat Pharmacokinetic Properties</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">MW</th><th class="colsep0 rowsep0" align="center" char=".">p<i>K</i><sub>a</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">cLogD<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">eLogD<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>plasma</sub> (mL/(min·kg))</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><sub>oral</sub> (%)</th><th class="colsep0 rowsep0" align="center" char=".">c-Met cell eLipE<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">372</td><td class="colsep0 rowsep0" align="char" char=".">4.66</td><td class="colsep0 rowsep0" align="char" char=".">1.68</td><td class="colsep0 rowsep0" align="char" char=".">1.38</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">7.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">355</td><td class="colsep0 rowsep0" align="char" char=".">4.79</td><td class="colsep0 rowsep0" align="char" char=".">2.07</td><td class="colsep0 rowsep0" align="char" char=".">2.05</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">6.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14C</b></td><td class="colsep0 rowsep0" align="char" char=".">387</td><td class="colsep0 rowsep0" align="char" char=".">4.79</td><td class="colsep0 rowsep0" align="char" char=".">3.79</td><td class="colsep0 rowsep0" align="char" char=".">3.07</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">4.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15C</b></td><td class="colsep0 rowsep0" align="char" char=".">376</td><td class="colsep0 rowsep0" align="char" char=".">4.79</td><td class="colsep0 rowsep0" align="char" char=".">4.00</td><td class="colsep0 rowsep0" align="char" char=".">2.80</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">5.60</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Calculated ionization constant of a molecule using ACD pchbat version 9.3.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Calculated logarithm of the octanol/water distribution coefficient at pH 7.4 using ACD pchbat version 9.3.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Experimentally measured bilayer participating coefficient at pH 7.4.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">eLipE = −pIC<sub>50</sub>(cell)– eLogD.</p></div></div></div><div class="NLM_p">Tumor growth inhibition (TGI) and the relationship to inhibition of c-Met autophosphorylation <i>in vivo</i> were evaluated in parallel for <b>8</b> and <b>9</b> in the c-Met amplified GTL-16 xenograft tumor model. No weight loss was observed at all dose levels in the efficacy studies for both <b>8</b> and <b>9</b>. The marked efficacy results and the potential mechanisms for the tumor growth inhibition of <b>9</b> were reported previously.<a onclick="showRef(event, 'ref16 ref27'); return false;" href="javascript:void(0);" class="ref ref16 ref27">(16, 27)</a> Similar to <b>9</b>, <b>8</b> demonstrated dose-dependent inhibition of c-Met phosphorylation and tumor growth in the c-Met amplified GTL-16 xenograft tumor model in mice (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Tumor regression (−34% TGI) was observed in the 100 mg/kg QD group, and tumor stasis (100% TGI) was achieved in the 30 mg/kg QD group. Near complete inhibition of c-Met activity for 24 h is consistent with tumor regression and tumor stasis. The potent inhibition of c-Met activity for only a portion of the dosing schedule is consistent with the observed significant but submaximal antitumor efficacy at lower doses (10 and 3 mg/kg QD, 84% to 75% TGI). These results suggest that near-complete inhibition of c-Met autophosphorylation (>90% inhibition) for the duration of the administration schedule is necessary for maximal efficacy. The total c-Met level was not changed in the study as reported previously in the same studies of <b>9</b>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of c-Met phosphorylation and tumor growth by <b>8</b> in the GTL-16 xenograft tumor model in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on the encouraging anti-c-Met and antitumor activities <i>in vitro</i> and <i>in vivo</i>, and the desired predicted human PK properties, <b>8</b> and <b>9</b>, representing two different series were chosen for kinase selectivity and preclinical <i>in vitro</i> and <i>in vivo</i> toxicity studies. Similar to <b>9</b> which demonstrated an exquisite c-Met kinase selectivity,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a><b>8</b> is a highly kinase-selective c-Met inhibitor (>1000 selectivity to 208 protein kinases). The cocrystal structure of <b>8</b> with the unphosphorylated c-Met kinase domain (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) resembles the original cocrystal structure of <b>7</b> with c-Met. As expected, the quinoline functions as a hinge binder hydrogen bound with the N–H of Met-1160. N-2 in [1,2,4]triazolo[4,3-<i>b</i>]pyridazine forms a strong hydrogen bond with N–H of Asp-1222. [1,2,4]Triazolo[4,3-<i>b</i>]pyridazine has the c-Met characteristic π–π stacking interaction with Tyr-1230, and the 6-pyrazol-4-yl group is coplanar with the [1,2,4]triazolo[4,3-<i>b</i>]pyridazine ring to strengthen the π–π stacking interaction. C–H at C-5 position of 6-pyrazol-4yl group has a close interaction with the conserved C═O of Arg-1208, and N-2 interacts with a water molecule. As originally designed, the (<i>S</i>)-methyl group on the methylene bridge is surrounded by a group of hydrophobic residues. Compounds <b>8</b> and <b>9</b> have near-complete overlay of cocrystal structures with c-Met in both ligands and proteins (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), which supports the exclusive kinase selectivity for both <b>8</b> and <b>9</b>.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of <b>8</b> with c-Met unphosphorylated kinase domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5">3zc5</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of cocrystal structures of <b>8</b> (green color) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5">3zc5</a>) and <b>9</b> (pink color) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz">3zxz</a>) with c-Met unphosphorylated kinase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The interaction of the [1,2,4]triazolo[4,3-<i>b</i>]pyridazine core with the A-loop anchors the whole molecule at the ATP binding site of c-Met, which tolerates different hinge binders and substituents at 6-position. The cocrystal structure of <b>28F</b> superimposes well with <b>8</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) at the [1,2,4]triazolo[4,3-<i>b</i>]pyridazine position even though <b>28F</b> has an azaindole hinge binder and an isopropylamino group at 6-position. As expected, the azaindole forms hydrogen bonds with the C═O of Pro-1158 and the N–H of Met-1160 at the hinge. The α-methyl groups from <b>28F</b> and <b>8</b> are positioned closely in the small hydrophobic pocket. The isopropyl group in <b>28F</b> is closer to the glycine rich loop, and the N–H from the 6-isopropylamino function forms a water bridged hydrogen bond with the C═O of Arg-1208. Taken together, the cocrystal structures of c-Met reveal the specific binding characteristics of unphosphorylated c-Met protein, which allows for the design of highly selective and druggable c-Met inhibitors.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Superimposition of <b>28F</b> (golden color) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zcl">3zcl</a>) with <b>8</b> (green color) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5">3zc5</a>) in c-Met cocrystal structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Notwithstanding the excellent selectivity to protein kinases, <b>8</b> and <b>9</b> were submitted to CEREP BioPrint (Poitiers, France) for enzymatic binding assays (68 targets) to assess the potential off-target pharmacology from inhibition of other enzyme classes (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> for targets with >50% inhibition at 10 μM). Out of 68 targets, <b>8</b> had four hits with >50% inhibition at 10 μM, and the IC<sub>50</sub>’s were obtained for these targets. Compound <b>8</b> potently inhibited GABA A BZD (IC<sub>50</sub> = 0.180 μM), and PDE3 (IC<sub>50</sub> = 0.170 μM). Compound <b>9</b> was a cleaner compound with only moderate inhibition against PDE3 (IC<sub>50</sub> = 1.30 μM).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Off-Target Hits of <b>8</b> and <b>9</b> in CEREP BioPrint Screen</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">% inhibition at 10 μM</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center" char=".">compd <b>8</b></th><th class="colsep0 rowsep0" align="center" char=".">compd <b>9</b></th><th class="colsep0 rowsep0" align="center" char=".">compd <b>8</b></th><th class="colsep0 rowsep0" align="center" char=".">compd <b>9</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GABA A BZD</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">0.180</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">muscarinic 2</td><td class="colsep0 rowsep0" align="char" char=".">59</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">7.00</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE3 (h)</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">71</td><td class="colsep0 rowsep0" align="char" char=".">0.170</td><td class="colsep0 rowsep0" align="char" char=".">1.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE4 (h)</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">44</td><td class="colsep0 rowsep0" align="char" char=".">3.70</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div><div class="NLM_p">Due to the off-target activity identified in CEREP BioPrint, <b>8</b> and <b>9</b> were further evaluated in an internal Pfizer PDE assay panel including PDE1A, PDE1B, PDE1C, PDE2, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5, PDE6, PDE7A, PDE7B, PDE8A, PDE8B, PDE9, PDE10, and PDE11 (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> for PDEs hits having IC<sub>50</sub> < 10 μM). Compound <b>9</b> had weak enzymatic activities against PDE3B (5.36 μM), PDE5 (8.06 μM), and PDE10 (2.7 μM). However, <b>8</b> was unexpectedly a pan-PDE inhibitor with more potent inhibition against PDE3B (0.15 μM) and PDE10 (0.085 μM). Compounds <b>14C</b> and <b>15C</b> from the same chemistry scaffold as <b>8</b> demonstrated a similar pan-PDE inhibition profile. The introduction of the α-methyl group into the [1,2,3]triazolo[4,5-<i>b</i>]pyrazine scaffold (D-series) increased the potency against c-Met and also the interactions with PDEs, as demonstrated with <b>8D</b> and <b>9D</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>) in comparison with <b>9</b>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. PDE Family Inhibition</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="10" align="center" char=".">PDE, IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">1A</th><th class="colsep0 rowsep0" align="center" char=".">1C</th><th class="colsep0 rowsep0" align="center" char=".">2</th><th class="colsep0 rowsep0" align="center" char=".">3A</th><th class="colsep0 rowsep0" align="center" char=".">3B</th><th class="colsep0 rowsep0" align="center" char=".">4C</th><th class="colsep0 rowsep0" align="center" char=".">4D</th><th class="colsep0 rowsep0" align="center" char=".">5</th><th class="colsep0 rowsep0" align="center" char=".">10</th><th class="colsep0 rowsep0" align="center" char=".">11</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">5.36</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">8.06</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">4.56</td><td class="colsep0 rowsep0" align="char" char=".">3.53</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char=".">9.61</td><td class="colsep0 rowsep0" align="char" char=".">4.89</td><td class="colsep0 rowsep0" align="char" char=".">0.085</td><td class="colsep0 rowsep0" align="char" char=".">3.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14C</b></td><td class="colsep0 rowsep0" align="char" char=".">0.452</td><td class="colsep0 rowsep0" align="char" char=".">0.963</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">2.87</td><td class="colsep0 rowsep0" align="char" char=".">0.107</td><td class="colsep0 rowsep0" align="char" char=".">2.91</td><td class="colsep0 rowsep0" align="char" char=".">2.23</td><td class="colsep0 rowsep0" align="char" char=".">1.75</td><td class="colsep0 rowsep0" align="char" char=".">0.403</td><td class="colsep0 rowsep0" align="char" char=".">2.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15C</b></td><td class="colsep0 rowsep0" align="char" char=".">0.462</td><td class="colsep0 rowsep0" align="char" char=".">1.48</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">0.088</td><td class="colsep0 rowsep0" align="char" char=".">1.97</td><td class="colsep0 rowsep0" align="char" char=".">2.06</td><td class="colsep0 rowsep0" align="char" char=".">0.287</td><td class="colsep0 rowsep0" align="char" char=".">0.432</td><td class="colsep0 rowsep0" align="char" char=".">0.963</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8D</b></td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">1.25</td><td class="colsep0 rowsep0" align="char" char=".">0.699</td><td class="colsep0 rowsep0" align="char" char=".">2.08</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9D</b></td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.589</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">3.26</td><td class="colsep0 rowsep0" align="char" char=".">2.12</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr></tbody></table></div></div><div class="NLM_p">The cardiovascular system controls blood pressure and beating of cardiac myocytes to accurately pump blood out of the heart to other parts of the body. These key physiological events are produced by contraction and relaxation of vascular smooth muscle and cardiac myocytes, which are regulated by intracellular cyclic nucleotide concentrations of second messengers, c-AMP and c-GMP.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The degradation of cyclic nucleotides is catalyzed by 3,5-cyclic nucleotide phosphodiesterases (PDEs).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Multiple PDEs function as a particular modulator of each cardiovascular function and regulate physiological homeostasis.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Therefore, inhibition of PDEs may imply a severe liability in cardiovascular safety. To further evaluate the potential cardio-toxicity and other liabilities, <b>8</b> and <b>9</b> were studied in rats for finding the maximum tolerance levels. Compound <b>8</b> in 2-, 6-, or 7-day single and repeat dose rat studies resulted in a sustained increase in heart rate (HR), increased cardiac output (CO), and decreased contractility indices, as well as myocardial degeneration at dose levels ≥40 mg/kg, which was equivalent to or below the predicted efficacious dose in human.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> Further mechanism investigation revealed that the broad inhibition of PDE family members especially PDE3B and the activation of c-AMP may contribute to the observed cardio-toxicity with <b>8</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Consistently, the intracellular calcium and oxidative stress signaling pathways were perturbed with a dose-dependent increase in intracellular calcium following the activation of c-AMP by the treatment with <b>8</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Compound <b>8</b>, a pan-PDE inhibitor that was proven <i>in vivo</i> to have cardio-toxicity was terminated as a preclinical candidate. As expected, the cardio-toxicity was not observed for <b>9</b> at 42–150-fold over the predicted free human <i>C</i><sub>eff</sub> of 36 nM because of a much cleaner off-target profile of <b>9</b> with only a weak inhibition against PDE3B (IC<sub>50</sub> 5.36 μM).</div><div class="NLM_p last">Compounds <b>8</b> and <b>9</b> from two different chemistry series having the same binding mode with c-Met, were evaluated in parallel for the selection of a potential preclinical candidate. The ovrall profiles of <b>8</b> and <b>9</b> were summarized in Table S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. Both compounds demonstrated attractive potency <i>in vitro</i> and <i>in vivo</i>, exclusive kinase selectivity, good <i>in vitro</i> human ADME properties, and <i>in vivo</i> rodent and dog pharmacokinetic profiles. Unexpectedly, <b>8</b> was shown to be a pan-PDE inhibitor, which might be linked with the observed <i>in vivo</i> cardio-toxicity of <b>8</b> in rat. Although the protein expression levels of PDEs in <i>in vivo</i> GTL-16 tumor model were not available, a similar PK/PD relationship of <b>8</b> and <b>9</b> implied that the inhibition of PDEs by <b>8</b> may not contribute significantly to the antitumor efficacy in GTL-16 c-Met-driven tumor model. Based on the overall profile, <b>9</b> was selected as a preclinical candidate for an early development evaluation and eventually went into human phase I clinical study.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47004" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47004" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The syntheses of [1,2,4]triazolo[4,3-<i>b</i>]pyridazine compounds are summarized in Scheme <a class="ref internalNav" href="#schI" aria-label="1">1</a>. 2-(Quinolin-6-yl)acetic acid (<b>31</b>) was synthesized from 2-(4-aminophenyl)acetic acid (<b>30</b>) using the Skraup quinoline synthesis conditions with a yield of 17.8%. After esterification, alkylation with methyl iodide in the presence of the base LDA, and hydrolysis, <b>32</b> was obtained in a combined yield of 65%. Compound <b>34</b> was obtained in 97% yield after Boc-protection was introduced on <b>33</b>. Following methylation, removal of the Boc-group, and hydrolysis, <b>35</b> was obtained in a combined yield of 88%. The [1,2,4]triazolo[4,3-<i>b</i>]pyridazine ring was built up via the coupling reaction of <b>36</b> with the activated carboxylic acid, and followed by heating under an acidic condition to afford <b>38</b>. A variety of substituents were introduced at 6-position of <b>38</b> via the conventional Suzuki coupling reaction or replacement of chloride with amino groups.</div><figure id="schI" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of [1,2,4]Triazolo[4,3-<i>b</i>]pyridazine Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=schI"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glycerol/FeSO<sub>4</sub>/conc. H<sub>2</sub>SO<sub>4</sub>, nitrobenzene, reflux, 5 h. (b) SOCl<sub>2</sub>, methanol, reflux. (c) LDA/MeI, anhydrous THF, −78 °C to ambient temperature, overnight. (d) LiOH, MeOH/H<sub>2</sub>O, 65 °C, 4 h. (e) (Boc)<sub>2</sub>O/DMAP, THF, overnight. (f) HCl/dioxane (4 N), CH<sub>2</sub>Cl<sub>2</sub>. (g) EDC or HATU, DMF, overnight. (h) SOCl<sub>2</sub>, DMF, 100 °C, 30 min. (i) Acetic acid, reflux, 2 h. (j) Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, overnight. (k) Amine, <i>n</i>-butanol, microwave at 125 °C, ∼1 h.</p></p></figure><div class="NLM_p">The syntheses of (<i>S</i>)-6-(1-(1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)ethyl)quinoline compounds are summarized in Scheme <a class="ref internalNav" href="#schII" aria-label="2">2</a>. Compound <b>47</b> was prepared with a four-step procedure. Quinoline-6-carboxylic acid <b>41</b> reacted with <i>N</i>,<i>O</i>-dimethyl hydroxylamine in the presence of the activation reagent CDI in DMF to afford <b>42</b> in 97% yield, which reacted with MeMgCl to provide the ketone <b>43</b> in 97% yield, followed by amination and hydrogenation to provide <b>45</b> in 97% yield. The thermal replacement of 2-bromo in <b>46</b> with <b>45</b> was accomplished in <i>n</i>-butanol in the presence of DIPEA after microwaving at 225 °C for 1 h to afford <b>47</b> in 66% yield. The [1,2,3]triazolo[4,5-<i>b</i>]pyrazine ring was constructed with isoamyl nitrile in DMF at 0 °C and then at 70 °C for 1 h to afford <b>48</b> in 72% yield. The racemic <b>48</b> was purified on a chiral SFC column using MeOH and liquid CO<sub>2</sub> as elution system to provide <b>49</b> and <b>50</b>. The absolute configuration of <b>49</b> was determined by the X-ray cocrystal structure with c-Met. A variety of compounds were made using the chiral intermediate <b>49</b> via the conventional Suzuki coupling reaction.</div><figure id="schII" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of (<i>S</i>)-6-(1-(1<i>H</i>-[1,2,3]Triazolo[4,5-<i>b</i>]pyrazin-1-yl)ethyl)quinoline Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=schII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeNHOMe/CDI, DMF, ambient temperature, overnight. (b) MeMgBr, anhydrous THF, 0 °C to ambient temperature, 16 h. (c) NH<sub>2</sub>OH·HCl/NaOH, ethanol, 16 h. (d) 7 N NH<sub>3</sub> in methanol, EtOH, H<sub>2</sub>, Raney nickel, 16 h. (e) DIPEA, <i>n</i>-BuOH, microwave at 225 °C, 1 h. (f) Isoamyl nitrile, DMF, 70 °C, 1 h. (g) Chiral separation on a chiral SFC column using MeOH and liquid CO<sub>2</sub> as elution system. (h) Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, overnight.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21583" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21583" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Receptor tyrosine kinases (RTKs) play fundamental roles in cell proliferation, migration, metabolism, differentiation, and survival. Alterations in the normal functions of protein kinases are linked with the pathological changes within cells that lead to diseases. Constitutively enhanced RTK activities have been implicated in the development and progression of many types of cancer.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Since the first approval of ABL protein kinase inhibitor Gleevec for the treatment of chronic myeloid leukemia patients with the <i>BCR-ABL</i> abnormal gene in 2001, a number of RTK inhibitors have been successfully discovered and developed against the aberrant RTK signaling in various cancers, including sunitinib and axitinib for targeting the VHL-dependent VEGF pathway in renal cell carcinoma, erlotinib and gefitinib targeting EGFR in non-small-cell lung cancer (NSCLC) with mutant EGFR, and crizotinib targeting c-Met, Alk, and Ros in NSCLC. The discovery and development of highly selective kinase inhibitors have been challenging because of the similarity of the protein kinase ATP binding sites. Most of the kinase inhibitor drugs approved for cancer treatments are multitarget kinase inhibitors and suffer side effects that limit their utility. From a highly specific HTS hit, we have discovered two c-Met inhibitors, <b>8</b> and <b>9</b>, exhibiting exquisite kinase selectivity, as well as many attractive properties. During the broad ligand off-target screens, it was discovered that <b>8</b> was a pan-PDE family inhibitor, which was correlated with a sustained increase in heart rate, increased cardiac output, and decreased contractility indices, as well as myocardial degeneration, in <i>in vivo</i> safety evaluations in rats. Compound <b>8</b> was terminated as a preclinical candidate because of narrow therapeutic window in cardio-related safety. Compound <b>9</b>, which has a higher LipE value for c-Met compared with <b>8</b> (7.02 vs 6.17), demonstrated a more selective profile in the broad ligand off-target screen and a large therapeutic window in <i>in vivo</i> animal tolerance studies. Compound <b>9</b> was selected as a preclinical candidate and later entered human clinical evaluations for cancer treatment. These findings reinforce the need for broad preclinical evaluations to identify a more complete range of affected pharmacology.</div><div class="NLM_p last">The attrition rate for drug development is rising, and late phase attrition remains high, which contributes to an unsustainable increase in R&D spending.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Although there are several factors that contribute to attrition, one of the major reasons is toxicity. Forty percent of NCEs that begin preclinical safety studies in animals fail due to toxicity.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> It is important to establish <i>in vitro</i> toxicity models to predict human <i>in vivo</i> toxicity and identify issues at early drug discovery stages. Broad off-target screening is one effective way to profile compounds at various stages and alert chemists to potential issues that can be addressed during optimization. Although both <b>8</b> and <b>9</b> have exquisite kinase selectivity for c-Met, and desired <i>in vitro</i> ADME and <i>in vivo</i> PK properties, the off-target inhibition of members of the PDE family by compound <b>8</b> caused severe cardio-toxicity in rats. Compound <b>8</b> was terminated at the early stage. It is challenging to design compounds with a completely clean profile in the off-target screens. LipE has been proposed as an index that may have some correlation with a good toxicity profile.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Indeed, <b>9</b> with a higher c-Met cell LipE value than <b>8</b> (7.02 vs 6.17, respectively) demonstrated a much better profile in broad ligand screens leading to a good safety profile in <i>in vivo</i> preclinical animal studies. Therefore, <b>9</b> was selected for early development. One of the major challenges in drug discovery is to identify a compound with a good balanced profile in biological functions and physicochemical properties. It is important at the early stage of drug discovery to establish an effective screen cascade for multiparameter optimizations and identify the key ADME and safety issues associated with the selected chemistry scaffolds. Optimization of multiple chemistry series, or at least two chemical series, is highly recommended to avoid late attrition of the project because of toxicity. Parallel optimization of both triazolopyrazine and triazolopyridazine series overcame the preclinical cardio-toxicity from the triazolopyridazine series and successfully selected <b>9</b> from the triazolopyrazine series into human clinical trials without a significant delay of the project progression.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Methods for Chemistry</h3><div class="NLM_p">All reagents and solvents were used as purchased from commercial sources. Reactions were carried out under nitrogen atmosphere unless otherwise indicated. Silica gel chromatography was done using the appropriate size Biotage prepacked silica filled cartridges. NMR spectra were generated on a Bruker 300 or 400 MHz instrument and obtained as CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> or MeOH-<i>d</i><sub>4</sub> solutions (reported in ppm), using CDCl<sub>3</sub> as the reference standard (7.27 ppm), DMSO-<i>d</i><sub>6</sub> (2.50 ppm), and MeOH-<i>d</i><sub>4</sub> (3.31 ppm). Multiplicities were given as s (singlet), b. s. (broad singlet), d (doublet), t (triplet), dt (double of triplets), and m (multiplet). Mass spectral data (APCI) was gathered on an Agilent 1100 LC with MSD (Agilent model G1946B upgraded to D model) single-quadrupole mass spec detectors running with atmospheric pressure chemical ionization source. The LC instrument includes a binary pump (Agilent model G1312A) with upper pressure limit of 400 bar attached to the autosampler (Agilent model G1313A), which uses an external tray for sample submission. The column compartment (Agilent model G1316A) is attached to a diode array (Agilent model G1315A). The instrument acquisition and data handling was done with ChemStation rev. B.02.01. The purity measurements were done by measuring peak area at 254 nm and 224 nm and total ion chromatogram. To evaluate the purity of each peak, a UV–vis spectrum from 190 to 700 nm at step size of 2 nm and a mass spectrum scan from 150 to 850 amu with cycle time of 0.29 cycle/s were performed. Retention times (RT) were in minutes, and purity was calculated as percentage of total area. Two HPLC methods were utilized for purity. Method A: Waters Acquity UPLC BEH C18 column, 1.7 μm, 2.1 × 100 mm<sup>2</sup>, column temperature 80 °C; solvent A water (0.1% formic acid and 0.05% ammonium formate); solvent B methanol (0.1% formic acid and 0.05% ammonium formate); gradient 5–95% B in 10 min, 95% B 10–12 min; flow rate 0.6 mL/min. Method B: EclipsXDB C8 column, 3.5 μm, 4.6 × 50 mm<sup>2</sup>, column temperature 40 °C; solvent A water (5% ACN, 2 mM ammonium acetate, 0.1% acetic acid); solvent B ACN (5% H<sub>2</sub>O, 2 mM ammonium acetate, 0.1% acetic acid); gradient 20–85 B% (0.0–2.5 min), 85–95 B% (2.5–3.5 min), 95 B% (5 min); flow rate =0.8 mL/min. Compound purity was determined by combustion analysis (Atlantic Microlabs, Inc.) or high-pressure liquid chromatography (HPLC) with a confirming purity of ≥95% for all of final biological testing compounds.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 2-(Quinolin-6-yl)acetic Acid (<b>31</b>)</h4><div class="NLM_p last">A mixture of 2-(4-aminophenyl)acetic acid (276 g, 1.8 mol), ferrous sulfate (63.6 g, 0.22 mol), glycerol (696 g, 7.56 mol), nitrobenzene (138 g, 1.12 mol), and concentrated sulfuric acid (324 mL) was heated gently. After the first vigorous reaction, the mixture was refluxed for 5 h and then was treated with aq. sodium hydroxide solution (2 N, 1320 mL), stirred with kieselguhr, and filtered. The filtrate was basified with aq. sodium hydroxide solution to pH 5–6, and a dark brown precipitate formed. The precipitate was filtered, washed with water, taken up with aq. sodium hydroxide solution (0.82 N, 3000 mL), then boiled with carbon (150 g). The mixture was filtered, the filtrate was treated with glacial acetic acid (240 mL), and the mixture was left standing overnight during which time a dark-brown crystalline precipitate formed. The precipitate was collected and dried in vacuum to give <b>31</b> (60 g, 17.8%). LC-MS <i>m</i>/<i>z</i> (M – 1)<sup>−</sup> 186; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.53 (br. s, 1H), 8.87 (dd, <i>J</i> = 4.29, 1.77 Hz, 1H), 8.30–8.35 (m, 1H), 7.97 (d, <i>J</i> = 8.59 Hz, 1H), 7.84 (d, <i>J</i> = 1.52 Hz, 1H), 7.68 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.52 (dd, <i>J</i> = 8.21, 4.17 Hz, 1H), 3.80 (s, 2H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 2-(Quinolin-6-yl)propanoic Acid (<b>32</b>)</h4><div class="NLM_p last">To a suspension of <b>31</b> (60 g, 0.32 mol) in MeOH (600 mL) cooled to 0–5 °C, SOCl<sub>2</sub> (30 mL, 0.35 mol) was added dropwise. After the mixture was heated to reflux for 2 h, the mixture was evaporated under reduced pressure, and the residue was taken up with EtOAc (600 mL). The mixture was washed with aq. NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give crude methyl ester, which was purified via a silica column chromatography (EtOAc/petroleum ether = 1:5) to give methyl 2-(quinolin-6-yl)acetate (50 g, 72.6%) as a yellow oil. To a solution of methyl 2-(quinolin-6-yl)acetate (20.00 g, 99.54 mmol) in anhydrous tetrahydrofuran (200 mL) was added LDA (1.8 M THF solution, 61 mL, 109.5 mmol) dropwise at −78 °C under nitrogen. The reaction mixture was stirred at −78 °C under nitrogen for half an hour. To the reaction mixture was added methyl iodide (6.20 mL, 99.54 mmol), and the mixture was stirred under nitrogen from −78 °C to ambient temperature overnight. The reaction was quenched with the careful addition of water. The product was extracted with ethyl acetate. The combined extracts were washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to provide methyl 2-(quinolin-6-yl)propanoate (21.49 g, ∼100% yield). To a solution of 2-(quinolin-6-yl)propanoate (21.17 g, 98.35 mmol) in methanol (200 mL) and water (50 mL) was added lithium hydroxide (12.02 g, 491.75 mmol). The reaction mixture was stirred at 65 °C in an oil bath for 4 h and cooled to ambient temperature, and the acidity was adjusted to pH ∼7 with 6 N HCl (65 mL). Much precipitate was formed. After filtration, the solid was washed with water, and the filtrate was concentrated to remove methanol. The solid was filtrated and washed with water. The combined solid product was dried under high vacuum to provide <b>32</b> (19.09 g, 90% yield). LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 202; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.78 (dd, <i>J</i> = 4.04, 1.77 Hz, 1H), 8.20–8.26 (m, 1 H), 7.82–7.89 (m, 1H), 7.72–7.80 (m, 2H), 7.43 (dd, <i>J</i> = 8.34, 4.04 Hz, 1H), 3.54 (q, <i>J</i> = 7.07 Hz, 1H), 1.37 (d, <i>J</i> = 7.07 Hz, 3H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 2-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)propanoic Acid (<b>35</b>)</h4><div class="NLM_p">To a solution of methyl (1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-acetate (5.10 g, 28.78 mmol) and 4-dimethylaminopyridine (175.8 mg, 1.44 mmol) in anhydrous THF (100 mL) was added di-<i>tert</i>-butyldicarbonate (34.6 g, 34.54 mmol). The reaction mixture was stirred overnight, diluted with ethyl acetate, washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was suspended in hexane, and the solid was filtered and dried to provide a white solid of 3-methoxycarbonylmethyl-pyrrolo[2,3-<i>b</i>]pyridine-1-carboxylic acid <i>tert</i>-butyl ester (6.07 g). The filtrate was concentrated and purified on a silica gel column eluting with hexane–ethyl acetate to provide additional product (1.71 g, total 7.78 g, 97% yield). <sup>1</sup>H NMR (400 MHz, chloroform-D) δ 8.38 (dd, <i>J</i> = 4.55, 1.52 Hz, 1H), 7.99 (dd, <i>J</i> = 7.83, 1.52 Hz, 1H), 7.73 (s, 1H), 7.28 (dd, <i>J</i> = 7.83, 4.80 Hz, 1H), 3.83 (s, 2H), 3.62 (s, 3H), 1.60 (s, 9H).</div><div class="NLM_p last">To a solution of 3-methoxycarbonylmethyl-pyrrolo[2,3-<i>b</i>]pyridine-1-carboxylic acid <i>tert</i>-butyl ester (6.07 g, 20.9 mmol) in anhydrous THF (100 mL) was added LDA (1.8 M THF solution, 12.7 mL, 22.99 mmol) at −78 °C under nitrogen. The reaction mixture was stirred at −78 °C under nitrogen for half an hour, and then methyl iodide was added. The reaction mixture was stirred from −78 °C to ambient temperature overnight under nitrogen, quenched with an addition of saturated ammonium chloride, and diluted with ethyl acetate. The ethyl acetate layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and dried under high vacuum to provide 3-(1-methoxycarbonyl-ethyl)-pyrrolo[2,3-<i>b</i>]pyridine-1-carboxylic acid <i>tert</i>-butyl ester (6.35 g, ∼100% yield). To a solution of 3-(1-methoxycarbonyl-ethyl)-pyrrolo[2,3-<i>b</i>]pyridine-1-carboxylic acid <i>tert</i>-butyl ester (6.35 g, 20.9 mmol) in dichloromethane (50 mL) was added HCl dioxane solution (4 N, 20 mL). The reaction mixture was stirred overnight. After evaporation and high vacuum dry, the product was used directly for the next step. To a solution of methyl 2-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-propionate (4.26 g, 20.9 mmol) in methanol (45 mL) and water (15 mL) was added LiOH (2.503 g, 104.5 mmol). The reaction mixture was stirred at 60 °C in an oil bath for 2 h. After cooling, the reaction mixture was neutralized to pH ∼6 with 6 N HCl solution. The solid was filtered and washed with water to provide <b>35</b> (2.45 g). The filtrate was concentrated and purified on a reverse-phase C-18 preparative HPLC to provide another portion of <b>35</b> (1.05 g, total 3.50 g).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (<i>S</i>)-6-(1-(6-Chloro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>38C</b>)</h4><div class="NLM_p last">To a solution of <b>32</b> (3.00 g, 14.9 mmol) in DMF (75 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.14 g, 16.4 mmol). The reaction mixture was stirred under nitrogen for half an hour and then (6-chloro-pyridazin-3-yl)-hydrazine (2.22 g, 14.9 mmol) was added. The reaction mixture was stirred under nitrogen overnight, diluted with ethyl acetate, washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to get the crude intermediate, which was dissolved in acetic acid (20 mL). The acetic acid solution was refluxed for 2 h and concentrated. The residue was purified on a silica gel column eluting with 5% methanol in ethyl acetate to provide 6-[1-(6-chloro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)-ethyl]-quinoline (1.16 g, 25% yield). The racemic compound was resolved with a chiral column (Chiralcel AD-H) eluting with 45% methanol in liquid carbon dioxide (100 bar, 2.5 mL/min). (<i>R</i>)-6-[1-(6-chloro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)-ethyl]-quinoline had an optical rotation of +0.157° in methanol (5.53 mg/mL), and (<i>S</i>)-6-[1-(6-chloro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)-ethyl]-quinoline (<b>38C</b>) had an optical rotation of −0.125° in methanol (5.22 mg/mL). The absolute configuration was proven with a cocrystal structure with c-Met. LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 310, 312; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.89 (d, <i>J</i> = 7.33 Hz, 3H), 5.00 (q, <i>J</i> = 7.07 Hz, 1H), 7.46 (d, <i>J</i> = 9.60 Hz, 1H), 7.51 (dd, <i>J</i> = 8.34, 4.29 Hz, 1H), 7.78 (dd, <i>J</i> = 8.84, 2.02 Hz, 1H), 7.87 (d, <i>J</i> = 1.77 Hz, 1H), 7.98 (d, <i>J</i> = 8.84 Hz, 1H), 8.33 (d, <i>J</i> = 8.34 Hz, 1H), 8.45 (d, <i>J</i> = 9.60 Hz, 1H), 8.86 (dd, <i>J</i> = 4.17, 1.64 Hz, 1H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 6-((6-Chloro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)methyl)quinoline (<b>38A</b>)</h4><div class="NLM_p last">Compound <b>38A</b> was prepared with the same method as <b>38C</b>. LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 295, 297; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (dd, <i>J</i> = 1.65, 4.22 Hz, 1H), 8.46 (d, <i>J</i> = 9.66 Hz, 1H), 8.27–8.34 (m, 1H), 7.98 (d, <i>J</i> = 8.56 Hz, 1H), 7.86 (d, <i>J</i> = 1.47 Hz, 1H), 7.74 (dd, <i>J</i> = 1.96, 8.68 Hz, 1H), 7.45–7.53 (m, 2H), 4.71 (s, 2H).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 3-((1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)methyl)-6-chloro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine (<b>38E</b>)</h4><div class="NLM_p last">To a solution of (1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-acetic acid (283 mg, 1.61 mmol) and (6-chloro-pyridazin-3-yl)-hydrazine (233 mg, 1.61 mmol) in DMF (8 mL) was added HATU (612 mg, 1.61 mmol). The reaction mixture was stirred at ambient temperature for 1 h and then heated at 120 °C for 2 h. After cooling, the reaction was concentrated and purified on a reverse-phase C-18 preparative HPLC eluting with acetonitrile–water containing 0.1% acetic acid to provide <b>38E</b> (99 mg, 20% yield). LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 285, 287; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.68 (s, 1H), 8.36–8.53 (m, 1H), 8.23 (d, <i>J</i> = 4.80 Hz, 1H), 8.03–8.13 (m, 1H), 7.40–7.51 (m, 2 H), 7.11 (dd, <i>J</i> = 7.83, 4.80 Hz, 1H), 4.59 (s, 1H).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>S</i>)-3-(1-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)ethyl)-6-chloro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine (<b>38F</b>)</h4><div class="NLM_p last">The suspension of <b>35</b> (542 mg, 2.85 mmol) in thionyl chloride (6 mL) was stirred at ambient temperature for 2 h, and then thionyl chloride was removed in vacuo. To the residue was added a solution of (6-chloro-pyridazin-3-yl)-hydrazine (412 mg, 2.85 mmol) in anhydrous DMF (5 mL). The reaction solution was stirred for 5 min at ambient temperature and then heated at 100 °C in an oil bath for 30 min. After cooling, DMF was removed with vacuum. The residue was dissolved in water and washed with ethyl acetate, and the water layer was lyophilized to provide 6-chloro-3-[1-(1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-ethyl]-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine (610 mg, 71.5% yield). The racemic compound was resolved on a chiral SFC column using MeOH and liquid CO<sub>2</sub> as elution system to provide <b>38F</b>. The absolute configuration of <b>38F</b> was determined by a cocrystal structure with c-Met. LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 310, 312; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (dd, <i>J</i> = 4.17, 1.64 Hz, 1H), 8.45 (d, <i>J</i> = 9.60 Hz, 1H), 8.33 (d, <i>J</i> = 8.34 Hz, 1H), 7.98 (d, <i>J</i> = 8.84 Hz, 1H), 7.87 (d, <i>J</i> = 1.77 Hz, 1H), 7.78 (dd, <i>J</i> = 8.84, 2.02 Hz, 1H), 7.51 (dd, <i>J</i> = 8.34, 4.29 Hz, 1H), 7.46 (d, <i>J</i> = 9.60 Hz,1H), 5.00 (q, <i>J</i> = 7.33 Hz, 1H), 1.89 (d, <i>J</i> = 7.33 Hz, 3H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>S</i>)-6-(1-(6-Bromo-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)ethyl)quinoline (<b>49</b>)</h4><div class="NLM_p">Step 1. To a solution of <b>41</b> (10 g, 57.75 mmol) in DMF (200 mL) was added carbonyl diimidazole (10.3 g, 62.5 mmol) under nitrogen. The reaction was stirred for 1 h. To the solution was added <i>N</i>,<i>O</i>-dimethyl hydroxylamine (5.6 g, 57.75 mmol), and the reaction was stirred at ambient temperature for 16 h. The reaction was diluted with EtOAc (150 mL) and water (150 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (5 × 100 mL). The organics were combined and washed with water (3 × 100 mL) and brine (2 × 100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give <b>42</b> (11.97 g, 97% yield).</div><div class="NLM_p">Step 2. To a solution of <b>42</b> (11.97g, 55.35 mmol) in anhydrous THF (200 mL) was added MeMgBr (1.5 M in THF, 55 mL, 83 mmol) at 0 °C under nitrogen. The reaction was allowed to warm to ambient temperature over 16 h. Saturated NH<sub>4</sub>Cl (20 mL) was added to quench the reaction. The reaction solution was then extracted with EtOAc (3 × 50 mL). The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give <b>43</b> (9.2 g, 97% yield).</div><div class="NLM_p">Step 3. To a suspension of hydroxylamine hydrochloride in EtOH (150 mL) was added a suspension of NaOH (2.4 g, 59.7 mmol) in EtOH (25 mL). The reaction mixture was stirred at ambient temperature for 15 min. The precipitated sodium hydrochloride was filtered off. A solution of 1-quinolin-6-yl-ethanone (9.3 g, 54.25 mmol) in EtOH (150 mL) was added. The reaction solution was stirred for 16 h at ambient temperature. EtOH was removed in vacuum to give <b>44</b> (10.1 g, >99% yield).</div><div class="NLM_p">Step 4. To a solution of <b>44</b> (4.54 g, 24.4 mmol) in EtOH (50 mL) was added methanol solution of NH<sub>3</sub> (7 N, 12 mL, 80 mmol). A slurry of Raney nickel (washed 3× with EtOH), about 2 g, was added followed by a hydrogen-filled balloon. The reaction was stirred at ambient temperature for 16 h under the hydrogen-filled balloon. The reaction mixture was filtered over a pad of Celite, and the mother liquor was concentrated to give quantitative <b>45</b> (4.1 g, 97.6%).</div><div class="NLM_p">Step 5. To a solution of 2-amino-dibromopyrazine (5.1 g, 20 mmol) and <b>45</b> (3.43 g, 20 mmol) in <i>n</i>-BuOH (5 mL) was added diisopropylethylamine (10.5 mL, 60 mmol). The reaction was irradiated in a microwave at 225 °C for 1 h. The reaction mixture was concentrated and purified by column chromatography, Biotage 40+M 0–50% EtOAc/hexanes (7 column volumes), 50–100% (10 column volumes), and EtOAc with 10% MeOH to give <b>47</b> (2.1 g, 66%).</div><div class="NLM_p">Step 6. To a solution of <b>47</b> in anhydrous DMF (25 mL) was added isoamyl nitrile (0.98 mL, 1.2 mmol) at 0 °C. The reaction was stirred at 0 °C for 5 min, then the ice bath was removed and allowed to stir at ambient temperature for 5 min. The reaction was then heated at 70 °C for 1 h, cooled, and quenched with sat. aqueous solution of Na<sub>2</sub>SO<sub>3</sub> (10 mL). Water (50 mL) and EtOAc (50 mL) were added. The organic layer was separated and the aqueous layer was extracted with EtOAc (4 × 100 mL). The combined organics were washed with NaHCO<sub>3</sub> (50 mL) and water (3 × 50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give <b>48</b> (1.56 g, 72% yield).</div><div class="NLM_p last">Step 7. The racemic <b>48</b> was resolved on a chiral SFC column using MeOH and liquid CO<sub>2</sub> as elution system to provide <b>49</b> and <b>50</b>. The absolute configuration of <b>49</b> was determined by a cocrystal structure with c-Met. LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 354, 356; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) 1H NMR (300 MHz, DMSO-<i>d</i>6) δ ppm 8.99 (s, 1H), 8.90 (dd, <i>J</i> = 4.14, 1.70 Hz, 1H), 8.38 (d, <i>J</i> = 8.10 Hz, 1H), 7.97–8.07 (m, 2H), 7.76–7.88 (m, 1H), 7.54 (dd, <i>J</i> = 8.38, 4.24 Hz, 1H), 6.45–6.73 (q, <i>J</i> = 6.97 Hz, 1H), 2.19 (d, <i>J</i> = 6.97 Hz, 3H).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure A for Suzuki Coupling Reaction</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>S</i>)-4-(3-(1-(Quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)benzonitrile (<b>16C</b>)</h4><div class="NLM_p">To a solution of <b>38C</b> (50 mg, 0.16 mmol) and 4-cyanophenyl boronic acid (26.4 mg, 0.18 mmol) in 1,2-dimethoxyethane (1.5 mL) were added a freshly prepared solution of Cs<sub>2</sub>CO<sub>3</sub> (186.3 mg, 0.528 mmol) in water (0.5 mL) and the catalyst Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub> (6.5 mg, 0.008 mmol). The reaction mixture was degassed and charged with nitrogen three times and heated at 80 °C in an oil bath overnight. The reaction solution was diluted with methanol, and filtered through a Celite pad. The filtrate was concentrated and purified on a reverse-phase C-18 preparative HPLC eluting with acetonitrile–water containing 0.1% acetic acid to provide <b>16C</b> (27 mg, 45% yield). LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 377; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (d, <i>J</i> = 2.69 Hz, 1H), 8.49 (d, <i>J</i> = 9.78 Hz, 1H), 8.35 (d, <i>J</i> = 8.44 Hz, 1H), 8.23 (d, <i>J</i> = 8.31 Hz, 2H), 8.04 (d, <i>J</i> = 8.31 Hz, 2H), 7.95–8.02 (m, 3H), 7.84 (d, <i>J</i> = 8.68 Hz, 1H), 7.45–7.53 (m, 1H), 5.11–5.23 (m, <i>J</i> = 7.00 Hz, 1H), 1.96 (d, <i>J</i> = 7.21 Hz, 3H); HPLC purity (method A) RT 5.717, >95%.</div><div class="NLM_p last">Compounds of 6-aryl-[1,2,4]triazolo[4,3-<i>b</i>]pyridazines and 6-aryl-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazines were prepared according to the General Procedure A.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 6-((6-(3,4-Difluorophenyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)methyl)quinoline (<b>14A</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 374; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (dd, <i>J</i> = 4.17, 1.64 Hz, 1H), 8.46 (d, <i>J</i> = 9.85 Hz, 1H), 8.28–8.34 (m, 1H), 8.14–8.24 (m, 1H), 7.93–8.05 (m, 3H), 7.80 (dd, <i>J</i> = 8.72, 1.89 Hz, 1H), 7.60–7.71 (m, 1H), 7.50 (dd, <i>J</i> = 8.34, 4.29 Hz, 1H), 7.21 (d, <i>J</i> = 4.80 Hz, 1H), 4.82 (s, 2H); HPLC purity (method A) RT 6.401, >95%.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3-(3-(Quinolin-6-ylmethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)benzonitrile (<b>15A</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 342; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 8.87 (dd, <i>J</i> = 4.14, 1.70 Hz, 1H), 8.60 (s, 1H), 8.52 (d, <i>J</i> = 9.80 Hz, 1H), 8.43–8.49 (m, 1H), 8.33 (d, <i>J</i> = 0.94 Hz, 1H), 7.97–8.11 (m, 4H), 7.78–7.87 (m, 2H), 7.52 (dd, <i>J</i> = 8.29, 4.33 Hz, 1H), 4.86 (s, 2H); HPLC purity (method A) RT 5.297, 99.1%.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-(3-(Quinolin-6-ylmethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)benzonitrile (<b>16A</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 363; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.87 (dd, <i>J</i> = 1.71, 4.16 Hz, 1H), 8.52 (d, <i>J</i> = 9.78 Hz, 1H), 8.28–8.38 (m, 3H), 7.94–8.12 (m, 5H), 7.83 (dd, <i>J</i> = 1.96, 8.80 Hz, 1H), 7.52 (dd, <i>J</i> = 4.28, 8.31 Hz, 1H), 4.85 (s, 2H); HPLC purity (method A) RT 6.160, >95%.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 6-((6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)methyl)quinoline (<b>17A</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 342; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (dd, <i>J</i> = 4.24, 1.60 Hz, 1H), 8.52 (s, 1H), 8.26–8.39 (m, 2H), 8.16 (s, 1H), 7.93–8.03 (m, 2H), 7.73–7.86 (m, 1H), 7.67 (d, <i>J</i> = 9.61 Hz, 1H), 7.50 (dd, <i>J</i> = 8.29, 4.33 Hz, 1H), 4.73 (s, 2H), 3.93 (s, 3H); HPLC purity (method A) RT 4.238, >99%.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>S</i>)-6-(1-(6-(3,4-Difluorophenyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>14C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 388; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (dd, <i>J</i> = 4 0.29, 1.77 Hz, 1H), 8.45 (d, <i>J</i> = 9.60 Hz, 1H), 8.35(d, <i>J</i> = 7.58 Hz, 1H), 8.03–8.11 (m, 1H), 7.97–8.02 (m, 2H), 7.95 (d, <i>J</i> = 4.04 Hz, 1H), 7.89–7.93 (m, 1H), 7.82 (dd, <i>J</i> = 8.84, 2.02 Hz, 1H), 7.63 (m, 1H), 7.50 (dd, <i>J</i> = 8.21, 4.17 Hz, 1H), 5.15 (q, <i>J</i> = 7.07 Hz, 1H), 3.15 (s, 3H), 1.94 (d, <i>J</i> = 7.33 Hz, 3H); HPLC purity (method A) RT 6.770, >95%.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>S</i>)-6-(1-(6-(3-Fluoro-4-methoxyphenyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>19C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 400; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (dd, <i>J</i> = 4.04, 1.77 Hz, 1H), 8.38(d, <i>J</i> = 9.85 Hz, 1H), 8.32(d, <i>J</i> = 1.01 Hz, 1H), 7.94–7.99 (m, 2H), 7.90 (d, <i>J</i> = 9.85 Hz, 1H), 7.84–7.88 (m, 1H), 7.78–7.85 (m, 2H), 7.50 (dd, <i>J</i> = 8.21, 4.17 Hz, 1H), 7.31 (q, 1H), 5.153(q, <i>J</i> = 7.33 Hz, 1H), 3.91 (s, 3H), 1.94 (d, <i>J</i> = 7.33 Hz, 3H); HPLC purity (method A) RT 6.539, 99%.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>S</i>)-6-(1-(6-(4-Methoxy-3-methylphenyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>20C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 396; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.843 (dd, <i>J</i> = 4.17, 1.64 Hz, 1H), 8.28–8.37 (m, 2H), 7.93–8.01 (m, 2H), 7.84 (d, <i>J</i> = 9.85 Hz, 2 H), 7.79 (dd, <i>J</i> = 8.84, 1.77 Hz, 1H), 7.71 (d, <i>J</i> = 1.77 Hz, 1H), 7.49 (dd, <i>J</i> = 8.34, 4.04 Hz, 1H), 7.05 (d, <i>J</i> = 8.59 Hz, 1H), 5.10 (q, <i>J</i> = 7.07 Hz, 1H), 2.17 (s, 3H), 1.94 (d, <i>J</i> = 7.07 Hz, 3H); HPLC purity (method A) RT 7.165, 96%.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>S</i>)-6-(1-(6-(3-Methylphenyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>21C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 366; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (dd, <i>J</i> = 4.04, 1.52 Hz, 1H), 8.38 (d, <i>J</i> = 9.85 Hz, 1H), 8.34 (d, <i>J</i> = 7.83 Hz, 1H), 8.97–8.01 (m, 2H), 7.87 (d, <i>J</i> = 9.85 Hz, 1H), 7.75–7.81 (m, 2H), 7.69 (s, 1H), 7.49 (dd, <i>J</i> = 8.34, 4.02 Hz, 1H), 7.40 (t, <i>J</i> = 7.71 Hz, 1H), 7.31–7.37 (m, 1H), 5.11 (q, <i>J</i> = 7.07 Hz, 1H), 2.34(s, 3H), 1.95 (d, <i>J</i> = 7.33 Hz, 3H); HPLC purity (method A) RT 6.985, 98%.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-3-(3-(1-(Quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)benzonitrile (<b>15C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 377; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (dd, <i>J</i> = 4.24, 1.60 Hz, 1H), 8.42–8.55 (m, 2H), 8.35 (d, <i>J</i> = 8.29 Hz, 2H), 7.91–8.12 (m, 4H), 7.71–7.86 (m, 2H), 7.49 (dd, <i>J</i> = 8.29, 4.14 Hz, 1H), 5.18 (q, <i>J</i> = 7.28 Hz, 1H), 1.96 (d, <i>J</i> = 7.16 Hz, 3H); Anal. Calcd for C<sub>23</sub>H<sub>16</sub>N<sub>6</sub>: C, 73.39; H, 4.28; N, 22.33. Found: C, 73.50; H, 4.37; N, 22.39.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>S</i>)-4-(3-(1-(Quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)benzonitrile (<b>16C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 377; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (d, <i>J</i> = 2.69 Hz, 1H), 8.49 (d, <i>J</i> = 9.78 Hz, 1H), 8.35 (d, <i>J</i> = 8.44 Hz, 1H), 8.23 (d, <i>J</i> = 8.31 Hz, 2H), 8.04 (d, <i>J</i> = 8.31 Hz, 2H), 7.95–8.02 (m, 3H), 7.84 (d, <i>J</i> = 8.68 Hz, 1H), 7.45–7.53 (m, 1H), 5.11–5.23 (m, <i>J</i> = 7.00 Hz, 1H), 1.96 (d, <i>J</i> = 7.21 Hz, 3H); HPLC purity (method A) RT 5.717, >95%.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>S</i>)-2-(3-(1-(Quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)benzonitrile (<b>22C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 377; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (dd, <i>J</i> = 1.77, 4.04 Hz, 1H), 8.56 (d, <i>J</i> = 9.60 Hz, 1H), 8.30 (d, <i>J</i> = 7.58 Hz, 1H), 8.10 (dd, <i>J</i> = 1.01, 7.58 Hz, 1H), 7.97 (dd, <i>J</i> = 2.78, 5.31 Hz, 3H), 7.73–7.93 (m, 4H), 7.49 (dd, <i>J</i> = 4.29, 8.34 Hz, 1H), 5.11–5.19 (m, 1H), 1.92–1.95 (m, 3H); HPLC purity (method B): RT 1.228, >95%.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-6-(1-(6-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>23C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 410; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (dd, <i>J</i> = 4.14, 1.70 Hz, 1H), 8.26–8.39 (m, 2H), 7.91–8.01 (m, 2H), 7.75–7.89 (m, 2H), 7.43–7.56 (m, 3H), 6.94–7.05 (m, 1H), 5.11 (q, <i>J</i> = 7.16 Hz, 1H), 4.30 (s, 4H), 1.93 (d, <i>J</i> = 7.35 Hz, 3H); HPLC purity (method A) RT 6.347, >95%.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>S</i>)-<i>N</i>-Methyl-4-(3-(1-(quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)benzamide (<b>24C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 430; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (dd, <i>J</i> = 4.04, 1.52 Hz, 1H), 8.58 (d, <i>J</i> = 4.55 Hz, 1H), 8.43 (d, <i>J</i> = 9.85 Hz, 1H), 8.35 (d, <i>J</i> = 8.08 Hz, 1H), 8.08 (d, <i>J</i> = 8.34 Hz, 2H), 7.91–8.02 (m, 5H), 7.82 (dd, <i>J</i> = 8.84, 1.77 Hz, 1H), 7.49 (dd, <i>J</i> = 8.34, 4.29 Hz, 1H), 5.15 (q, <i>J</i> = 7.33 Hz, 1H), 2.80 (d, <i>J</i> = 4.55 Hz, 3H), 1.95 (d, <i>J</i> = 7.33 Hz, 3H); HPLC purity (method A) RT 4.857, 98.5%.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>S</i>)-6-(1-(6-(4-Ethanesulfonylphenyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>25C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 445; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (dd, <i>J</i> = 4.04, 1.77 Hz, 1H), 8.49 (d, <i>J</i> = 9.60 Hz, 1H), 8.37 (dd, <i>J</i> = 8.46, 1.14 Hz, 1H), 8.27 (d, <i>J</i> = 8.84 Hz, 2H), 8.04 (d, <i>J</i> = 8.59 Hz, 2H), 7.95–8.01 (m, 3H), 7.83 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.49 (dd, <i>J</i> = 8.34, 4.04 Hz, 1H), 5.15 (q, <i>J</i> = 7.33 Hz, 1H), 3.37 (q, <i>J</i> = 7.33 Hz, 2H), 1.95 (d, <i>J</i> = 7.33 Hz, 3H), 1.11 (t, <i>J</i> = 7.33 Hz, 3H); HPLC purity (method A) RT 5.280, >95%.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>S</i>)-6-(1-(6-(4-Methanesulfonylphenyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>26C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 430; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (dd, <i>J</i> = 4.17, 1.64 Hz, 1H), 8.49 (d, <i>J</i> = 9.60 Hz, 1H), 8.36(dd, <i>J</i> = 8.21 Hz, 1.39 Hz, 1H), 8.26 (d, <i>J</i> = 8.59 Hz, 2H), 8.08 (d, <i>J</i> = 8.59 Hz, 2H), 7.96–8.01 (m, 3H), 7.83 (dd, <i>J</i> = 8.57, 2.02 Hz, 1H), 7.49 (dd, <i>J</i> = 8.34, 4.29 Hz, 1H), 5.15 (q, <i>J</i> = 7.33 Hz, 1H), 3.28 (s, 3H), 1.95 (d, <i>J</i> = 7.33 Hz, 3H); HPLC purity (method A) RT 4.857, 98.5%.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>S</i>)-<i>N</i>,<i>N</i>-Dimethyl-5-(3-(1-(quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)pyridin-2-amine (<b>27C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 396; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.73–8.88 (m, 2H), 8.26–8.39 (m, 2H), 8.11 (dd, <i>J</i> = 9.04, 2.45 Hz, 1H), 7.93–8.03 (m, 2H), 7.77–7.90 (m, 2H) 7.49 (dd, <i>J</i> = 8.29, 4.14 Hz, 1H), 6.76 (d, <i>J</i> = 9.23 Hz, 1H), 5.04–5.17 (m, <i>J</i> = 7.35 Hz, 1H), 3.11 (s, 6H), 1.93 (d, <i>J</i> = 7.35 Hz, 3H); HPLC purity (method A) RT 6.007, >99%.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>S</i>)-6-(1-(6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3-yl)ethyl)quinoline (<b>8</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> (M + 1)<sup>+</sup> 356; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.83 (d, <i>J</i> = 2.78 Hz, 1H), 8.46 (s, 1H), 8.35 (d, <i>J</i> = 8.08 Hz, 1H), 8.30 (d, <i>J</i> = 9.60 Hz, 1H), 8.08 (s, 1H), 8.00 (s, 1H), 7.96 (d, <i>J</i> = 8.84 Hz, 1H), 7.83 (d, <i>J</i> = 8.59 Hz, 1H), 7.62 (d, <i>J</i> = 9.85 Hz, 1H), 7.49 (dd, <i>J</i> = 8.34, 4.29 Hz, 1H), 5.04 (q, <i>J</i> = 6.91 Hz, 1H), 3.90 (s, 3H), 1.92 (d, <i>J</i> = 7.33 Hz, 3 H); HPLC purity (method A) RT 4.687, >95%.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>S</i>)-6-(1-(6-(1-Methyl-1<i>H</i>-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-1-yl)ethyl)quinoline (<b>8D</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 357 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.18 (s, 1H), 8.89 (d, <i>J</i> = 4.14 Hz, 1H), 8.62 (s, 1H), 8.40 (d, <i>J</i> = 7.91 Hz, 1H), 8.28 (s, 1H), 7.96–8.11 (m, 2H), 7.84–7.93 (m, 1H), 7.53 (dd, <i>J</i> = 4.14, 8.29 Hz, 1H), 6.52–6.63 (m, <i>J</i> = 7.30 Hz, 1H), 3.94 (s, 3H), 2.25 (d, <i>J</i> = 7.16 Hz, 3H); HPLC purity (method A) RT 11.213, >99%.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>S</i>)-2-(4-(1-(1-(Quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (<b>9D</b>)</h4><div class="NLM_p last">LCMS <i>m</i>/<i>z</i> 387 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (s, 1H), 8.89 (dd, <i>J</i> = 1.51, 4.14 Hz, 1H), 8.62 (s, 1H), 8.39 (d, <i>J</i> = 7.54 Hz, 1H), 8.30 (s, 1H), 8.08 (s, 1H), 8.02 (d, <i>J</i> = 8.85 Hz, 1H), 7.83–7.92 (m, 1H), 7.53 (dd, <i>J</i> = 4.24, 8.19 Hz, 1H), 6.53–6.67 (m, <i>J</i> = 7.20 Hz, 1H), 4.98 (br. s., 1H), 4.24 (t, <i>J</i> = 5.46 Hz, 2H), 3.78 (d, <i>J</i> = 4.71 Hz, 2H), 2.24 (d, <i>J</i> = 7.16 Hz, 3H); HPLC purity (method A) RT 10.960, >95%. Anal. Calcd. for C<sub>20</sub>H<sub>18</sub>N<sub>8</sub>O<b>·</b>0.78H<sub>2</sub>O: C, 59.99; H, 4.92; N, 27.98. Found: C, 60.07; H, 4.63; N, 27.78.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-((1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)methyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine (<b>8E</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 331 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.50 (d, <i>J</i> = 1.01 Hz, 1H), 8.56 (s, 1H), 8.27–8.33 (m, 1H), 8.15–8.22 (m, 2 H), 8.04 (d, <i>J</i> = 6.57 Hz, 1H), 7.66 (d, <i>J</i> = 9.85 Hz, 1H), 7.53 (d, <i>J</i> = 2.53 Hz, 1H), 7.03 (dd, <i>J</i> = 7.83,4.80 Hz, 1H), 4.60 (s, 2H), 3.94 (s, 3H); HPLC purity (method A) RT 4.080, >97%.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>S</i>)-3-(1-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)ethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine (<b>8F</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 345 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.47 (s, 1H), 8.50 (s, 1H), 8.27 (d, <i>J</i> = 9.61 Hz, 1H), 8.08–8.15 (m, 2H), 7.92–8.00 (m, 1H), 7.61 (d, <i>J</i> = 9.80 Hz, 1H), 7.54 (s, 1H), 6.97 (dd, <i>J</i> = 7.72, 4.90 Hz, 1H), 5.00–5.14 (m, <i>J</i> = 7.35 Hz, 1H), 3.92 (s, 3H), 1.91 (d, <i>J</i> = 7.35 Hz, 3H); HPLC purity (method A) RT 4.557, >95%.</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>S</i>)-4-(3-(1-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)ethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)benzonitrile (<b>16F</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 366 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.54 (s, 1H), 8.47 (d, <i>J</i> = 9.61 Hz, 1H), 8.25–8.32 (m, 2H), 8.16 (dd, <i>J</i> = 4.71, 1.51 Hz, 1H), 8.03–8.09 (m, 2H), 7.95–8.01 (m, 2H), 7.51 (d, <i>J</i> = 2.26 Hz, 1H), 7.01 (dd, <i>J</i> = 7.91, 4.71 Hz, 1H), 5.14 −5.24 (m, <i>J</i> = 7.16 Hz, 1H), 1.91–1.99 (d, <i>J</i> = 7.35, 3 H); HPLC purity (method A) RT 5.486, >95%.</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-(Quinolin-6-ylmethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-amine (<b>17A</b>)</h4><div class="NLM_p last">A solution of <b>38A</b> (100 mg, 0.338 mmol) in NH<sub>4</sub>OH (3 mL, 0.11 M, 28%) was heated in a microwave at 100 °C for 1 h. After evaporation, the residue was purified by a preparative HPLC (acetonitrile/water, with 0.1% HOAc) to obtain <b>17A</b> (32 mg, 34% yield). LC-MS <i>m</i>/<i>z</i> 276 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (dd, <i>J</i> = 4.29, 1.77 Hz, 1H), 8.29 (d, <i>J</i> = 7.33 Hz, 1H), 7.94 (t, <i>J</i> = 8.84 Hz, 2H), 7.78 (s, 1 H), 7.71 (dd, <i>J</i> = 8.84, 2.02 Hz, 1H), 7.50 (dd, <i>J</i> = 8.21, 4.17 Hz, 1H), 6.71–6.84 (m, 3H), 4.52 (s, 2H); HPLC purity (method A) RT 2.564, >95%.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> General Procedure B for N-Replacement Reaction</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (S)-3-(1-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)ethyl)-<i>N</i>-isopropyl-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-amine (<b>28F</b>)</h4><div class="NLM_p">To a microwave vial was added <b>38F</b> (50 mgs, 0.17 mmol), nBuOH (1 mL), and isopropylamine (1 mL). The reaction was irradiated at 120 °C for 1 h. LCMS showed 80% conversion. Isopropylamine (0.5 mL) was added and irradiated again for 30 min at 120 °C. This was repeated three times for full conversion. The reaction was concentrated and purified by preparatory HPLC eluting with 10–30% acetonitrile/water having 0.1% HOAc to give <b>28F</b> as a white amorphous solid (30 mg, 56% yield) after lyophilization. LC-MS <i>m</i>/<i>z</i> (M + H)<sup>+</sup> 322; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.44 (s, 1H), 8.13 (dd, <i>J</i> = 4.71, 1.51 Hz, 1H), 7.85 (dd, <i>J</i> = 7.82, 1.22 Hz, 1H), 7.80 (d, <i>J</i> = 9.98 Hz, 1H), 7.36 (d, <i>J</i> = 2.26 Hz, 1H), 7.13 (d, <i>J</i> = 6.97 Hz, 1H), 6.95 (dd, <i>J</i> = 7.91, 4.71 Hz, 1H), 6.66 (d, <i>J</i> = 9.98 Hz, 1H), 4.85 (q, <i>J</i> = 7.16 Hz, 1H), 3.74–3.91 (m, 1H), 1.84 (d, <i>J</i> = 7.35 Hz, 3H), 1.17 (d, <i>J</i> = 6.40 Hz, 3H), 1.09 (d, <i>J</i> = 6.40 Hz, 3H); HPLC purity (method A) RT 5.601, >99%.</div><div class="NLM_p last">General procedure B was followed for <b>18A</b>, <b>28C</b>, and <b>29F</b>.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>,<i>N</i>-Dimethyl-3-(quinolin-6-ylmethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-amine (<b>18A</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 305 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (dd, <i>J</i> = 4.28, 1.76 Hz, 1H), 8.28–8.37 (m, 1H), 8.00 (d, <i>J</i> = 10.07 Hz, 1H), 7.87–7.97 (m, 2H), 7.76 (dd, <i>J</i> = 8.81, 2.01 Hz, 1H), 7.50 (dd, <i>J</i> = 8.31, 4.28 Hz, 1H), 7.21 (d, <i>J</i> = 10.32 Hz, 1H), 4.57 (s, 2 H), 3.07 (s, 6 H); HPLC purity (method A) RT 4.691, 96.3%.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>S</i>)-<i>N</i>-Isopropyl-3-(1-(quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-amine (<b>28C</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 333 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.78–8.86 (m, 1H), 8.30 (d, <i>J</i> = 8.34 Hz, 1H), 7.93 (d, <i>J</i> = 8.84 Hz, 1H), 7.87 (s, 1H), 7.82 (d, <i>J</i> = 9.85 Hz, 1H), 7.70 (d, <i>J</i> = 8.59 Hz, 1H), 7.48 (dd, <i>J</i> = 4.29, 8.34 Hz, 1H), 7.12 (d, <i>J</i> = 6.82 Hz, 1H), 6.65 (d, <i>J</i> = 9.85 Hz, 1H), 4.80 (d, <i>J</i> = 7.33 Hz, 1H), 3.76 (d, <i>J</i> = 6.57 Hz, 1H), 1.85 (d, <i>J</i> = 7.33 Hz, 3H), 1.15 (d, <i>J</i> = 6.57 Hz, 3H), 0.93 (d, <i>J</i> = 6.32 Hz, 3H); HPLC purity (method A) RT 5.947, >99%.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>S</i>)-3-(1-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin-3-yl)ethyl)-<i>N</i>-ethyl-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-amine (<b>29F</b>)</h4><div class="NLM_p last">LC-MS <i>m</i>/<i>z</i> 308 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.44 (s, 1H), 8.14 (dd, <i>J</i> = 4.71, 1.51 Hz, 1H), 7.88 (dd, <i>J</i> = 7.91, 1.13 Hz, 1H), 7.81 (d, <i>J</i> = 9.80 Hz, 1H), 7.38 (d, <i>J</i> = 2.26 Hz, 1H), 7.27 (t, <i>J</i> = 5.18 Hz, 1H), 6.96 (dd, <i>J</i> = 7.82, 4.62 Hz, 1H), 6.68 (d, <i>J</i> = 9.80 Hz, 1H), 4.79–4.93 (m, <i>J</i> = 7.35 Hz, 1H), 3.13–3.26 (m, 2H), 1.84 (d, <i>J</i> = 7.16 Hz, 3H), 1.13 (t, <i>J</i> = 7.16 Hz, 3H); HPLC purity (method A) RT 5.080, >95%.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Biochemical Kinase Assays</h3><div class="NLM_p last">c-Met enzyme inhibition was measured by continuous coupled spectrophotometric assay as previously described.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The assay monitored ATP consumption coupled to oxidation of NADH (measured at 340 nm) while regenerating ATP in the presence of phosphoenol pyruvate (PEP) and coupling enzymes, pyruvate kinase (PK) and lactic dehydrogenase (LDH). Assay reactions contained 0.30 mM ATP (4<i>K</i><sub>m</sub>), 0.5 mM Met2 peptide (Ac-ARDMYDKEYYSVHNK), 20 mM MgCl<sub>2</sub>, 1 mM PEP, 330 μM NADH, 2 mM DTT, 15 units/mL LDH, 15 units/mL PK, and test compound (1% DMSO final) in 100 mM HEPES, pH 7.5, 37 °C, and the reactions were initiated by adding 50 nM c-Met N-terminal His6-tagged recombinant human enzyme, aa residues 974–1390 (Millipore Corp./Upstate Ltd., Billerica, MA). The inhibitors were shown to be ATP-competitive from kinetic and crystallographic studies, and the dose–response data were fit to the equation for competitive inhibition by the method of nonlinear least-squares (GraphPad Prism, GraphPad Software, San Diego, CA).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Cellular Kinase Phosphorylation ELISA Assays<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h3><div class="NLM_p last">All experiments were done under standard conditions (37 °C and 5% CO<sub>2</sub>). IC<sub>50</sub> values were calculated by concentration–response curve fitting using a Microsoft Excel-based four-parameter method. Cells were seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors were added for up to 20 min. After incubation of cells with an inhibitor for 1 h or appropriate ligands for the designated times, cells were washed once with HBSS supplemented with 1 mmol/L Na<sub>3</sub>VO<sub>4</sub>, and protein lysates were generated from cells. Subsequently, phosphorylation of selected protein kinases was assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates were (a) incubated in the presence of protein lysates at 4 °C overnight, (b) washed seven times in 1% Tween 20 in PBS, (c) incubated in a horseradish peroxidase-conjugated anti-total-phosphotyrosine (PY-20) antibody (1:500) for 30 min, (d) washed seven times again, (e) incubated in 3,3,5,5-tetramethylbenzidine peroxidase substrate (Bio-Rad) to initiate a colorimetric reaction that was stopped by adding 0.09 N H<sub>2</sub>SO<sub>4</sub>, and (f) measured for absorbance in 450 nm using a spectrophotometer. A549 cell line was used for c-Met cellular kinase phosphorylation ELISA assay.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>In Vivo</i> Subcutaneous Xenograft Models in Athymic Mice<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h3><div class="NLM_p last">Female nu/nu mice were obtained from Charles River. Animals, maintained under clean room conditions in sterile filter top cages with Alpha-Dri bedding, and housed on high-efficiency particulate air (HEPA)-filtered ventilated racks. Animals received sterile rodent chow and water ad libitum. All of the procedures were conducted in accordance with the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals and with Pfizer Animal Care and Use Committee guidelines. Tumor cells were implanted subcutaneously into the right flank region of each mouse and allowed to grow to the designated size. The athymic mice bearing established tumors were administered <b>8</b> by oral gavage in 0.5% methylcellulose suspension or 0.5% methylcellulose solution for the control group. Tumor volume was measured using electronic digital calipers. Percent (%) inhibition values were calculated as 100 × {1 – [(treated-final day – treated-day 1)/(control-final day – control-day 1)]}. Tumor volumes were analyzed using one-way ANOVA. At the end of study, mice were humanely euthanized, and tumors were resected. Proteins were extracted from the tumor samples, and protein concentrations were determined using a BSA assay (Pierce). The level of proteins of interest in the tumor sample was determined using a capture ELISA method or immunoblotting.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Human Microsomal Stability Studies</h3><div class="NLM_p last">Compounds (1 μM) were incubated at 37 °C for 30 min in a final volume of 200 μL of 100 mM potassium phosphate buffer (pH 7.4) containing pooled human liver microsomes (0.8 mg/mL protein) and 2 mM NADPH. Reactions were initiated with the addition of NADPH following a 10-min preincubation. Aliquots of incubation samples were protein precipitated with cold methanol containing 0.1 μM buspirone (internal standard) and centrifuged, and supernatants were analyzed by LC-MS/MS. All incubations were performed in triplicate and % remaining of parent drug at the end of incubation was determined by LC-MS/MS peak area ratio.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Cocrystal Structures</h3><div class="NLM_p last">c-Met cocrystals were obtained at 13 °C by the hanging drop vapor diffusion method by mixing 1.2 μL of protein solution (containing 7–13 mg/mL c-Met KD (residues 1051–1348) with a 5-fold molar excess of selected c-Met inhibitor) with 1.2 μL of solution containing (0.05 M citrate–phosphate, pH 4.6, 0–0.275 M NaCl, and 21% poly(ethylene glycol), MW = 3350). Details of the crystal structure determinations can be accessed from the PDB database.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60"><a href="/doi/suppl/10.1021/jm400926x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26374" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26374" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Metabolite profile of <b>8F</b> in human liver microsomes and profiles of <b>8</b> and <b>9</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400926x/suppl_file/jm400926x_si_001.pdf">jm400926x_si_001.pdf (145.59 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB accession codes are unphosphorylated c-Met kinase domain with <b>7</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zbx">3zbx</a>), <b>8</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5">3zc5</a>), <b>9</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz">3zxz</a>), and <b>28F</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zcl">3zcl</a>).</p><div class="testing" data-doi="10.1021/jm400926x" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01877" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01877" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Jean Cui</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cea4abafa0e0adbba78ebea8a7b4abbce0ada1a3"><span class="__cf_email__" data-cfemail="84eee1e5eaaae7f1edc4f4e2edfee1f6aae7ebe9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shen</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Tran-Dubé</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mitchell Nambu</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele McTigue</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil Grodsky</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Ryan</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shinji Yamazaki</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shirley Aguirre</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Max Parker</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiuhua Li</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen Zou</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Christensen</span> - <span class="hlFld-Affiliation affiliation">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1237e4609-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34035" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34035" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Dr. Brion Murray’s critical reading and suggestions on writing, Muhammad Alimuddin for analytical support, Pfizer PDM department for <i>in vitro</i> ADME and <i>in vivo</i> pharmacokinetic studies, and Pfizer DSRD department for <i>in vitro</i> and <i>in vivo</i> toxicity studies.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i63" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i63"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i64" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i64"> Abbreviations</h2><tr><td class="NLM_term">A-loop</td><td class="NLM_def"><p class="first last">activation loop</p></td></tr><tr><td class="NLM_term">BCR-ABL</td><td class="NLM_def"><p class="first last">breakpoint cluster region-abelson</p></td></tr><tr><td class="NLM_term">BZD</td><td class="NLM_def"><p class="first last">benzodiazepine</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term">GABA A</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid A receptor</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>N</i>-[(dimethylamino)-1<i>H</i>-1,2,3-triazolo-[4,5-<i>b</i>]pyridin-1-ylmethylene]-<i>N</i>-methylmethanaminium hexafluorophosphate <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">HGF</td><td class="NLM_def"><p class="first last">hepatocyte growth factor</p></td></tr><tr><td class="NLM_term">HGFR</td><td class="NLM_def"><p class="first last">hepatocyte growth factor receptor</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase domain</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">NCE</td><td class="NLM_def"><p class="first last">new chemical entity</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">Pd(dppf)Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">[1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium(II)</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once daily</p></td></tr><tr><td class="NLM_term">R&D</td><td class="NLM_def"><p class="first last">research and development</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SF</td><td class="NLM_def"><p class="first last">scatter factor</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">VHL</td><td class="NLM_def"><p class="first last">von Hippel-Lindau</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70044" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70044" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Boccaccio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Invasive growth: A Met-driven generic programme for cancer and stem cells</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">–</span> <span class="NLM_lpage">645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnrc1912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=16862193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFGlu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=637-645&author=C.+Boccaccioauthor=P.+M.+Comoglio&title=Invasive+growth%3A+A+Met-driven+generic+programme+for+cancer+and+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Invasive growth: a MET-driven genetic programme for cancer and stem cells</span></div><div class="casAuthors">Boccaccio, Carla; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metastasis follows the inappropriate activation of a genetic program termed invasive growth, which is a physiol. process that occurs during embryonic development and post-natal organ regeneration.  Burgeoning evidence indicates that invasive growth is also executed by stem and progenitor cells, and is usurped by cancer stem cells.  The MET proto-oncogene, which is expressed in both stem and cancer cells, is a key regulator of invasive growth.  Recent findings indicate that the MET tyrosine-kinase receptor is a sensor of adverse microenvironmental conditions (such as hypoxia) and drives cell invasion and metastasis through the transcriptional activation of a set of genes that control blood coagulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNb2dfp5v27Vg90H21EOLACvtfcHk0lh1wImUzZN-dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFGlu70%253D&md5=79319c46d57d395726d389e6cd03068f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1912%26sid%3Dliteratum%253Aachs%26aulast%3DBoccaccio%26aufirst%3DC.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DInvasive%2520growth%253A%2520A%2520Met-driven%2520generic%2520programme%2520for%2520cancer%2520and%2520stem%2520cells%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D637%26epage%3D645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Knudsen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span> </span><span class="NLM_article-title">Showering c-MET-dependent cancers with drugs</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1016%2Fj.gde.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=18406132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-96&author=B.+S.+Knudsenauthor=G.+Vande+Woude&title=Showering+c-MET-dependent+cancers+with+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Showering c-MET-dependent cancers with drugs</span></div><div class="casAuthors">Knudsen, Beatrice S.; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies.  Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors (http://www.vai.org/met), contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and HGF/SF participate in all stages of malignant progression and represent promising drug targets in a variety of cancer types, including carcinomas, sarcomas, and brain tumors.  While many are in pre-clin. testing, a few inhibitors have entered clin. trials.  With hundreds of thousands of potential responding cancers that express c-MET, the interest in this mol. as a drug target is not surprising.  However, the cognate c-MET diagnostic tests lag behind.  In addn., despite the great enthusiasm based on response rates in phase I trials, there is a need for caution.  It is almost without question that combination therapies with c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic tumor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjBq7fWvKhrVg90H21EOLACvtfcHk0lh1wImUzZN-dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D&md5=d0744275be94658bab067f20644c98d6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DB.%2BS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DShowering%2520c-MET-dependent%2520cancers%2520with%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKinnon, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramnath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Expression and mutational analysis of <i>MET</i> in human solid cancers</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1025</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1002%2Fgcc.20604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=18709663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1025-1037&author=P.+C.+Maauthor=M.+S.+Tretiakovaauthor=A.+C.+MacKinnonauthor=N.+Ramnathauthor=C.+Johnsonauthor=S.+Dietrichauthor=T.+Seiwertauthor=J.+G.+Christensenauthor=R.+Jagadeeswaranauthor=T.+Krauszauthor=E.+E.+Vokesauthor=A.+N.+Husainauthor=R.+Salgia&title=Expression+and+mutational+analysis+of+MET+in+human+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and mutational analysis of MET in human solid cancers</span></div><div class="casAuthors">Ma, Patrick C.; Tretiakova, Maria S.; MacKinnon, Alexander C.; Ramnath, Nithya; Johnson, Candace; Dietrich, Sascha; Seiwert, Tanguy; Christensen, James G.; Jagadeeswaran, Ramasamy; Krausz, Thomas; Vokes, Everett E.; Husain, Aliya N.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1025-1037</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) regulate a variety of cellular functions, many of which can be dysregulated in human cancers.  Activated MET signaling can lead to cell motility and scattering, angiogenesis, proliferation, branching morphogenesis, invasion, and eventual metastasis.  We performed systematic anal. of the expression of the MET receptor and its ligand HGF in tumor tissue microarrays (TMA) from human solid cancers.  Std. immunohistochem. (IHC) and a computerized automated scoring system were used.  DNA sequencing for MET mutations in both nonkinase and kinase domains was also performed.  MET was differentially overexpressed in human solid cancers.  The ligand HGF was widely expressed in both tumors, primarily intratumoral, and nonmalignant tissues.  The MET/HGF likely is functional and may be activated in autocrine fashion in vivo.  MET and stem cell factor (SCF) were found to be pos. stained in the bronchioalevolar junctions of lung tumors.  A no. of novel mutations of MET were identified, particularly in the extracellular semaphorin domain and the juxtamembrane domain.  MET-HGF pathway can be assayed in TMAs and is often overexpressed in a wide variety of human solid cancers.  MET can be activated through overexpression, mutation, or autocrine signaling in malignant cells.  Mutations in the nonkinase regions of MET might play an important role in tumorigenesis and tumor progression.  MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnenTNgIcAbVg90H21EOLACvtfcHk0lg5BNNOTurpzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE&md5=cf53884177f20939300673fb034ac91f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fgcc.20604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.20604%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DMacKinnon%26aufirst%3DA.%2BC.%26aulast%3DRamnath%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DDietrich%26aufirst%3DS.%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DExpression%2520and%2520mutational%2520analysis%2520of%2520MET%2520in%2520human%2520solid%2520cancers%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2008%26volume%3D47%26spage%3D1025%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET amplication leads to Gefitinib resistance in lung cancer by activating ERBB signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+amplication+leads+to+Gefitinib+resistance+in+lung+cancer+by+activating+ERBB+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplication%2520leads%2520to%2520Gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Wilson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridlyand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penuel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=505-509&author=T.+R.+Wilsonauthor=J.+Fridlyandauthor=Y.+Yanauthor=E.+Penuelauthor=L.+Burtonauthor=E.+Chanauthor=J.+Pengauthor=E.+Linauthor=Y.+Wangauthor=J.+Sosmanauthor=A.+Ribasauthor=J.+Liauthor=J.+Moffatauthor=D.+P.+Sutherlinauthor=H.+Koeppenauthor=M.+Merchantauthor=R.+Neveauthor=J.+Settleman&title=Widespread+potential+for+growth-factor-driven+resistance+to+anticancer+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DFridlyand%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DNeve%26aufirst%3DR.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DWidespread%2520potential%2520for%2520growth-factor-driven%2520resistance%2520to%2520anticancer%2520kinase%2520inhibitors%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D505%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Straussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barzily-Rokni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mongare, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span> </span><span class="NLM_article-title">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnature11183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22763439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=500-504&author=R.+Straussmanauthor=T.+Morikawaauthor=K.+Sheeauthor=M.+Barzily-Rokniauthor=Z.+R.+Qianauthor=J.+Duauthor=A.+Davisauthor=M.+M.+Mongareauthor=J.+Gouldauthor=D.+T.+Frederickauthor=Z.+A.+Cooperauthor=P.+B.+Chapmanauthor=D.+B.+Solitauthor=A.+Ribasauthor=R.+S.+Loauthor=K.+T.+Flahertyauthor=S.+Oginoauthor=J.+A.+Wargoauthor=T.+R.+Golub&title=Tumour+micro-environment+elicits+innate+resistance+to+RAF+inhibitors+through+HGF+secretion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span></div><div class="casAuthors">Straussman, Ravid; Morikawa, Teppei; Shee, Kevin; Barzily-Rokni, Michal; Qian, Zhi Rong; Du, Jinyan; Davis, Ashli; Mongare, Margaret M.; Gould, Joshua; Frederick, Dennie T.; Cooper, Zachary A.; Chapman, Paul B.; Solit, David B.; Ribas, Antoni; Lo, Roger S.; Flaherty, Keith T.; Ogino, Shuji; Wargo, Jennifer A.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">500-504</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drug resistance presents a challenge to the treatment of cancer patients.  Many studies have focused on cell-autonomous mechanisms of drug resistance.  By contrast, the authors proposed that the tumor micro-environment confers innate resistance to therapy.  Here the authors developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs.  The authors found that stroma-mediated resistance is common, particularly to targeted agents.  The authors characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance.  Proteomic anal. showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signaling pathways, and immediate resistance to RAF inhibition.  Immunohistochem. expts. confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment.  Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma.  A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines.  More generally, this study indicates that the systematic dissection of interactions between tumors and their micro-environment can uncover important mechanisms underlying drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwanlhJUTP4LVg90H21EOLACvtfcHk0lipKN6qi1lCZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J&md5=0616b5feed3c5dc2a53ee2ee382a6c33</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11183%26sid%3Dliteratum%253Aachs%26aulast%3DStraussman%26aufirst%3DR.%26aulast%3DMorikawa%26aufirst%3DT.%26aulast%3DShee%26aufirst%3DK.%26aulast%3DBarzily-Rokni%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DZ.%2BR.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DMongare%26aufirst%3DM.%2BM.%26aulast%3DGould%26aufirst%3DJ.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DTumour%2520micro-environment%2520elicits%2520innate%2520resistance%2520to%2520RAF%2520inhibitors%2520through%2520HGF%2520secretion%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D500%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">HGF/c-MET targeted therapeutics: Novel strategies for cancer medicine</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2058</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.2174%2F138945011798829348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=21777195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=2045-2058&author=T.+A.+Yapauthor=S.+K.+Sandhuauthor=S.+M.+Alamauthor=J.+S.+de+Bono&title=HGF%2Fc-MET+targeted+therapeutics%3A+Novel+strategies+for+cancer+medicine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">HGF/c-MET targeted therapeutics: novel strategies for cancer medicine</span></div><div class="casAuthors">Yap, Timothy A.; Sandhu, Shahneen K.; Alam, Salma M.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2045-2058</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/c-MET) receptor tyrosine kinase (RTK) pathway plays a pleotropic role in cell proliferation, migration, invasion, angiogenesis and survival.  Although it has crit. physiol. functions in embryonic development and tissue repair, this signaling cascade is frequently deregulated in a wide range of tumors.  Aberrant HGF/c-MET signaling, driven by various mechanisms, including constitutive activation and over-expression, has multifunctional effects in oncogenesis and is implicated in the acquisition of an aggressive phenotype with metastatic potential.  The central role of c-MET activity in cancer progression, as well as disparities between quiescent HGF/c-MET signaling in normal tissue and overexpression in tumor may provide a degree of tumor selectivity for therapeutic intervention, making HGF or c-MET inhibition an attractive proposition in oncol.  This review focuses on the underlying oncogenic role of aberrant HGF/c-MET signaling in malignant progression, as well as recent preclin. and clin. data on the different strategies employed in inhibiting HGF/c-MET function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeZy3Mk8Qz8LVg90H21EOLACvtfcHk0lipKN6qi1lCZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFyisQ%253D%253D&md5=cef2aa1557af1928b2fa176363455356</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F138945011798829348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011798829348%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3DAlam%26aufirst%3DS.%2BM.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DHGF%252Fc-MET%2520targeted%2520therapeutics%253A%2520Novel%2520strategies%2520for%2520cancer%2520medicine%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D2045%26epage%3D2058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Tuma, R. S.</span><span> </span><span class="NLM_article-title">Novel antibody, rilotumumab (AMG 102) shows activity in metastatic colorectal cancer patients</span> <span class="citation_source-journal">Oncol. Times</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=22-23&author=R.+S.+Tuma&title=Novel+antibody%2C+rilotumumab+%28AMG+102%29+shows+activity+in+metastatic+colorectal+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DNovel%2520antibody%252C%2520rilotumumab%2520%2528AMG%2520102%2529%2520shows%2520activity%2520in%2520metastatic%2520colorectal%2520cancer%2520patients%26jtitle%3DOncol.%2520Times%26date%3D2011%26volume%3D33%26spage%3D22%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Surati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of MetMAb (OA-5D5) in c-MET active lung malignancies</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1517%2F14712598.2011.626762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22047509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVags7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1655-1662&author=M.+Suratiauthor=P.+Patelauthor=A.+Petersonauthor=R.+Salgia&title=Role+of+MetMAb+%28OA-5D5%29+in+c-MET+active+lung+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of MetMAb (OA-5D5) in c-MET active lung malignancies</span></div><div class="casAuthors">Surati, Mosmi; Patel, Premal; Peterson, Amy; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1655-1662</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: MetMAb (OA-5D5) is a one-armed monoclonal antibody developed to bind to and inhibit c-MET receptor tyrosine kinase.  Though only in early clin. testing, this agent holds great promise in diseases thought to be driven by c-MET activation, as evidenced by the Phase II results in NSCLC where a benefit in overall survival was obsd. in patients with MET-diagnostic-pos. disease.  Thus far, both alone and in combination with other targeted agents, this drug has been well tolerated and no new significant safety signals have been identified.  Areas covered: This review summarizes the structure and function of the c-MET receptor and its ligand hepatic growth factor (HGF), provides an overview of select targeted monotherapies developed to interfere in the MET-HGF signaling pathway, discusses pre-clin. and clin. data surrounding MetMAb, and concludes with an expert opinion regarding this novel agent.  Expert opinion: MetMAb has been well tolerated and based on Phase II data testing it, in combination with erlotinib in advanced NSCLC, may have a role in improving survival in patients with disease driven by c-MET activation.  However, Phase III validation is underway and the results of these studies will help elucidate which patients will benefit most from this novel agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNNaynTSW2ErVg90H21EOLACvtfcHk0lgmpdHyqOElrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVags7%252FN&md5=78a25ac9a8b03aa9e3113776d40854e2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.626762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.626762%26sid%3Dliteratum%253Aachs%26aulast%3DSurati%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520MetMAb%2520%2528OA-5D5%2529%2520in%2520c-MET%2520active%2520lung%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D1655%26epage%3D1662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lgmpdHyqOElrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span> <span class="citation_source-journal">Mol Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2298</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0lgmpdHyqOElrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leggett, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. J.</span><span> </span><span class="NLM_article-title">ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.+R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+novel+and+selective+inhibitor+of+the+human+c-Met+receptor+tyrosine+kinase+with+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0lg_wvXmcjDf1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BR.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520the%2520human%2520c-Met%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Peters, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">MET: A promising anticancer therapeutic target</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnrclinonc.2012.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=314-326&author=S.+Petersauthor=A.+A.+Adjei&title=MET%3A+A+promising+anticancer+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">MET: a promising anticancer therapeutic target</span></div><div class="casAuthors">Peters, Solange; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">314-326</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Targeting the MET pathway is an increasingly attractive anticancer strategy.  In this Review, this pathway is viewed from the clin. perspective, assessing the available agents in terms of efficacy and toxicity and looking forward to biomarker-driven application in the clinic.  The MET pathway is dysregulated in many human cancers and promotes tumor growth, invasion and dissemination.  Abnormalities in MET signalling have been reported to correlate with poor clin. outcomes and drug resistance in patients with cancer.  Thus, MET has emerged as an attractive target for cancer therapy.  Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clin. trials.  In general, initial results from these studies indicate only a modest benefit in unselected populations.  In this Review, we discuss current challenges in developing MET inhibitors-including identification of predictive biomarkers-as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1VV_hiW_CLVg90H21EOLACvtfcHk0lg_wvXmcjDf1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOrtL0%253D&md5=db84521545ee290e245a5b541b103ff1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.71%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DMET%253A%2520A%2520promising%2520anticancer%2520therapeutic%2520target%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D314%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Spigel, D. R.; Ervin, T. J.; Ramlau, R.; Daniel, D. B.; Goldschmidt, J. H.; Blumenschein, G. R.; Krzakowski, M. J.; Robinet, G.; Clement-Duchene, C.; Barlesi, F.; Govindan, R.; Patel, T.; Orlov, S. V.; Wertheim, M. S.; Zha, J.; Pandita, A.; Yu, W.; Yauch, R. L.; Patel, P. H.; Peterson, A. C.</span><span> </span><span class="NLM_article-title">Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>Abstr. 7505.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+R.+Spigel&author=T.+J.+Ervin&author=R.+Ramlau&author=D.+B.+Daniel&author=J.+H.+Goldschmidt&author=G.+R.+Blumenschein&author=M.+J.+Krzakowski&author=G.+Robinet&author=C.+Clement-Duchene&author=F.+Barlesi&author=R.+Govindan&author=T.+Patel&author=S.+V.+Orlov&author=M.+S.+Wertheim&author=J.+Zha&author=A.+Pandita&author=W.+Yu&author=R.+L.+Yauch&author=P.+H.+Patel&author=A.+C.+Peterson&title=Final+efficacy+results+from+OAM4558g%2C+a+randomized+phase+II+study+evaluating+MetMAb+or+placebo+in+combination+with+erlotinib+in+advanced+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DFinal%2520efficacy%2520results%2520from%2520OAM4558g%252C%2520a%2520randomized%2520phase%2520II%2520study%2520evaluating%2520MetMAb%2520or%2520placebo%2520in%2520combination%2520with%2520erlotinib%2520in%2520advanced%2520NSCLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1097%2FJTO.0b013e31821528d3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=21623265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=942-946&author=S.-H.+I.+Ouauthor=E.+L.+Kwakauthor=C.+Siwak-Tappauthor=J.+Dyauthor=K.+Bergethonauthor=J.+W.+Clarkauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=R.+G.+Makiauthor=Y.-J.+Bangauthor=D.-W.+Kimauthor=J.+Christensenauthor=W.+Tanauthor=K.+D.+Wilnerauthor=R.+Salgiaauthor=A.+J.+Iafrate&title=Activity+of+crizotinib+%28PF02341066%29%2C+a+dual+mesenchymal-epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor%2C+in+a+non-small+cell+lung+cancer+patient+with+de+novo+MET+amplification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Kwak Eunice L; Siwak-Tapp Christina; Dy Joni; Bergethon Kristin; Clark Jeffrey W; Camidge D Ross; Solomon Benjamin J; Maki Robert G; Bang Yung-Jue; Kim Dong-Wan; Christensen James; Tan Weiwei; Wilner Keith D; Salgia Ravi; Iafrate A John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is a dual MET and ALK inhibitor.  Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC).  Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1REpDHXMT37jnyZkbE8yXfW6udTcc2ebSsl_vRESf9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D&md5=920657051f20d097e6cd1d83b0aa7e10</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31821528d3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31821528d3%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DDy%26aufirst%3DJ.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DActivity%2520of%2520crizotinib%2520%2528PF02341066%2529%252C%2520a%2520dual%2520mesenchymal-epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%252C%2520in%2520a%2520non-small%2520cell%2520lung%2520cancer%2520patient%2520with%2520de%2520novo%2520MET%2520amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8091</span><span class="NLM_x">–</span> <span class="NLM_lpage">8109</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300967g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8091-8109&author=J.+J.+Cuiauthor=M.+McTigueauthor=M.+Nambuauthor=M.+Tran-Dub%C3%A9author=M.+Pairishauthor=H.+Shenauthor=L.+Jiaauthor=H.+Chengauthor=J.+Hoffmanauthor=P.+Leauthor=M.+Jalaieauthor=G.+H.+Goetzauthor=K.+Ryanauthor=N.+Grodskyauthor=Y.+L.+Dengauthor=M.+Parkerauthor=S.+Timofeevskiauthor=B.+W.+Murrayauthor=S.+Yamazakiauthor=S.+Aguirreauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Discovery+of+a+novel+class+of+exquisitely+selective+mesenchymal-epithelial+transition+factor+%28c-MET%29+protein+kinase+inhibitors+and+identification+of+the+clinical+candidate+2-%284-%281-%28quinolin-6-ylmethyl%29-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-b%5Dpyrazin-6-yl%29-1H-pyrazol-1-yl%29ethanol+%28PF-04217903%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300967g%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%2BH.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520exquisitely%2520selective%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520protein%2520kinase%2520inhibitors%2520and%2520identification%2520of%2520the%2520clinical%2520candidate%25202-%25284-%25281-%2528quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2520%2528PF-04217903%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8091%26epage%3D8109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Koenig, M.; Cui, J.; Wei, C. C.; Do, S. H.; Zhang, F.-J.; Vojkovsky, T.; Ramphal, J.; Yang, G.; Mattson, M.; Nelson, C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Indolinone hydrazides as c-met inhibitors</span>. PCT Int. Appl. WO2005005378,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Koenig&author=J.+Cui&author=C.+C.+Wei&author=S.+H.+Do&author=F.-J.+Zhang&author=T.+Vojkovsky&author=J.+Ramphal&author=G.+Yang&author=M.+Mattson&author=C.+Nelson&author=P.+C.+Tang&title=Indolinone+hydrazides+as+c-met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoenig%26aufirst%3DM.%26atitle%3DIndolinone%2520hydrazides%2520as%2520c-met%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="note"><p class="first last">The first cocrystal structure of an analogue of <b>2</b> with c-Met kinase domain proving the unusual binding mode for exquisite c-MET kinase selectivity was obtained by Nikolaus Schiering and Cinzia Cristiani at legacy Pharmacia in 2002 and was not deposited in PDB.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Vojkovsky, T.; Koenig, M.; Zhang, F.-J.; Cui, J.</span><span> </span><span class="NLM_article-title">Tetracyclic compounds as c-Met inhibitors</span>. PCT Int. Appl. WO2005004808,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Vojkovsky&author=M.+Koenig&author=F.-J.+Zhang&author=J.+Cui&title=Tetracyclic+compounds+as+c-Met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVojkovsky%26aufirst%3DT.%26atitle%3DTetracyclic%2520compounds%2520as%2520c-Met%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Zhang, F.-J.; Vojkovsky, T.; Huang, P.; Liang, C.; Do, S. H.; Koenig, M.; Cui, J.</span><span> </span><span class="NLM_article-title">Preparation of triazolotriazines as c-Met modulators for treating cancer</span>. PCT Int. Appl. WO2005010005,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=F.-J.+Zhang&author=T.+Vojkovsky&author=P.+Huang&author=C.+Liang&author=S.+H.+Do&author=M.+Koenig&author=J.+Cui&title=Preparation+of+triazolotriazines+as+c-Met+modulators+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.-J.%26atitle%3DPreparation%2520of%2520triazolotriazines%2520as%2520c-Met%2520modulators%2520for%2520treating%2520cancer%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Cui, J.; Botrous, I.</span><span> </span><span class="NLM_article-title">Arylmethyl triazolo and imidazopyrazines as c-MET inhibitors</span>. PCT Int. Appl. WO2005004607,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+Cui&author=I.+Botrous&title=Arylmethyl+triazolo+and+imidazopyrazines+as+c-MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DArylmethyl%2520triazolo%2520and%2520imidazopyrazines%2520as%2520c-MET%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bounaud, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huser, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felce, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froning, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterman, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubol, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessert, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwinn, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leon, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emtage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burley, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, S. H.</span><span> </span><span class="NLM_article-title">SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3181</span><span class="NLM_x">–</span> <span class="NLM_lpage">3190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1535-7163.MCT-09-0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=19934279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3181-3190&author=S.+G.+Buchananauthor=J.+Hendleauthor=P.+S.+Leeauthor=C.+R.+Smithauthor=P.+Y.+Bounaudauthor=K.+A.+Jessenauthor=C.+M.+Tangauthor=N.+H.+Huserauthor=J.+D.+Felceauthor=K.+J.+Froningauthor=M.+C.+Petermanauthor=B.+E.+Aubolauthor=S.+F.+Gessertauthor=J.+M.+Sauderauthor=K.+D.+Schwinnauthor=M.+Russellauthor=I.+A.+Rooneyauthor=J.+Adamsauthor=B.+C.+Leonauthor=T.+H.+Doauthor=J.+M.+Blaneyauthor=P.+A.+Sprengelerauthor=D.+A.+Thompsonauthor=L.+Smythauthor=L.+A.+Pelletierauthor=S.+Atwellauthor=K.+Holmeauthor=S.+R.+Wassermanauthor=S.+Emtageauthor=S.+K.+Burleyauthor=S.+H.+Reich&title=SGX523+is+an+exquisitely+selective%2C+ATP-competitive+inhibitor+of+the+MET+receptor+tyrosine+kinase+with+antitumor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo</span></div><div class="casAuthors">Buchanan, Sean G.; Hendle, Jorg; Lee, Patrick S.; Smith, Christopher R.; Bounaud, Pierre-Yves; Jessen, Katti A.; Tang, Crystal M.; Huser, Nanni H.; Felce, Jeremy D.; Froning, Karen J.; Peterman, Marshall C.; Aubol, Brandon E.; Gessert, Steve F.; Sauder, J. Michael; Schwinn, Kenneth D.; Russell, Marijane; Rooney, Isabelle A.; Adams, Jason; Leon, Barbara C.; Do, Tuan H.; Blaney, Jeff M.; Sprengeler, Paul A.; Thompson, Devon A.; Smyth, Lydia; Pelletier, Laura A.; Atwell, Shane; Holme, Kevin; Wasserman, Stephen R.; Emtage, Spencer; Burley, Stephen K.; Reich, Siegfried H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3181-3190</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics.  Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers.  In other cancers, such as glioblastoma, autocrine activation of MET has been demonstrated.  Several classes of ATP-competitive inhibitor have been described, which inhibit MET but also other kinases.  Here, we describe SGX523, a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET.  SGX523 potently inhibited MET with an IC50 of 4 nmol/L and is >1000-fold selective vs. the >200-fold selectivity of other protein kinases tested in biochem. assays.  Crystallog. study revealed that SGX523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for the selectivity.  SGX523 inhibited MET-mediated signaling, cell proliferation, and cell migration at nanomolar concns. but had no effect on signaling dependent on other protein kinases, including the closely related RON, even at micromolar concns.  SGX523 inhibition of MET in vivo was assocd. with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers, confirming the dependence of these tumors on MET catalytic activity.  Our results show that SGX523 is the most selective inhibitor of MET catalytic activity described to date and is thus a useful tool to investigate the role of MET kinase in cancer without the confounding effects of promiscuous protein kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplt9w6z--VQ7Vg90H21EOLACvtfcHk0lgqndrO1WO5sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbzI&md5=7410ae811f0bf2d3298691ed34d35878</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0477%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DHendle%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DBounaud%26aufirst%3DP.%2BY.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DTang%26aufirst%3DC.%2BM.%26aulast%3DHuser%26aufirst%3DN.%2BH.%26aulast%3DFelce%26aufirst%3DJ.%2BD.%26aulast%3DFroning%26aufirst%3DK.%2BJ.%26aulast%3DPeterman%26aufirst%3DM.%2BC.%26aulast%3DAubol%26aufirst%3DB.%2BE.%26aulast%3DGessert%26aufirst%3DS.%2BF.%26aulast%3DSauder%26aufirst%3DJ.%2BM.%26aulast%3DSchwinn%26aufirst%3DK.%2BD.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DRooney%26aufirst%3DI.%2BA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DLeon%26aufirst%3DB.%2BC.%26aulast%3DDo%26aufirst%3DT.%2BH.%26aulast%3DBlaney%26aufirst%3DJ.%2BM.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DSmyth%26aufirst%3DL.%26aulast%3DPelletier%26aufirst%3DL.%2BA.%26aulast%3DAtwell%26aufirst%3DS.%26aulast%3DHolme%26aufirst%3DK.%26aulast%3DWasserman%26aufirst%3DS.%2BR.%26aulast%3DEmtage%26aufirst%3DS.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DReich%26aufirst%3DS.%2BH.%26atitle%3DSGX523%2520is%2520an%2520exquisitely%2520selective%252C%2520ATP-competitive%2520inhibitor%2520of%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther%26date%3D2009%26volume%3D8%26spage%3D3181%26epage%3D3190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Perera, T.; Lavrijssen, T.; Janssens, B.; Geerts, T.; King, P.; Mevellec, L.; Cummings, M. D.; Lu, T.; Johnson, D.; Page, M.</span><span> </span><span class="NLM_article-title">JNJ-38877605: A selective Met kinase inhibitor inducing regression of Met-driven tumor models</span>. Presented at the 99th AACR Annual Meeting,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">, </span>Apr 12–16, San Diego (CA), Abstr 4837.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+Perera&author=T.+Lavrijssen&author=B.+Janssens&author=T.+Geerts&author=P.+King&author=L.+Mevellec&author=M.+D.+Cummings&author=T.+Lu&author=D.+Johnson&author=M.+Page&title=JNJ-38877605%3A+A+selective+Met+kinase+inhibitor+inducing+regression+of+Met-driven+tumor+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%26atitle%3DJNJ-38877605%253A%2520A%2520selective%2520Met%2520kinase%2520inhibitor%2520inducing%2520regression%2520of%2520Met-driven%2520tumor%2520models%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marando, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblish, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behshad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span> </span><span class="NLM_article-title">A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7127</span><span class="NLM_x">–</span> <span class="NLM_lpage">7138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1078-0432.CCR-11-1157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=21918175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7127-7138&author=X.+Liuauthor=Q.+Wangauthor=G.+Yangauthor=C.+Marandoauthor=H.+K.+Koblishauthor=L.+M.+Hallauthor=J.+S.+Fridmanauthor=E.+Behshadauthor=R.+Wynnauthor=Y.+Liauthor=J.+Boerauthor=S.+Diamondauthor=C.+Heauthor=M.+Xuauthor=J.+Zhuoauthor=W.+Yaoauthor=R.+C.+Newtonauthor=P.+A.+Scherle&title=A+novel+kinase+inhibitor%2C+INCB28060%2C+blocks+c-MET-dependent+signaling%2C+neoplastic+activities%2C+and+cross-talk+with+EGFR+and+HER-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3</span></div><div class="casAuthors">Liu, Xiangdong; Wang, Qian; Yang, Gengjie; Marando, Cindy; Koblish, Holly K.; Hall, Leslie M.; Fridman, Jordan S.; Behshad, Elham; Wynn, Richard; Li, Yu; Boer, Jason; Diamond, Sharon; He, Chunhong; Xu, Meizhong; Zhuo, Jincong; Yao, Wenqing; Newton, Robert C.; Scherle, Peggy A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7127-7138</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The c-MET receptor tyrosine kinase plays important roles in the formation, progression, and dissemination of human cancer and presents an attractive therapeutic target.  This study describes the preclin. characterization of INCB28060, a novel inhibitor of c-MET kinase.  Exptl. Design: Studies were conducted using a series of in vitro and in vivo biochem. and biol. expts.  RESULTS: INCB28060 exhibits picomolar enzymic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases.  This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines.  As a result, INCB28060 potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro.  Oral dosing of INCB28060 results in time- and dose-dependent inhibition of c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models, and the inhibitor is well tolerated at doses that achieve complete tumor inhibition.  In a further exploration of potential interactions between c-MET and other signaling pathways, we found that activated c-MET pos. regulates the activity of epidermal growth factor receptors (EGFR) and HER-3, as well as expression of their ligands.  These effects are reversed with INCB28060 treatment.  Finally, we confirmed that circulating hepatocyte growth factor levels are significantly elevated in patients with various cancers.  CONCLUSIONS: Activated c-MET has pleiotropic effects on multiple cancer-promoting signaling pathways and may play a crit. role in driving tumor cell growth and survival.  INCB28060 is a potent and selective c-MET kinase inhibitor that may have therapeutic potential in cancer treatment.  Clin Cancer Res; 17(22); 7127-38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqqT6dM1mGprVg90H21EOLACvtfcHk0lgqndrO1WO5sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7nK&md5=c272514704702cb5cbcc9e405bea3c53</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1157%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMarando%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DHall%26aufirst%3DL.%2BM.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBehshad%26aufirst%3DE.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZhuo%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520kinase%2520inhibitor%252C%2520INCB28060%252C%2520blocks%2520c-MET-dependent%2520signaling%252C%2520neoplastic%2520activities%252C%2520and%2520cross-talk%2520with%2520EGFR%2520and%2520HER-3%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7127%26epage%3D7138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridrich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasmine Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimanovich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yajing Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span> </span><span class="NLM_article-title">Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2879</span><span class="NLM_x">–</span> <span class="NLM_lpage">2882</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800043g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFShtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2879-2882&author=B.+K.+Albrechtauthor=J.-C.+Harmangeauthor=D.+Bauerauthor=L.+Berryauthor=C.+Bodeauthor=A.+A.+Boezioauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=C.+Fridrichauthor=S.+Hiraiauthor=D.+Hoffmanauthor=J.+F.+Larrowauthor=P.+Kaplan-Lefkoauthor=J.+Jasmine+Linauthor=J.+Lohmanauthor=A.+M.+Longauthor=J.+Moriguchiauthor=A.+O%E2%80%99Connorauthor=M.+H.+Potashmanauthor=M.+Reeseauthor=K.+Rexauthor=A.+Siegmundauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yajing+Yangauthor=Y.+Zhangauthor=S.+F.+Bellon&title=Discovery+and+optimization+of+triazolopyridazines+as+potent+and+selective+inhibitors+of+the+c-Met+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase</span></div><div class="casAuthors">Albrecht, Brian K.; Harmange, Jean-Christophe; Bauer, David; Berry, Loren; Bode, Christiane; Boezio, Alessandro A.; Chen, April; Choquette, Deborah; Dussault, Isabelle; Fridrich, Cary; Hirai, Satoko; Hoffman, Doug; Larrow, Jay F.; Kaplan-Lefko, Paula; Lin, Jasmine; Lohman, Julia; Long, Alexander M.; Moriguchi, Jodi; O'Connor, Anne; Potashman, Michele H.; Reese, Monica; Rex, Karen; Siegmund, Aaron; Shah, Kavita; Shimanovich, Roman; Springer, Stephanie K.; Teffera, Yohannes; Yang, Yajing; Zhang, Yihong; Bellon, Steven F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2879-2882</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumorigenesis is a multistep process in which oncogenes play a key role in tumor formation, growth, and maintenance.  MET was discovered as an oncogene that is activated by its ligand, hepatocyte growth factor.  Deregulated signaling in the c-Met pathway has been obsd. in multiple tumor types.  Herein we report the discovery of potent and selective triazolopyridazine small mols. that inhibit c-Met activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVeQ8sYpasHLVg90H21EOLACvtfcHk0liVgorp_19Ftg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFShtLk%253D&md5=c0aec3ca102d90869884c139372f60a0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm800043g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800043g%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DJasmine%2BLin%26aufirst%3DJ.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMoriguchi%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DA.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DReese%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYajing%2BYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520triazolopyridazines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520c-Met%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2879%26epage%3D2882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Schiering, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, Rita.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET and its complex with the microbial alkaloid K-252a</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12654</span><span class="NLM_x">–</span> <span class="NLM_lpage">12659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1073%2Fpnas.1734128100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=14559966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=Rita.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+c-MET+and+its+complex+with+the+microbial+alkaloid+K-252a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a</span></div><div class="casAuthors">Schiering, Nikolaus; Knapp, Stefan; Marconi, Marina; Flocco, Maria M.; Cui, Jean; Perego, Rita; Rusconi, Luisa; Cristiani, Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">12654-12659</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase.  Binding of its ligand, hepatocyte growth factor/scatter factor, stimulates receptor autophosphorylation, which leads to pleiotropic downstream signaling events in epithelial cells, including cell growth, motility, and invasion.  These events are mediated by interaction of cytoplasmic effectors, generally through Src homol. 2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  There is a strong link between aberrant c-Met activity and oncogenesis, which makes this kinase an important cancer drug target.  The furanosylated indolocarbazole K-252a belongs to a family of microbial alkaloids that also includes staurosporine.  It was recently shown to be a potent inhibitor of c-Met.  Here we report the crystal structures of an unphosphorylated c-Met kinase domain harboring a human cancer mutation and its complex with K-252a at 1.8-Å resoln.  The structure follows the well established architecture of protein kinases.  It adopts a unique, inhibitory conformation of the activation loop, a catalytically noncompetent orientation of helix αC, and reveals the complete C-terminal docking site.  The first SH2-binding motif (1349YVHV) adopts an extended conformation, whereas the second motif (1356YVNV), a binding site for Grb2-SH2, folds as a type II β-turn.  The intermediate portion of the supersite (1353NATY) assumes a type I β-turn conformation as in an Shc-phosphotyrosine binding domain peptide complex.  K-252a is bound in the adenosine pocket with an analogous binding mode to those obsd. in previously reported structures of protein kinases in complex with staurosporine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13Yf3cKB-ybVg90H21EOLACvtfcHk0liVgorp_19Ftg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D&md5=d8cd3494f2583dfcb11efb6862aff607</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1734128100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1734128100%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DRita.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520c-MET%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1036</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1535-7163.MCT-11-0839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22389468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1036-1047&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=K.+Burgessauthor=M.+Qiuauthor=L.+Engstromauthor=S.+Yamazakiauthor=M.+Parkerauthor=S.+Timofeevskiauthor=J.+J.+Cuiauthor=M.+McTigueauthor=M.+G.+Losauthor=S.+Benderauthor=T.+Smealauthor=J.+G.+Christensen&title=Sensitivity+of+Selected+Human+Tumor+Models+to+PF-04217903%2C+a+Novel+Selective+c-Met+Kinase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; Burgess, Kristina; Qiu, Ming; Engstrom, Lars D.; Yamazaki, Shinji; Parker, Max; Timofeevski, Sergei; Cui, Jingrong Jean; McTigue, Michele; Los, Gerrit; Bender, Steven L.; Smeal, Tod; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1036-1047</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met pathway has been implicated in a variety of human cancers for its crit. role in tumor growth, invasion, and metastasis.  PF-04217903 is a novel ATP-competitive small-mol. inhibitor of c-Met kinase.  PF-04217903 showed more than 1,000-fold selectivity for c-Met compared with more than 150 kinases, making it one of the most selective c-Met inhibitors described to date.  PF-04217903 inhibited tumor cell proliferation, survival, migration/invasion in MET-amplified cell lines in vitro, and showed marked antitumor activity in tumor models harboring either MET gene amplification or a hepatocyte growth factor (HGF)/c-Met autocrine loop at well-tolerated dose levels in vivo.  Antitumor efficacy of PF-04217903 was dose-dependent and showed a strong correlation with inhibition of c-Met phosphorylation, downstream signaling, and tumor cell proliferation/survival.  In human xenograft models that express relatively high levels of c-Met, complete inhibition of c-Met activity by PF-04217903 only led to partial tumor growth inhibition (38%-46%) in vivo.  The combination of PF-04217903 with Recepteur d'origine nantais (RON) short hairpin RNA (shRNA) knockdown in the HT29 model that also expresses activated RON kinase-induced tumor cell apoptosis and resulted in enhanced antitumor efficacy (77%) compared with either PF-04217903 (38%) or RON shRNA alone (56%).  PF-04217903 also showed potent antiangiogenic properties in vitro and in vivo.  Furthermore, PF-04217903 strongly induced phospho-PDGFRβ (platelet-derived growth factor receptor) levels in U87MG xenograft tumors, indicating a possible oncogene switching mechanism in tumor cell signaling as a potential resistance mechanism that might compromise tumor responses to c-Met inhibitors.  Collectively, these results show the use of highly selective inhibition of c-Met and provide insight toward targeting tumors exhibiting different mechanisms of c-Met dysregulation.  Mol Cancer Ther; 11(4); 1036-47.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZrrZdx_x0SrVg90H21EOLACvtfcHk0ljW9sOxtaVKnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntLk%253D&md5=bd5d2896768e7ae6a65b9c5e2ec3ce15</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0839%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DBurgess%26aufirst%3DK.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DEngstrom%26aufirst%3DL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DLos%26aufirst%3DM.%2BG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DSensitivity%2520of%2520Selected%2520Human%2520Tumor%2520Models%2520to%2520PF-04217903%252C%2520a%2520Novel%2520Selective%2520c-Met%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1036%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Timofeevski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Enzymatic characterization of c-MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5339</span><span class="NLM_x">–</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900438w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5339-5349&author=S.+L.+Timofeevskiauthor=M.+A.+McTigueauthor=K.+Ryanauthor=J.+Cuiauthor=H.+Y.+Zouauthor=J.+X.+Zhuauthor=F.+Chauauthor=G.+Altonauthor=S.+Karlicekauthor=J.+G.+Christensenauthor=B.+W.+Murray&title=Enzymatic+characterization+of+c-MET+receptor+tyrosine+kinase+oncogenic+mutants+and+kinetic+studies+with+aminopyridine+and+triazolopyrazine+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi900438w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900438w%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeevski%26aufirst%3DS.%2BL.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DJ.%2BX.%26aulast%3DChau%26aufirst%3DF.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DEnzymatic%2520characterization%2520of%2520c-MET%2520receptor%2520tyrosine%2520kinase%2520oncogenic%2520mutants%2520and%2520kinetic%2520studies%2520with%2520aminopyridine%2520and%2520triazolopyrazine%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D5339%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Omori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotera, J.</span><span> </span><span class="NLM_article-title">Overview of PDEs and their regulation</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1161%2F01.RES.0000256354.95791.f1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=17307970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsF2kurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=309-327&author=K.+Omoriauthor=J.+Kotera&title=Overview+of+PDEs+and+their+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of PDEs and their regulation</span></div><div class="casAuthors">Omori, Kenji; Kotera, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-327</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Contraction and relaxation of vascular smooth muscle and cardiac myocytes are key physiol. events in the cardiovascular system.  These events are regulated by 2nd messengers, cAMP and cGMP, in response to extracellular stimulants.  The strength of signal transduction is controlled by intracellular cyclic nucleotide concns., which are detd. by a balance in the prodn. and degrdn. of cAMP and cGMP.  The degrdn. of cyclic nucleotides is catalyzed by 3',5'-cyclic nucleotide phosphodiesterases (PDEs), and therefore regulation of PDEs hydrolytic activity is important for modulation of cellular functions.  Mammalian PDEs are composed of 21 genes and are categorized into 11 families based on sequence homol., enzymic properties, and sensitivity to inhibitors.  PDE families contain many splice variants that mostly are unique in tissue-expression patterns, gene regulation, enzymic regulation by phosphorylation and regulatory proteins, subcellular localization, and interaction with assocn. proteins.  Each unique variant is closely related to the regulation of a specific cellular signaling.  Thus, multiple PDEs function as a particular modulator of each cardiovascular function and regulate physiol. homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctQ0OjiRTE7Vg90H21EOLACvtfcHk0ljW9sOxtaVKnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsF2kurY%253D&md5=932f5158c5ebdd9a75a41317b0b12955</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000256354.95791.f1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000256354.95791.f1%26sid%3Dliteratum%253Aachs%26aulast%3DOmori%26aufirst%3DK.%26aulast%3DKotera%26aufirst%3DJ.%26atitle%3DOverview%2520of%2520PDEs%2520and%2520their%2520regulation%26jtitle%3DCirc.%2520Res.%26date%3D2007%26volume%3D100%26spage%3D309%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Aguirre, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collette, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobrowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasi, E. R.</span><span> </span><span class="NLM_article-title">Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1177%2F0192623310364027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=20231546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1Ontbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=416-428&author=S.+A.+Aguirreauthor=J.+R.+Heyenauthor=W.+Colletteauthor=W.+Bobrowskiauthor=E.+R.+Blasi&title=Cardiovascular+effects+in+rats+following+exposure+to+a+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Aguirre, Shirley A.; Heyen, Jonathan R.; Collette, Walter, III; Bobrowski, Walter; Blasi, Eileen R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">416-428</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase receptor (RTK) signaling pathway, mesenchymal-epithelial transition factor (c-Met)/hepatocyte growth factor receptor (HGFR), has been implicated in oncogenesis and is a target of interest in cancer therapy.  PF-04254644 is a potent and selective inhibitor of c-Met/HGFR.  Wide ligand binding profiling of PF-04254644 revealed a potentially significant interaction with phosphodiesterase (PDE) 3, and follow-up PDE enzyme activity assays confirmed PF-04254644 as a potent inhibitor of PDE3 as well as other PDEs (1, 2, 5, 10, and 11).  Clin. observations, lab., and echocardiog. parameters were recorded in Sprague-Dawley (SD) rats that received PF-04254644 oral dosing for up to seven consecutive days.  Toxicol. evaluations revealed myocardial degeneration as an adverse event at all tested doses.  Echocardiog. evaluations revealed an increase in heart rate (HR) and contractility after the first dose with PF-04254644 and myocardial fibrosis correlated with decreased cardiac function after repeat dosing.  A study in telemetry-instrumented rats substantiated that PF-04254644 induced a sustained increased HR and decreased contractility after six days of treatment.  Data suggest that the decreased cardiac function and cardiotoxicity are likely due to inhibition of multiple PDEs by PF-04254644.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_6wrzHn8abVg90H21EOLACvtfcHk0lguQGZMQz4TLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1Ontbc%253D&md5=59dc667b0b8436e87cb5b4ae1ec56778</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1177%2F0192623310364027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623310364027%26sid%3Dliteratum%253Aachs%26aulast%3DAguirre%26aufirst%3DS.%2BA.%26aulast%3DHeyen%26aufirst%3DJ.%2BR.%26aulast%3DCollette%26aufirst%3DW.%26aulast%3DBobrowski%26aufirst%3DW.%26aulast%3DBlasi%26aufirst%3DE.%2BR.%26atitle%3DCardiovascular%2520effects%2520in%2520rats%2520following%2520exposure%2520to%2520a%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DToxicol.%2520Pathol.%26date%3D2010%26volume%3D38%26spage%3D416%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirakawa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition</span> <span class="citation_source-journal">J. Appl. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1008</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1002%2Fjat.2801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22936366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yks7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=1008-1020&author=W.+Huauthor=B.+Hirakawaauthor=B.+Jessenauthor=M.+Leeauthor=S.+A.+Aguirre&title=Tyrosine+kinase+inhibitor-induced+myocardial+degeneration+in+rats+through+off-target+phosphodiesterase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition</span></div><div class="casAuthors">Hu, Wenyue; Hirakawa, Brad; Jessen, Bart; Lee, Michelle; Aguirre, Shirley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1008-1020</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">PF-04254644 is a selective kinase inhibitor of mesenchymal epithelial transition factor/hepatocyte growth factor receptor with known off-target inhibitory activity against the phosphodiesterase (PDE) family.  Rats given repeated oral doses of PF-04254644 developed a mild to moderate myocardial degeneration accompanied by sustained increase in heart rate and contractility.  Investigative studies were conducted to delineate the mechanisms of toxicity.  Microarray anal. of Sprague-Dawley rat hearts in a 6 day repeat dose study with PF-04254644 or milrinone, a selective PDE3 inhibitor, revealed similar perturbation of the cyclic adenosine monophosphate (c-AMP) pathway.  PDE inhibition and activation of c-AMP were further substantiated using PDE3B immunofluorescence staining and through a c-AMP response element reporter gene assay.  The intracellular calcium and oxidative stress signaling pathways were more perturbed by treatment with PF-04254644 than milrinone.  The rat cardiomyocytes calcium assay found a dose-dependent increase in intracellular calcium with PF-04254644 treatment.  These data suggest that cardiotoxicity of PF-04254644 was probably due to activation of c-AMP signaling, and possibly subsequent disruption of intracellular calcium and oxidative stress signaling pathways.  The greater response with PF-04254644 as compared with milrinone in gene expression and micro- and ultrastructural changes is probably due to the broader panel of PDEs inhibition.  Copyright © 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3XR4RRu0a4rVg90H21EOLACvtfcHk0lguQGZMQz4TLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yks7bM&md5=5565a0333f18d96b4a9524f5decc6425</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fjat.2801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.2801%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHirakawa%26aufirst%3DB.%26aulast%3DJessen%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DAguirre%26aufirst%3DS.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitor-induced%2520myocardial%2520degeneration%2520in%2520rats%2520through%2520off-target%2520phosphodiesterase%2520inhibition%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2012%26volume%3D32%26spage%3D1008%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: Targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&issue=5&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+Targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0lguQGZMQz4TLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520Targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26issue%3D5%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Scannell, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanckley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, B.</span><span> </span><span class="NLM_article-title">Diagnosing the decline in pharmaceutical R&D efficiency</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&author=J.+W.+Scannellauthor=A.+Blanckleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+decline+in+pharmaceutical+R%26D+efficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0liZZx5KXGLtrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%2BW.%26aulast%3DBlanckley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520decline%2520in%2520pharmaceutical%2520R%2526D%2520efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D191%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">McKim, J. M.,  Jr.</span><span> </span><span class="NLM_article-title">Building a tiered approach to in vitro predictive toxicity screening: A focus on assays with in vivo relevance</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.2174%2F138620710790596736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=20053163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtV2gsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=188-206&author=J.+M.+McKim&title=Building+a+tiered+approach+to+in+vitro+predictive+toxicity+screening%3A+A+focus+on+assays+with+in+vivo+relevance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance</span></div><div class="casAuthors">McKim, James M., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-206</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the greatest challenges facing the pharmaceutical industry today is the failure of promising new drug candidates due to unanticipated adverse effects discovered during preclin. animal safety studies and clin. trials.  Late stage attrition increases the time required to bring a new drug to market, inflates development costs, and represents a major source of inefficiency in the drug discovery/development process.  It is generally recognized that early evaluation of new drug candidates is necessary to improve the process.  Building in vitro data sets that can accurately predict adverse effects in vivo would allow compds. with high risk profiles to be deprioritized, while those that possess the requisite drug attributes and a lower risk profile are brought forward.  In vitro cytotoxicity assays were used for decades as a tool to understand hypotheses driven questions regarding mechanisms of toxicity.  However, when used in a prospective manner, they were not highly predictive of in vivo toxicity.  Therefore, the issue may not be how to collect in vitro toxicity data, but rather how to translate in vitro toxicity data into meaningful in vivo effects.  This review will focus on the development of an in vitro toxicity screening strategy that is based on a tiered approach to data collection combined with data interpretation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0IZCIjrA-XrVg90H21EOLACvtfcHk0liZZx5KXGLtrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtV2gsbY%253D&md5=c1c9b2ec303d2df41df5c06b4b2a2d89</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F138620710790596736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620710790596736%26sid%3Dliteratum%253Aachs%26aulast%3DMcKim%26aufirst%3DJ.%2BM.%26atitle%3DBuilding%2520a%2520tiered%2520approach%2520to%2520in%2520vitro%2520predictive%2520toxicity%2520screening%253A%2520A%2520focus%2520on%2520assays%2520with%2520in%2520vivo%2520relevance%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2010%26volume%3D13%26spage%3D188%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and lipophilic ligand efficiency (LipE or LLE) in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+lipophilic+ligand+efficiency+%28LipE+or+LLE%29+in+addressing+drug+safety+risks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520lipophilic%2520ligand%2520efficiency%2520%2528LipE%2520or%2520LLE%2529%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':[],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 21 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Samy Mohamady, Mahmoud Galal, Wagdy M. Eldehna, David C. Gutierrez, Hany S. Ibrahim, Mohey M. Elmazar, <span class="NLM_string-name hlFld-ContribAuthor">Hamed I. Ali</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (30)
                                     , 18872-18886. <a href="https://doi.org/10.1021/acsomega.0c02038" title="DOI URL">https://doi.org/10.1021/acsomega.0c02038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c02038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c02038%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDual%252BTargeting%252Bof%252BVEGFR2%252Band%252BC-Met%252BKinases%252Bvia%252Bthe%252BDesign%252Band%252BSynthesis%252Bof%252BSubstituted%252B3-%252528Triazolo-thiadiazin-3-yl%252529indolin-2-one%252BDerivatives%252Bas%252BAngiogenesis%252BInhibitors%26aulast%3DMohamady%26aufirst%3DSamy%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03052020%26date%3D03072020%26date%3D24072020%26volume%3D5%26issue%3D30%26spage%3D18872%26epage%3D18886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Jia</span>, <span class="hlFld-ContribAuthor ">Guangxiu  Dai</span>, <span class="hlFld-ContribAuthor ">Jianyang  Weng</span>, <span class="hlFld-ContribAuthor ">Zhulin  Zhang</span>, <span class="hlFld-ContribAuthor ">Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Zhou</span>, <span class="hlFld-ContribAuthor ">Longxian  Jiao</span>, <span class="hlFld-ContribAuthor ">Yumin  Cui</span>, <span class="hlFld-ContribAuthor ">Yongxin  Ren</span>, <span class="hlFld-ContribAuthor ">Shiming  Fan</span>, <span class="hlFld-ContribAuthor ">Jinghong  Zhou</span>, <span class="hlFld-ContribAuthor ">Weiguo  Qing</span>, <span class="hlFld-ContribAuthor ">Yi  Gu</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Yang  Sai</span>, and <span class="hlFld-ContribAuthor ">Weiguo  Su</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (18)
                                     , 7577-7589. <a href="https://doi.org/10.1021/jm500510f" title="DOI URL">https://doi.org/10.1021/jm500510f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500510f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500510f%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528S%252529-1-%2525281-%252528Imidazo%25255B1%25252C2-a%25255Dpyridin-6-yl%252529ethyl%252529-6-%2525281-methyl-1H-pyrazol-4-yl%252529-1H-%25255B1%25252C2%25252C3%25255Dtriazolo%25255B4%25252C5-b%25255Dpyrazine%252B%252528Volitinib%252529%252Bas%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BMesenchymal%2525E2%252580%252593Epithelial%252BTransition%252BFactor%252B%252528c-Met%252529%252BInhibitor%252Bin%252BClinical%252BDevelopment%252Bfor%252BTreatment%252Bof%252BCancer%26aulast%3DJia%26aufirst%3DHong%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D31032014%26date%3D15092014%26date%3D25092014%26date%3D22082014%26volume%3D57%26issue%3D18%26spage%3D7577%26epage%3D7589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. Jean  Cui</span>  . </span><span class="cited-content_cbyCitation_article-title">Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (11)
                                     , 4427-4453. <a href="https://doi.org/10.1021/jm401427c" title="DOI URL">https://doi.org/10.1021/jm401427c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401427c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401427c%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BReceptor%252BTyrosine%252BKinase%252BMET%252Bin%252BCancer%25253A%252BSmall%252BMolecule%252BInhibitors%252Band%252BClinical%252BProgress%26aulast%3DCui%26aufirst%3DJ.%2BJean%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D16092013%26date%3D18122013%26date%3D12062014%26date%3D09122013%26volume%3D57%26issue%3D11%26spage%3D4427%26epage%3D4453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tahereh  Damghani</span>, <span class="hlFld-ContribAuthor ">Maryam  Elyasi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Pirhadi</span>, <span class="hlFld-ContribAuthor ">Zahra  Haghighijoo</span>, <span class="hlFld-ContribAuthor ">Somayeh  Ghazi</span>. </span><span class="cited-content_cbyCitation_article-title">Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>66 </em><a href="https://doi.org/10.1007/s11030-021-10267-7" title="DOI URL">https://doi.org/10.1007/s11030-021-10267-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-021-10267-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-021-10267-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DType%252BII%252Bc-Met%252Binhibitors%25253A%252Bmolecular%252Binsight%252Binto%252Bcrucial%252Binteractions%252Bfor%252Beffective%252Binhibition%26aulast%3DDamghani%26aufirst%3DTahereh%26date%3D2021%26date%3D2021%26volume%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biao  Nie</span>, <span class="hlFld-ContribAuthor ">Wanqing  Wu</span>, <span class="hlFld-ContribAuthor ">Yingjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Huanfeng  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the synthesis of bridgehead (or ring-junction) nitrogen heterocycles
              via
              transition metal-catalyzed C–H bond activation and functionalization. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2020,</strong> <em>7 </em>
                                    (19)
                                     , 3067-3099. <a href="https://doi.org/10.1039/D0QO00510J" title="DOI URL">https://doi.org/10.1039/D0QO00510J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0QO00510J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0QO00510J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bsynthesis%252Bof%252Bbridgehead%252B%252528or%252Bring-junction%252529%252Bnitrogen%252Bheterocycles%252Bvia%252Btransition%252Bmetal-catalyzed%252BC%2525E2%252580%252593H%252Bbond%252Bactivation%252Band%252Bfunctionalization%26aulast%3DNie%26aufirst%3DBiao%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D19%26spage%3D3067%26epage%3D3099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Konstantin L'vovich  Obydennov</span>, <span class="hlFld-ContribAuthor ">Tatiana Andreevna  Kalinina</span>, <span class="hlFld-ContribAuthor ">Olga Alexandrovna  Vysokova</span>, <span class="hlFld-ContribAuthor ">Pavel Alexandrovich  Slepukhin</span>, <span class="hlFld-ContribAuthor ">Varvara Alexandrovna  Pozdina</span>, <span class="hlFld-ContribAuthor ">Maria Valer'evna  Ulitko</span>, <span class="hlFld-ContribAuthor ">Tatiana Vladimirovna  Glukhareva</span>. </span><span class="cited-content_cbyCitation_article-title">The different modes of chiral [1,2,3]triazolo[5,1-
              b
              ][1,3,4]thiadiazines: crystal packing, conformation investigation and cellular activity. </span><span class="cited-content_cbyCitation_journal-name">Acta Crystallographica Section C Structural Chemistry</span><span> <strong>2020,</strong> <em>76 </em>
                                    (8)
                                     , 795-809. <a href="https://doi.org/10.1107/S2053229620009328" title="DOI URL">https://doi.org/10.1107/S2053229620009328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1107/S2053229620009328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1107%2FS2053229620009328%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Crystallographica%2520Section%2520C%2520Structural%2520Chemistry%26atitle%3DThe%252Bdifferent%252Bmodes%252Bof%252Bchiral%252B%25255B1%25252C2%25252C3%25255Dtriazolo%25255B5%25252C1-%252Bb%252B%25255D%25255B1%25252C3%25252C4%25255Dthiadiazines%25253A%252Bcrystal%252Bpacking%25252C%252Bconformation%252Binvestigation%252Band%252Bcellular%252Bactivity%26aulast%3DObydennov%26aufirst%3DKonstantin%2BL%2527vovich%26date%3D2020%26date%3D2020%26volume%3D76%26issue%3D8%26spage%3D795%26epage%3D809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jooseok  Kim</span>, <span class="hlFld-ContribAuthor ">Kyung Eui  Park</span>, <span class="hlFld-ContribAuthor ">Yoo-Seong  Jeong</span>, <span class="hlFld-ContribAuthor ">YeongMun  Kim</span>, <span class="hlFld-ContribAuthor ">Hayeon  Park</span>, <span class="hlFld-ContribAuthor ">Ji-Hye  Nam</span>, <span class="hlFld-ContribAuthor ">Kyungsoo  Jung</span>, <span class="hlFld-ContribAuthor ">Woo Sung  Son</span>, <span class="hlFld-ContribAuthor ">Hun Soon  Jung</span>, <span class="hlFld-ContribAuthor ">Jong-Hwa  Lee</span>, <span class="hlFld-ContribAuthor ">Seong Hoon  Jeong</span>, <span class="hlFld-ContribAuthor ">Nam Ah  Kim</span>, <span class="hlFld-ContribAuthor ">Jae Du  Ha</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>, <span class="hlFld-ContribAuthor ">Yoon-La  Choi</span>, <span class="hlFld-ContribAuthor ">Suk-Jae  Chung</span>, <span class="hlFld-ContribAuthor ">Jun Young  Choi</span>, <span class="hlFld-ContribAuthor ">Sungyoul  Hong</span>, <span class="hlFld-ContribAuthor ">Young Kee  Shin</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (6)
                                     , 1575. <a href="https://doi.org/10.3390/cancers12061575" title="DOI URL">https://doi.org/10.3390/cancers12061575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12061575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12061575%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTherapeutic%252BEfficacy%252Bof%252BABN401%25252C%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BMET%252BInhibitor%25252C%252BBased%252Bon%252BDiagnostic%252BBiomarker%252BTest%252Bin%252BMET-Addicted%252BCancer%26aulast%3DKim%26aufirst%3DJooseok%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D6%26spage%3D1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiyu  Wang</span>, <span class="hlFld-ContribAuthor ">Benchen  Rao</span>, <span class="hlFld-ContribAuthor ">Jiamin  Lou</span>, <span class="hlFld-ContribAuthor ">Jianhao  Li</span>, <span class="hlFld-ContribAuthor ">Zhenguo  Liu</span>, <span class="hlFld-ContribAuthor ">Ang  Li</span>, <span class="hlFld-ContribAuthor ">Guangying  Cui</span>, <span class="hlFld-ContribAuthor ">Zhigang  Ren</span>, <span class="hlFld-ContribAuthor ">Zujiang  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcell.2020.00055" title="DOI URL">https://doi.org/10.3389/fcell.2020.00055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2020.00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2020.00055%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DThe%252BFunction%252Bof%252Bthe%252BHGF%25252Fc-Met%252BAxis%252Bin%252BHepatocellular%252BCarcinoma%26aulast%3DWang%26aufirst%3DHaiyu%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Hai Bing  Deng</span>, <span class="hlFld-ContribAuthor ">Chun Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing Quan  Dai</span>, <span class="hlFld-ContribAuthor ">Qian  Li</span>, <span class="hlFld-ContribAuthor ">Qian Gang  Zheng</span>, <span class="hlFld-ContribAuthor ">Hui Xin  Wan</span>, <span class="hlFld-ContribAuthor ">Hong Ping  Yu</span>, <span class="hlFld-ContribAuthor ">Feng  He</span>, <span class="hlFld-ContribAuthor ">Yao Chang  Xu</span>, <span class="hlFld-ContribAuthor ">Sylvia  Zhao</span>, <span class="hlFld-ContribAuthor ">Ji Yue Jeff  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Drug Metabolism and Pharmacokinetics</span><span> <strong>2019,</strong> <em>44 </em>
                                    (5)
                                     , 669-680. <a href="https://doi.org/10.1007/s13318-019-00557-9" title="DOI URL">https://doi.org/10.1007/s13318-019-00557-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13318-019-00557-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13318-019-00557-9%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Drug%2520Metabolism%2520and%2520Pharmacokinetics%26atitle%3DIn%252BVitro%252BMetabolism%252Bby%252BAldehyde%252BOxidase%252BLeads%252Bto%252BPoor%252BPharmacokinetic%252BProfile%252Bin%252BRats%252Bfor%252Bc-Met%252BInhibitor%252BMET401%26aulast%3DZhang%26aufirst%3DJiang%2BWei%26date%3D2019%26date%3D2019%26volume%3D44%26issue%3D5%26spage%3D669%26epage%3D680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng-Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Yu-Shun  Yang</span>, <span class="hlFld-ContribAuthor ">Zhong-Chang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress in the Development of Small Molecule c-Met Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (15)
                                     , 1276-1288. <a href="https://doi.org/10.2174/1568026619666190712205353" title="DOI URL">https://doi.org/10.2174/1568026619666190712205353</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190712205353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190712205353%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bin%252Bthe%252BDevelopment%252Bof%252BSmall%252BMolecule%252Bc-Met%252BInhibitors%26aulast%3DLv%26aufirst%3DPeng-Cheng%26date%3D2019%26volume%3D19%26issue%3D15%26spage%3D1276%26epage%3D1288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ranjana  Aggarwal</span>, <span class="hlFld-ContribAuthor ">Mamta</span>, <span class="hlFld-ContribAuthor ">Garima  Sumran</span>, <span class="hlFld-ContribAuthor ">Mari Carmen  Torralba</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structural studies of 3,6-disubstituted-bis-1,2,4-triazolo-[4,3-b][3′,4′-f]pyridazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2019,</strong> <em>1185 </em>, 379-391. <a href="https://doi.org/10.1016/j.molstruc.2019.02.082" title="DOI URL">https://doi.org/10.1016/j.molstruc.2019.02.082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2019.02.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2019.02.082%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DSynthesis%252Band%252Bstructural%252Bstudies%252Bof%252B3%25252C6-disubstituted-bis-1%25252C2%25252C4-triazolo-%25255B4%25252C3-b%25255D%25255B3%2525E2%252580%2525B2%25252C4%2525E2%252580%2525B2-f%25255Dpyridazines%26aulast%3DAggarwal%26aufirst%3DRanjana%26date%3D2019%26volume%3D1185%26spage%3D379%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mamta</span>, <span class="hlFld-ContribAuthor ">Ranjana  Aggarwal</span>, <span class="hlFld-ContribAuthor ">Rachna  Sadana</span>, <span class="hlFld-ContribAuthor ">Jeziel  Ilag</span>, <span class="hlFld-ContribAuthor ">Garima  Sumran</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and bioevaluation of 6-chloropyridazin-3-yl hydrazones and 6-chloro-3-substituted-[1,2,4]triazolo[4,3-b]pyridazines as cytotoxic agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>86 </em>, 288-295. <a href="https://doi.org/10.1016/j.bioorg.2019.01.049" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.01.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.01.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.01.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbioevaluation%252Bof%252B6-chloropyridazin-3-yl%252Bhydrazones%252Band%252B6-chloro-3-substituted-%25255B1%25252C2%25252C4%25255Dtriazolo%25255B4%25252C3-b%25255Dpyridazines%252Bas%252Bcytotoxic%252Bagents%26aulast%3DMamta%26date%3D2019%26volume%3D86%26spage%3D288%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Wen  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhen Ting  Gao</span>, <span class="hlFld-ContribAuthor ">Zheng Tian  Yu</span>, <span class="hlFld-ContribAuthor ">Ji Yue (Jeff)  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolism of c-Met Kinase Inhibitors Containing Quinoline by Aldehyde Oxidase, Electron Donating, and Steric Hindrance Effect. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2018,</strong> <em>46 </em>
                                    (12)
                                     , 1847-1855. <a href="https://doi.org/10.1124/dmd.118.081919" title="DOI URL">https://doi.org/10.1124/dmd.118.081919</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.118.081919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.118.081919%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DMetabolism%252Bof%252Bc-Met%252BKinase%252BInhibitors%252BContaining%252BQuinoline%252Bby%252BAldehyde%252BOxidase%25252C%252BElectron%252BDonating%25252C%252Band%252BSteric%252BHindrance%252BEffect%26aulast%3DZhang%26aufirst%3DJiang%2BWei%26date%3D2018%26date%3D2018%26volume%3D46%26issue%3D12%26spage%3D1847%26epage%3D1855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Palak K.  Parikh</span>, <span class="hlFld-ContribAuthor ">Manjunath D.  Ghate</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the discovery of small molecule c-Met Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1103-1138. <a href="https://doi.org/10.1016/j.ejmech.2017.08.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bdiscovery%252Bof%252Bsmall%252Bmolecule%252Bc-Met%252BKinase%252Binhibitors%26aulast%3DParikh%26aufirst%3DPalak%2BK.%26date%3D2018%26volume%3D143%26spage%3D1103%26epage%3D1138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chi-Tan  Hu</span>, <span class="hlFld-ContribAuthor ">Jia-Ru  Wu</span>, <span class="hlFld-ContribAuthor ">Chuan-Chu  Cheng</span>, <span class="hlFld-ContribAuthor ">Wen-Sheng  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2017,</strong> <em>9 </em>
                                    (12)
                                     , 58. <a href="https://doi.org/10.3390/cancers9060058" title="DOI URL">https://doi.org/10.3390/cancers9060058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers9060058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers9060058%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DThe%252BTherapeutic%252BTargeting%252Bof%252BHGF%25252Fc-Met%252BSignaling%252Bin%252BHepatocellular%252BCarcinoma%25253A%252BAlternative%252BApproaches%26aulast%3DHu%26aufirst%3DChi-Tan%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D12%26spage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daowei  Huang</span>, <span class="hlFld-ContribAuthor ">Lei  Huang</span>, <span class="hlFld-ContribAuthor ">Qingwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianqi  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel 6,11-dihydro-5 H -benzo[e]pyrimido- [5,4- b ][1,4]diazepine derivatives as potential c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 212-228. <a href="https://doi.org/10.1016/j.ejmech.2017.08.060" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.060%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B6%25252C11-dihydro-5%252BH%252B-benzo%25255Be%25255Dpyrimido-%252B%25255B5%25252C4-%252Bb%252B%25255D%25255B1%25252C4%25255Ddiazepine%252Bderivatives%252Bas%252Bpotential%252Bc-Met%252Binhibitors%26aulast%3DHuang%26aufirst%3DDaowei%26date%3D2017%26volume%3D140%26spage%3D212%26epage%3D228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zu-Jun  Sun</span>, <span class="hlFld-ContribAuthor ">Yi  Wu</span>, <span class="hlFld-ContribAuthor ">Wei-Hua  Hou</span>, <span class="hlFld-ContribAuthor ">Yu-Xiong  Wang</span>, <span class="hlFld-ContribAuthor ">Qing-Yun  Yuan</span>, <span class="hlFld-ContribAuthor ">Hui-Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Min  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (17)
                                     , 29067-29079. <a href="https://doi.org/10.18632/oncotarget.16173" title="DOI URL">https://doi.org/10.18632/oncotarget.16173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.16173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.16173%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DA%252Bnovel%252Bbispecific%252Bc-MET%25252FPD-1%252Bantibody%252Bwith%252Btherapeutic%252Bpotential%252Bin%252Bsolid%252Bcancer%26aulast%3DSun%26aufirst%3DZu-Jun%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D17%26spage%3D29067%26epage%3D29079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Majid M.  Heravi</span>, <span class="hlFld-ContribAuthor ">Mahzad  Dehghani</span>, <span class="hlFld-ContribAuthor ">Vahideh  Zadsirjan</span>. </span><span class="cited-content_cbyCitation_article-title">Rh-catalyzed asymmetric 1,4-addition reactions to α,β-unsaturated carbonyl and related compounds: an update. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron: Asymmetry</span><span> <strong>2016,</strong> <em>27 </em>
                                    (13)
                                     , 513-588. <a href="https://doi.org/10.1016/j.tetasy.2016.05.004" title="DOI URL">https://doi.org/10.1016/j.tetasy.2016.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetasy.2016.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetasy.2016.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%253A%2520Asymmetry%26atitle%3DRh-catalyzed%252Basymmetric%252B1%25252C4-addition%252Breactions%252Bto%252B%2525CE%2525B1%25252C%2525CE%2525B2-unsaturated%252Bcarbonyl%252Band%252Brelated%252Bcompounds%25253A%252Ban%252Bupdate%26aulast%3DHeravi%26aufirst%3DMajid%2BM.%26date%3D2016%26volume%3D27%26issue%3D13%26spage%3D513%26epage%3D588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minghui  Dong</span>, <span class="hlFld-ContribAuthor ">Yujie  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of triazolo[4,5-b]pyrazine derivatives as hepatocyte growth factor receptor inhibitors through structure–activity relationships and molecular docking simulations. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (19)
                                     , 4118-4126. <a href="https://doi.org/10.1016/j.bmcl.2015.08.025" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.08.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.08.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.08.025%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252Btriazolo%25255B4%25252C5-b%25255Dpyrazine%252Bderivatives%252Bas%252Bhepatocyte%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%252Bthrough%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Band%252Bmolecular%252Bdocking%252Bsimulations%26aulast%3DDong%26aufirst%3DMinghui%26date%3D2015%26volume%3D25%26issue%3D19%26spage%3D4118%26epage%3D4126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiqiang  Xing</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Shiyu  Jin</span>, <span class="hlFld-ContribAuthor ">Zhangxing  Shi</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Lang  Wang</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Dong  Lu</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Youhong  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>95 </em>, 302-312. <a href="https://doi.org/10.1016/j.ejmech.2015.03.041" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.03.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.03.041%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEnhancing%252Bthe%252Bcellular%252Banti-proliferation%252Bactivity%252Bof%252Bpyridazinones%252Bas%252Bc-met%252Binhibitors%252Busing%252Bdocking%252Banalysis%26aulast%3DXing%26aufirst%3DWeiqiang%26date%3D2015%26volume%3D95%26spage%3D302%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean W.  Reilly</span>, <span class="hlFld-ContribAuthor ">Hannah K.  Box</span>, <span class="hlFld-ContribAuthor ">Glenn R.  Kuchenbeiser</span>, <span class="hlFld-ContribAuthor ">Ramel J.  Rubio</span>, <span class="hlFld-ContribAuthor ">Christopher S.  Letko</span>, <span class="hlFld-ContribAuthor ">Kandarpa D.  Cousineau</span>, <span class="hlFld-ContribAuthor ">T. Keith  Hollis</span>. </span><span class="cited-content_cbyCitation_article-title">1,4-Addition of aryl boronic acids to α,β-unsaturated ketones catalyzed by a CCC–NHC pincer rhodium complex. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2014,</strong> <em>55 </em>
                                    (49)
                                     , 6738-6742. <a href="https://doi.org/10.1016/j.tetlet.2014.09.107" title="DOI URL">https://doi.org/10.1016/j.tetlet.2014.09.107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2014.09.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2014.09.107%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3D1%25252C4-Addition%252Bof%252Baryl%252Bboronic%252Bacids%252Bto%252B%2525CE%2525B1%25252C%2525CE%2525B2-unsaturated%252Bketones%252Bcatalyzed%252Bby%252Ba%252BCCC%2525E2%252580%252593NHC%252Bpincer%252Brhodium%252Bcomplex%26aulast%3DReilly%26aufirst%3DSean%2BW.%26date%3D2014%26volume%3D55%26issue%3D49%26spage%3D6738%26epage%3D6742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. The Discovery of Highly Selective c-Met Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Exquisitely Selective c-Met Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Cocrystal structure of <b>7</b> with the unphosphorylated c-Met kinase domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zbx">3zbx</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Metabolic clearance in human liver microsomes vs cLogD (red color for the triazolopyrazine series, and blue color for the triazolopyridazine series).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of c-Met phosphorylation and tumor growth by <b>8</b> in the GTL-16 xenograft tumor model in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of <b>8</b> with c-Met unphosphorylated kinase domain (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5">3zc5</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of cocrystal structures of <b>8</b> (green color) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5">3zc5</a>) and <b>9</b> (pink color) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz">3zxz</a>) with c-Met unphosphorylated kinase domain.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Superimposition of <b>28F</b> (golden color) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zcl">3zcl</a>) with <b>8</b> (green color) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5">3zc5</a>) in c-Met cocrystal structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="schI" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Syntheses of [1,2,4]Triazolo[4,3-<i>b</i>]pyridazine Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=schI"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) glycerol/FeSO<sub>4</sub>/conc. H<sub>2</sub>SO<sub>4</sub>, nitrobenzene, reflux, 5 h. (b) SOCl<sub>2</sub>, methanol, reflux. (c) LDA/MeI, anhydrous THF, −78 °C to ambient temperature, overnight. (d) LiOH, MeOH/H<sub>2</sub>O, 65 °C, 4 h. (e) (Boc)<sub>2</sub>O/DMAP, THF, overnight. (f) HCl/dioxane (4 N), CH<sub>2</sub>Cl<sub>2</sub>. (g) EDC or HATU, DMF, overnight. (h) SOCl<sub>2</sub>, DMF, 100 °C, 30 min. (i) Acetic acid, reflux, 2 h. (j) Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, overnight. (k) Amine, <i>n</i>-butanol, microwave at 125 °C, ∼1 h.</p></p></figure><figure data-id="schII" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/medium/jm-2013-00926x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Syntheses of (<i>S</i>)-6-(1-(1<i>H</i>-[1,2,3]Triazolo[4,5-<i>b</i>]pyrazin-1-yl)ethyl)quinoline Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400926x/production/images/large/jm-2013-00926x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400926x&amp;id=schII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeNHOMe/CDI, DMF, ambient temperature, overnight. (b) MeMgBr, anhydrous THF, 0 °C to ambient temperature, 16 h. (c) NH<sub>2</sub>OH·HCl/NaOH, ethanol, 16 h. (d) 7 N NH<sub>3</sub> in methanol, EtOH, H<sub>2</sub>, Raney nickel, 16 h. (e) DIPEA, <i>n</i>-BuOH, microwave at 225 °C, 1 h. (f) Isoamyl nitrile, DMF, 70 °C, 1 h. (g) Chiral separation on a chiral SFC column using MeOH and liquid CO<sub>2</sub> as elution system. (h) Pd(dppf)Cl<sub>2</sub>·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME/H<sub>2</sub>O, 80 °C, overnight.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i65">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22671" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22671" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Boccaccio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span> </span><span class="NLM_article-title">Invasive growth: A Met-driven generic programme for cancer and stem cells</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">–</span> <span class="NLM_lpage">645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnrc1912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=16862193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFGlu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=637-645&author=C.+Boccaccioauthor=P.+M.+Comoglio&title=Invasive+growth%3A+A+Met-driven+generic+programme+for+cancer+and+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Invasive growth: a MET-driven genetic programme for cancer and stem cells</span></div><div class="casAuthors">Boccaccio, Carla; Comoglio, Paolo M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metastasis follows the inappropriate activation of a genetic program termed invasive growth, which is a physiol. process that occurs during embryonic development and post-natal organ regeneration.  Burgeoning evidence indicates that invasive growth is also executed by stem and progenitor cells, and is usurped by cancer stem cells.  The MET proto-oncogene, which is expressed in both stem and cancer cells, is a key regulator of invasive growth.  Recent findings indicate that the MET tyrosine-kinase receptor is a sensor of adverse microenvironmental conditions (such as hypoxia) and drives cell invasion and metastasis through the transcriptional activation of a set of genes that control blood coagulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrNb2dfp5v27Vg90H21EOLACvtfcHk0lg9bGZ4eIa--w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFGlu70%253D&md5=79319c46d57d395726d389e6cd03068f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1912%26sid%3Dliteratum%253Aachs%26aulast%3DBoccaccio%26aufirst%3DC.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26atitle%3DInvasive%2520growth%253A%2520A%2520Met-driven%2520generic%2520programme%2520for%2520cancer%2520and%2520stem%2520cells%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D637%26epage%3D645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Knudsen, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vande Woude, G.</span><span> </span><span class="NLM_article-title">Showering c-MET-dependent cancers with drugs</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1016%2Fj.gde.2008.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=18406132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=87-96&author=B.+S.+Knudsenauthor=G.+Vande+Woude&title=Showering+c-MET-dependent+cancers+with+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Showering c-MET-dependent cancers with drugs</span></div><div class="casAuthors">Knudsen, Beatrice S.; Vande Woude, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Genetics & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-96</span>CODEN:
                <span class="NLM_cas:coden">COGDET</span>;
        ISSN:<span class="NLM_cas:issn">0959-437X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase, c-MET and its ligand hepatocyte growth factor/scatter factor (HGF/SF) have become leading candidates for targeted cancer therapies.  Inappropriate c-MET signaling through autocrine, paracrine, amplification, and mutational activation occurs in virtually all types of solid tumors (http://www.vai.org/met), contributing to one or a combination of proliferative, invasive, survival, or angiogenic cancer phenotypes. c-MET and HGF/SF participate in all stages of malignant progression and represent promising drug targets in a variety of cancer types, including carcinomas, sarcomas, and brain tumors.  While many are in pre-clin. testing, a few inhibitors have entered clin. trials.  With hundreds of thousands of potential responding cancers that express c-MET, the interest in this mol. as a drug target is not surprising.  However, the cognate c-MET diagnostic tests lag behind.  In addn., despite the great enthusiasm based on response rates in phase I trials, there is a need for caution.  It is almost without question that combination therapies with c-MET-HGF/SF inhibitors will be required for most cancers to achieve a cytotoxic tumor response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonjBq7fWvKhrVg90H21EOLACvtfcHk0lg9bGZ4eIa--w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVarur8%253D&md5=d0744275be94658bab067f20644c98d6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2008.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2008.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DKnudsen%26aufirst%3DB.%2BS.%26aulast%3DVande%2BWoude%26aufirst%3DG.%26atitle%3DShowering%2520c-MET-dependent%2520cancers%2520with%2520drugs%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2008%26volume%3D18%26spage%3D87%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tretiakova, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKinnon, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramnath, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiwert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagadeeswaran, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krausz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vokes, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Expression and mutational analysis of <i>MET</i> in human solid cancers</span> <span class="citation_source-journal">Genes, Chromosomes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1025</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1002%2Fgcc.20604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=18709663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1025-1037&author=P.+C.+Maauthor=M.+S.+Tretiakovaauthor=A.+C.+MacKinnonauthor=N.+Ramnathauthor=C.+Johnsonauthor=S.+Dietrichauthor=T.+Seiwertauthor=J.+G.+Christensenauthor=R.+Jagadeeswaranauthor=T.+Krauszauthor=E.+E.+Vokesauthor=A.+N.+Husainauthor=R.+Salgia&title=Expression+and+mutational+analysis+of+MET+in+human+solid+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Expression and mutational analysis of MET in human solid cancers</span></div><div class="casAuthors">Ma, Patrick C.; Tretiakova, Maria S.; MacKinnon, Alexander C.; Ramnath, Nithya; Johnson, Candace; Dietrich, Sascha; Seiwert, Tanguy; Christensen, James G.; Jagadeeswaran, Ramasamy; Krausz, Thomas; Vokes, Everett E.; Husain, Aliya N.; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Genes, Chromosomes & Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1025-1037</span>CODEN:
                <span class="NLM_cas:coden">GCCAES</span>;
        ISSN:<span class="NLM_cas:issn">1045-2257</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) regulate a variety of cellular functions, many of which can be dysregulated in human cancers.  Activated MET signaling can lead to cell motility and scattering, angiogenesis, proliferation, branching morphogenesis, invasion, and eventual metastasis.  We performed systematic anal. of the expression of the MET receptor and its ligand HGF in tumor tissue microarrays (TMA) from human solid cancers.  Std. immunohistochem. (IHC) and a computerized automated scoring system were used.  DNA sequencing for MET mutations in both nonkinase and kinase domains was also performed.  MET was differentially overexpressed in human solid cancers.  The ligand HGF was widely expressed in both tumors, primarily intratumoral, and nonmalignant tissues.  The MET/HGF likely is functional and may be activated in autocrine fashion in vivo.  MET and stem cell factor (SCF) were found to be pos. stained in the bronchioalevolar junctions of lung tumors.  A no. of novel mutations of MET were identified, particularly in the extracellular semaphorin domain and the juxtamembrane domain.  MET-HGF pathway can be assayed in TMAs and is often overexpressed in a wide variety of human solid cancers.  MET can be activated through overexpression, mutation, or autocrine signaling in malignant cells.  Mutations in the nonkinase regions of MET might play an important role in tumorigenesis and tumor progression.  MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnenTNgIcAbVg90H21EOLACvtfcHk0lhEjujbWdpS2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWns7vE&md5=cf53884177f20939300673fb034ac91f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fgcc.20604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgcc.20604%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DMacKinnon%26aufirst%3DA.%2BC.%26aulast%3DRamnath%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DDietrich%26aufirst%3DS.%26aulast%3DSeiwert%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DJagadeeswaran%26aufirst%3DR.%26aulast%3DKrausz%26aufirst%3DT.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DExpression%2520and%2520mutational%2520analysis%2520of%2520MET%2520in%2520human%2520solid%2520cancers%26jtitle%3DGenes%252C%2520Chromosomes%2520Cancer%26date%3D2008%26volume%3D47%26spage%3D1025%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">MET amplication leads to Gefitinib resistance in lung cancer by activating ERBB signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Mitsudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.+M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.+J.+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+J%C3%A4nne&title=MET+amplication+leads+to+Gefitinib+resistance+in+lung+cancer+by+activating+ERBB+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplication%2520leads%2520to%2520Gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Wilson, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridlyand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penuel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">509</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=505-509&author=T.+R.+Wilsonauthor=J.+Fridlyandauthor=Y.+Yanauthor=E.+Penuelauthor=L.+Burtonauthor=E.+Chanauthor=J.+Pengauthor=E.+Linauthor=Y.+Wangauthor=J.+Sosmanauthor=A.+Ribasauthor=J.+Liauthor=J.+Moffatauthor=D.+P.+Sutherlinauthor=H.+Koeppenauthor=M.+Merchantauthor=R.+Neveauthor=J.+Settleman&title=Widespread+potential+for+growth-factor-driven+resistance+to+anticancer+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DFridlyand%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMoffat%26aufirst%3DJ.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DNeve%26aufirst%3DR.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DWidespread%2520potential%2520for%2520growth-factor-driven%2520resistance%2520to%2520anticancer%2520kinase%2520inhibitors%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D505%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Straussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barzily-Rokni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mongare, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gould, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solit, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wargo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span> </span><span class="NLM_article-title">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">487</span><span class="NLM_x">, </span> <span class="NLM_fpage">500</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnature11183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22763439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=500-504&author=R.+Straussmanauthor=T.+Morikawaauthor=K.+Sheeauthor=M.+Barzily-Rokniauthor=Z.+R.+Qianauthor=J.+Duauthor=A.+Davisauthor=M.+M.+Mongareauthor=J.+Gouldauthor=D.+T.+Frederickauthor=Z.+A.+Cooperauthor=P.+B.+Chapmanauthor=D.+B.+Solitauthor=A.+Ribasauthor=R.+S.+Loauthor=K.+T.+Flahertyauthor=S.+Oginoauthor=J.+A.+Wargoauthor=T.+R.+Golub&title=Tumour+micro-environment+elicits+innate+resistance+to+RAF+inhibitors+through+HGF+secretion"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion</span></div><div class="casAuthors">Straussman, Ravid; Morikawa, Teppei; Shee, Kevin; Barzily-Rokni, Michal; Qian, Zhi Rong; Du, Jinyan; Davis, Ashli; Mongare, Margaret M.; Gould, Joshua; Frederick, Dennie T.; Cooper, Zachary A.; Chapman, Paul B.; Solit, David B.; Ribas, Antoni; Lo, Roger S.; Flaherty, Keith T.; Ogino, Shuji; Wargo, Jennifer A.; Golub, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7408</span>),
    <span class="NLM_cas:pages">500-504</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Drug resistance presents a challenge to the treatment of cancer patients.  Many studies have focused on cell-autonomous mechanisms of drug resistance.  By contrast, the authors proposed that the tumor micro-environment confers innate resistance to therapy.  Here the authors developed a co-culture system to systematically assay the ability of 23 stromal cell types to influence the innate resistance of 45 cancer cell lines to 35 anticancer drugs.  The authors found that stroma-mediated resistance is common, particularly to targeted agents.  The authors characterized further the stroma-mediated resistance of BRAF-mutant melanoma to RAF inhibitors because most patients with this type of cancer show some degree of innate resistance.  Proteomic anal. showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of the HGF receptor MET, reactivation of the mitogen-activated protein kinase (MAPK), and phosphatidylinositol-3-OH kinase (PI(3)K)-AKT signaling pathways, and immediate resistance to RAF inhibition.  Immunohistochem. expts. confirmed stromal cell expression of HGF in patients with BRAF-mutant melanoma and showed a significant correlation between HGF expression by stromal cells and innate resistance to RAF inhibitor treatment.  Dual inhibition of RAF and either HGF or MET resulted in reversal of drug resistance, suggesting RAF plus HGF or MET inhibitory combination therapy as a potential therapeutic strategy for BRAF-mutant melanoma.  A similar resistance mechanism was uncovered in a subset of BRAF-mutant colorectal and glioblastoma cell lines.  More generally, this study indicates that the systematic dissection of interactions between tumors and their micro-environment can uncover important mechanisms underlying drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwanlhJUTP4LVg90H21EOLACvtfcHk0ljh2fe4oFOIQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtL3J&md5=0616b5feed3c5dc2a53ee2ee382a6c33</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11183%26sid%3Dliteratum%253Aachs%26aulast%3DStraussman%26aufirst%3DR.%26aulast%3DMorikawa%26aufirst%3DT.%26aulast%3DShee%26aufirst%3DK.%26aulast%3DBarzily-Rokni%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DZ.%2BR.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DA.%26aulast%3DMongare%26aufirst%3DM.%2BM.%26aulast%3DGould%26aufirst%3DJ.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DCooper%26aufirst%3DZ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DOgino%26aufirst%3DS.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DTumour%2520micro-environment%2520elicits%2520innate%2520resistance%2520to%2520RAF%2520inhibitors%2520through%2520HGF%2520secretion%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D500%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandhu, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span> </span><span class="NLM_article-title">HGF/c-MET targeted therapeutics: Novel strategies for cancer medicine</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2045</span><span class="NLM_x">–</span> <span class="NLM_lpage">2058</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.2174%2F138945011798829348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=21777195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=2045-2058&author=T.+A.+Yapauthor=S.+K.+Sandhuauthor=S.+M.+Alamauthor=J.+S.+de+Bono&title=HGF%2Fc-MET+targeted+therapeutics%3A+Novel+strategies+for+cancer+medicine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">HGF/c-MET targeted therapeutics: novel strategies for cancer medicine</span></div><div class="casAuthors">Yap, Timothy A.; Sandhu, Shahneen K.; Alam, Salma M.; de Bono, Johann S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2045-2058</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/c-MET) receptor tyrosine kinase (RTK) pathway plays a pleotropic role in cell proliferation, migration, invasion, angiogenesis and survival.  Although it has crit. physiol. functions in embryonic development and tissue repair, this signaling cascade is frequently deregulated in a wide range of tumors.  Aberrant HGF/c-MET signaling, driven by various mechanisms, including constitutive activation and over-expression, has multifunctional effects in oncogenesis and is implicated in the acquisition of an aggressive phenotype with metastatic potential.  The central role of c-MET activity in cancer progression, as well as disparities between quiescent HGF/c-MET signaling in normal tissue and overexpression in tumor may provide a degree of tumor selectivity for therapeutic intervention, making HGF or c-MET inhibition an attractive proposition in oncol.  This review focuses on the underlying oncogenic role of aberrant HGF/c-MET signaling in malignant progression, as well as recent preclin. and clin. data on the different strategies employed in inhibiting HGF/c-MET function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeZy3Mk8Qz8LVg90H21EOLACvtfcHk0ljh2fe4oFOIQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFyisQ%253D%253D&md5=cef2aa1557af1928b2fa176363455356</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F138945011798829348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945011798829348%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DSandhu%26aufirst%3DS.%2BK.%26aulast%3DAlam%26aufirst%3DS.%2BM.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26atitle%3DHGF%252Fc-MET%2520targeted%2520therapeutics%253A%2520Novel%2520strategies%2520for%2520cancer%2520medicine%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2011%26volume%3D12%26spage%3D2045%26epage%3D2058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Tuma, R. S.</span><span> </span><span class="NLM_article-title">Novel antibody, rilotumumab (AMG 102) shows activity in metastatic colorectal cancer patients</span> <span class="citation_source-journal">Oncol. Times</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=22-23&author=R.+S.+Tuma&title=Novel+antibody%2C+rilotumumab+%28AMG+102%29+shows+activity+in+metastatic+colorectal+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTuma%26aufirst%3DR.%2BS.%26atitle%3DNovel%2520antibody%252C%2520rilotumumab%2520%2528AMG%2520102%2529%2520shows%2520activity%2520in%2520metastatic%2520colorectal%2520cancer%2520patients%26jtitle%3DOncol.%2520Times%26date%3D2011%26volume%3D33%26spage%3D22%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Surati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span> </span><span class="NLM_article-title">Role of MetMAb (OA-5D5) in c-MET active lung malignancies</span> <span class="citation_source-journal">Expert Opin. Biol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1655</span><span class="NLM_x">–</span> <span class="NLM_lpage">1662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1517%2F14712598.2011.626762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22047509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVags7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1655-1662&author=M.+Suratiauthor=P.+Patelauthor=A.+Petersonauthor=R.+Salgia&title=Role+of+MetMAb+%28OA-5D5%29+in+c-MET+active+lung+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Role of MetMAb (OA-5D5) in c-MET active lung malignancies</span></div><div class="casAuthors">Surati, Mosmi; Patel, Premal; Peterson, Amy; Salgia, Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Biological Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1655-1662</span>CODEN:
                <span class="NLM_cas:coden">EOBTA2</span>;
        ISSN:<span class="NLM_cas:issn">1471-2598</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: MetMAb (OA-5D5) is a one-armed monoclonal antibody developed to bind to and inhibit c-MET receptor tyrosine kinase.  Though only in early clin. testing, this agent holds great promise in diseases thought to be driven by c-MET activation, as evidenced by the Phase II results in NSCLC where a benefit in overall survival was obsd. in patients with MET-diagnostic-pos. disease.  Thus far, both alone and in combination with other targeted agents, this drug has been well tolerated and no new significant safety signals have been identified.  Areas covered: This review summarizes the structure and function of the c-MET receptor and its ligand hepatic growth factor (HGF), provides an overview of select targeted monotherapies developed to interfere in the MET-HGF signaling pathway, discusses pre-clin. and clin. data surrounding MetMAb, and concludes with an expert opinion regarding this novel agent.  Expert opinion: MetMAb has been well tolerated and based on Phase II data testing it, in combination with erlotinib in advanced NSCLC, may have a role in improving survival in patients with disease driven by c-MET activation.  However, Phase III validation is underway and the results of these studies will help elucidate which patients will benefit most from this novel agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNNaynTSW2ErVg90H21EOLACvtfcHk0ljh2fe4oFOIQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVags7%252FN&md5=78a25ac9a8b03aa9e3113776d40854e2</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F14712598.2011.626762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14712598.2011.626762%26sid%3Dliteratum%253Aachs%26aulast%3DSurati%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DPeterson%26aufirst%3DA.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DRole%2520of%2520MetMAb%2520%2528OA-5D5%2529%2520in%2520c-MET%2520active%2520lung%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Biol.%2520Ther.%26date%3D2011%26volume%3D11%26spage%3D1655%26epage%3D1662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal-epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lgmgXLIv-fr9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span> <span class="citation_source-journal">Mol Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2298</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0lgmgXLIv-fr9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Munshi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">France, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashwell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussa, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leggett, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. J.</span><span> </span><span class="NLM_article-title">ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1535-7163.MCT-09-1173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=20484018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1544-1553&author=N.+Munshiauthor=S.+Jeayauthor=Y.+Liauthor=C.+R.+Chenauthor=D.+S.+Franceauthor=M.+A.+Ashwellauthor=J.+Hillauthor=M.+M.+Moussaauthor=D.+S.+Leggettauthor=C.+J.+Li&title=ARQ+197%2C+a+novel+and+selective+inhibitor+of+the+human+c-Met+receptor+tyrosine+kinase+with+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity</span></div><div class="casAuthors">Munshi, Neru; Jeay, Sebastien; Li, Youzhi; Chen, Chang-Rung; France, Dennis S.; Ashwell, Mark A.; Hill, Jason; Moussa, Magdi M.; Leggett, David S.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1544-1553</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The met proto-oncogene is functionally linked with tumorigenesis and metastatic progression.  Validation of the receptor tyrosine kinase c-Met as a selective anticancer target has awaited the emergence of selective c-Met inhibitors.  Herein, we report ARQ 197 as the first non-ATP-competitive small mol. that selectively targets the c-Met receptor tyrosine kinase.  Exposure to ARQ 197 resulted in the inhibition of proliferation of c-Met-expressing cancer cell lines as well as the induction of caspase-dependent apoptosis in cell lines with constitutive c-Met activity.  These cellular responses to ARQ 197 were phenocopied by RNAi-mediated c-Met depletion and further demonstrated by the growth inhibition of human tumors following oral administration of ARQ 197 in multiple mouse xenograft efficacy studies.  Cumulatively, these data suggest that ARQ 197, currently in phase II clin. trials, is a promising agent for targeting cancers in which c-Met-driven signaling is important for their survival and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYa8M1T1wfLVg90H21EOLACvtfcHk0lgmgXLIv-fr9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntFGgsL0%253D&md5=2fd9c4ad5be6e1a119f2aa9699bb9519</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-1173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-1173%26sid%3Dliteratum%253Aachs%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DJeay%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DC.%2BR.%26aulast%3DFrance%26aufirst%3DD.%2BS.%26aulast%3DAshwell%26aufirst%3DM.%2BA.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DMoussa%26aufirst%3DM.%2BM.%26aulast%3DLeggett%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DARQ%2520197%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520the%2520human%2520c-Met%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1544%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Peters, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">MET: A promising anticancer therapeutic target</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnrclinonc.2012.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVOrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=314-326&author=S.+Petersauthor=A.+A.+Adjei&title=MET%3A+A+promising+anticancer+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">MET: a promising anticancer therapeutic target</span></div><div class="casAuthors">Peters, Solange; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">314-326</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Targeting the MET pathway is an increasingly attractive anticancer strategy.  In this Review, this pathway is viewed from the clin. perspective, assessing the available agents in terms of efficacy and toxicity and looking forward to biomarker-driven application in the clinic.  The MET pathway is dysregulated in many human cancers and promotes tumor growth, invasion and dissemination.  Abnormalities in MET signalling have been reported to correlate with poor clin. outcomes and drug resistance in patients with cancer.  Thus, MET has emerged as an attractive target for cancer therapy.  Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clin. trials.  In general, initial results from these studies indicate only a modest benefit in unselected populations.  In this Review, we discuss current challenges in developing MET inhibitors-including identification of predictive biomarkers-as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1VV_hiW_CLVg90H21EOLACvtfcHk0li-hC6KMUtIqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVOrtL0%253D&md5=db84521545ee290e245a5b541b103ff1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.71%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DMET%253A%2520A%2520promising%2520anticancer%2520therapeutic%2520target%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D314%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Spigel, D. R.; Ervin, T. J.; Ramlau, R.; Daniel, D. B.; Goldschmidt, J. H.; Blumenschein, G. R.; Krzakowski, M. J.; Robinet, G.; Clement-Duchene, C.; Barlesi, F.; Govindan, R.; Patel, T.; Orlov, S. V.; Wertheim, M. S.; Zha, J.; Pandita, A.; Yu, W.; Yauch, R. L.; Patel, P. H.; Peterson, A. C.</span><span> </span><span class="NLM_article-title">Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC</span>. Presented at ASCO 2011 Annual Meeting, Chicago, IL, June 3–7,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">, </span>Abstr. 7505.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=D.+R.+Spigel&author=T.+J.+Ervin&author=R.+Ramlau&author=D.+B.+Daniel&author=J.+H.+Goldschmidt&author=G.+R.+Blumenschein&author=M.+J.+Krzakowski&author=G.+Robinet&author=C.+Clement-Duchene&author=F.+Barlesi&author=R.+Govindan&author=T.+Patel&author=S.+V.+Orlov&author=M.+S.+Wertheim&author=J.+Zha&author=A.+Pandita&author=W.+Yu&author=R.+L.+Yauch&author=P.+H.+Patel&author=A.+C.+Peterson&title=Final+efficacy+results+from+OAM4558g%2C+a+randomized+phase+II+study+evaluating+MetMAb+or+placebo+in+combination+with+erlotinib+in+advanced+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DFinal%2520efficacy%2520results%2520from%2520OAM4558g%252C%2520a%2520randomized%2520phase%2520II%2520study%2520evaluating%2520MetMAb%2520or%2520placebo%2520in%2520combination%2520with%2520erlotinib%2520in%2520advanced%2520NSCLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Ou, S.-H. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwak-Tapp, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">942</span><span class="NLM_x">–</span> <span class="NLM_lpage">946</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1097%2FJTO.0b013e31821528d3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=21623265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=942-946&author=S.-H.+I.+Ouauthor=E.+L.+Kwakauthor=C.+Siwak-Tappauthor=J.+Dyauthor=K.+Bergethonauthor=J.+W.+Clarkauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=R.+G.+Makiauthor=Y.-J.+Bangauthor=D.-W.+Kimauthor=J.+Christensenauthor=W.+Tanauthor=K.+D.+Wilnerauthor=R.+Salgiaauthor=A.+J.+Iafrate&title=Activity+of+crizotinib+%28PF02341066%29%2C+a+dual+mesenchymal-epithelial+transition+%28MET%29+and+anaplastic+lymphoma+kinase+%28ALK%29+inhibitor%2C+in+a+non-small+cell+lung+cancer+patient+with+de+novo+MET+amplification"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Kwak Eunice L; Siwak-Tapp Christina; Dy Joni; Bergethon Kristin; Clark Jeffrey W; Camidge D Ross; Solomon Benjamin J; Maki Robert G; Bang Yung-Jue; Kim Dong-Wan; Christensen James; Tan Weiwei; Wilner Keith D; Salgia Ravi; Iafrate A John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">942-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Crizotinib is a dual MET and ALK inhibitor.  Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC).  Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1REpDHXMT37jnyZkbE8yXfW6udTcc2eaO6WnnCBluD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnotlGqug%253D%253D&md5=920657051f20d097e6cd1d83b0aa7e10</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e31821528d3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e31821528d3%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.-H.%2BI.%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSiwak-Tapp%26aufirst%3DC.%26aulast%3DDy%26aufirst%3DJ.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBang%26aufirst%3DY.-J.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DActivity%2520of%2520crizotinib%2520%2528PF02341066%2529%252C%2520a%2520dual%2520mesenchymal-epithelial%2520transition%2520%2528MET%2529%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitor%252C%2520in%2520a%2520non-small%2520cell%2520lung%2520cancer%2520patient%2520with%2520de%2520novo%2520MET%2520amplification%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2011%26volume%3D6%26spage%3D942%26epage%3D946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazin-6-yl)-1<i>H</i>-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8091</span><span class="NLM_x">–</span> <span class="NLM_lpage">8109</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300967g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8091-8109&author=J.+J.+Cuiauthor=M.+McTigueauthor=M.+Nambuauthor=M.+Tran-Dub%C3%A9author=M.+Pairishauthor=H.+Shenauthor=L.+Jiaauthor=H.+Chengauthor=J.+Hoffmanauthor=P.+Leauthor=M.+Jalaieauthor=G.+H.+Goetzauthor=K.+Ryanauthor=N.+Grodskyauthor=Y.+L.+Dengauthor=M.+Parkerauthor=S.+Timofeevskiauthor=B.+W.+Murrayauthor=S.+Yamazakiauthor=S.+Aguirreauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Discovery+of+a+novel+class+of+exquisitely+selective+mesenchymal-epithelial+transition+factor+%28c-MET%29+protein+kinase+inhibitors+and+identification+of+the+clinical+candidate+2-%284-%281-%28quinolin-6-ylmethyl%29-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-b%5Dpyrazin-6-yl%29-1H-pyrazol-1-yl%29ethanol+%28PF-04217903%29+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300967g%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%2BH.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DY.%2BL.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520exquisitely%2520selective%2520mesenchymal-epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520protein%2520kinase%2520inhibitors%2520and%2520identification%2520of%2520the%2520clinical%2520candidate%25202-%25284-%25281-%2528quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2520%2528PF-04217903%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8091%26epage%3D8109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Koenig, M.; Cui, J.; Wei, C. C.; Do, S. H.; Zhang, F.-J.; Vojkovsky, T.; Ramphal, J.; Yang, G.; Mattson, M.; Nelson, C.; Tang, P. C.</span><span> </span><span class="NLM_article-title">Indolinone hydrazides as c-met inhibitors</span>. PCT Int. Appl. WO2005005378,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=M.+Koenig&author=J.+Cui&author=C.+C.+Wei&author=S.+H.+Do&author=F.-J.+Zhang&author=T.+Vojkovsky&author=J.+Ramphal&author=G.+Yang&author=M.+Mattson&author=C.+Nelson&author=P.+C.+Tang&title=Indolinone+hydrazides+as+c-met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKoenig%26aufirst%3DM.%26atitle%3DIndolinone%2520hydrazides%2520as%2520c-met%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="note"><p class="first last">The first cocrystal structure of an analogue of <b>2</b> with c-Met kinase domain proving the unusual binding mode for exquisite c-MET kinase selectivity was obtained by Nikolaus Schiering and Cinzia Cristiani at legacy Pharmacia in 2002 and was not deposited in PDB.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Vojkovsky, T.; Koenig, M.; Zhang, F.-J.; Cui, J.</span><span> </span><span class="NLM_article-title">Tetracyclic compounds as c-Met inhibitors</span>. PCT Int. Appl. WO2005004808,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=T.+Vojkovsky&author=M.+Koenig&author=F.-J.+Zhang&author=J.+Cui&title=Tetracyclic+compounds+as+c-Met+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVojkovsky%26aufirst%3DT.%26atitle%3DTetracyclic%2520compounds%2520as%2520c-Met%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Zhang, F.-J.; Vojkovsky, T.; Huang, P.; Liang, C.; Do, S. H.; Koenig, M.; Cui, J.</span><span> </span><span class="NLM_article-title">Preparation of triazolotriazines as c-Met modulators for treating cancer</span>. PCT Int. Appl. WO2005010005,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=F.-J.+Zhang&author=T.+Vojkovsky&author=P.+Huang&author=C.+Liang&author=S.+H.+Do&author=M.+Koenig&author=J.+Cui&title=Preparation+of+triazolotriazines+as+c-Met+modulators+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.-J.%26atitle%3DPreparation%2520of%2520triazolotriazines%2520as%2520c-Met%2520modulators%2520for%2520treating%2520cancer%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Cui, J.; Botrous, I.</span><span> </span><span class="NLM_article-title">Arylmethyl triazolo and imidazopyrazines as c-MET inhibitors</span>. PCT Int. Appl. WO2005004607,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+Cui&author=I.+Botrous&title=Arylmethyl+triazolo+and+imidazopyrazines+as+c-MET+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DArylmethyl%2520triazolo%2520and%2520imidazopyrazines%2520as%2520c-MET%2520inhibitors%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bounaud, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huser, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felce, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froning, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterman, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aubol, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessert, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwinn, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rooney, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leon, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasserman, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emtage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burley, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, S. H.</span><span> </span><span class="NLM_article-title">SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo</span> <span class="citation_source-journal">Mol. Cancer Ther</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">3181</span><span class="NLM_x">–</span> <span class="NLM_lpage">3190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1535-7163.MCT-09-0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=19934279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3181-3190&author=S.+G.+Buchananauthor=J.+Hendleauthor=P.+S.+Leeauthor=C.+R.+Smithauthor=P.+Y.+Bounaudauthor=K.+A.+Jessenauthor=C.+M.+Tangauthor=N.+H.+Huserauthor=J.+D.+Felceauthor=K.+J.+Froningauthor=M.+C.+Petermanauthor=B.+E.+Aubolauthor=S.+F.+Gessertauthor=J.+M.+Sauderauthor=K.+D.+Schwinnauthor=M.+Russellauthor=I.+A.+Rooneyauthor=J.+Adamsauthor=B.+C.+Leonauthor=T.+H.+Doauthor=J.+M.+Blaneyauthor=P.+A.+Sprengelerauthor=D.+A.+Thompsonauthor=L.+Smythauthor=L.+A.+Pelletierauthor=S.+Atwellauthor=K.+Holmeauthor=S.+R.+Wassermanauthor=S.+Emtageauthor=S.+K.+Burleyauthor=S.+H.+Reich&title=SGX523+is+an+exquisitely+selective%2C+ATP-competitive+inhibitor+of+the+MET+receptor+tyrosine+kinase+with+antitumor+activity+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo</span></div><div class="casAuthors">Buchanan, Sean G.; Hendle, Jorg; Lee, Patrick S.; Smith, Christopher R.; Bounaud, Pierre-Yves; Jessen, Katti A.; Tang, Crystal M.; Huser, Nanni H.; Felce, Jeremy D.; Froning, Karen J.; Peterman, Marshall C.; Aubol, Brandon E.; Gessert, Steve F.; Sauder, J. Michael; Schwinn, Kenneth D.; Russell, Marijane; Rooney, Isabelle A.; Adams, Jason; Leon, Barbara C.; Do, Tuan H.; Blaney, Jeff M.; Sprengeler, Paul A.; Thompson, Devon A.; Smyth, Lydia; Pelletier, Laura A.; Atwell, Shane; Holme, Kevin; Wasserman, Stephen R.; Emtage, Spencer; Burley, Stephen K.; Reich, Siegfried H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3181-3190</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics.  Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers.  In other cancers, such as glioblastoma, autocrine activation of MET has been demonstrated.  Several classes of ATP-competitive inhibitor have been described, which inhibit MET but also other kinases.  Here, we describe SGX523, a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET.  SGX523 potently inhibited MET with an IC50 of 4 nmol/L and is >1000-fold selective vs. the >200-fold selectivity of other protein kinases tested in biochem. assays.  Crystallog. study revealed that SGX523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for the selectivity.  SGX523 inhibited MET-mediated signaling, cell proliferation, and cell migration at nanomolar concns. but had no effect on signaling dependent on other protein kinases, including the closely related RON, even at micromolar concns.  SGX523 inhibition of MET in vivo was assocd. with the dose-dependent inhibition of growth of tumor xenografts derived from human glioblastoma and lung and gastric cancers, confirming the dependence of these tumors on MET catalytic activity.  Our results show that SGX523 is the most selective inhibitor of MET catalytic activity described to date and is thus a useful tool to investigate the role of MET kinase in cancer without the confounding effects of promiscuous protein kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplt9w6z--VQ7Vg90H21EOLACvtfcHk0lixS4MTMP-miQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFCitbzI&md5=7410ae811f0bf2d3298691ed34d35878</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0477%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DHendle%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DBounaud%26aufirst%3DP.%2BY.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DTang%26aufirst%3DC.%2BM.%26aulast%3DHuser%26aufirst%3DN.%2BH.%26aulast%3DFelce%26aufirst%3DJ.%2BD.%26aulast%3DFroning%26aufirst%3DK.%2BJ.%26aulast%3DPeterman%26aufirst%3DM.%2BC.%26aulast%3DAubol%26aufirst%3DB.%2BE.%26aulast%3DGessert%26aufirst%3DS.%2BF.%26aulast%3DSauder%26aufirst%3DJ.%2BM.%26aulast%3DSchwinn%26aufirst%3DK.%2BD.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DRooney%26aufirst%3DI.%2BA.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DLeon%26aufirst%3DB.%2BC.%26aulast%3DDo%26aufirst%3DT.%2BH.%26aulast%3DBlaney%26aufirst%3DJ.%2BM.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DSmyth%26aufirst%3DL.%26aulast%3DPelletier%26aufirst%3DL.%2BA.%26aulast%3DAtwell%26aufirst%3DS.%26aulast%3DHolme%26aufirst%3DK.%26aulast%3DWasserman%26aufirst%3DS.%2BR.%26aulast%3DEmtage%26aufirst%3DS.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DReich%26aufirst%3DS.%2BH.%26atitle%3DSGX523%2520is%2520an%2520exquisitely%2520selective%252C%2520ATP-competitive%2520inhibitor%2520of%2520the%2520MET%2520receptor%2520tyrosine%2520kinase%2520with%2520antitumor%2520activity%2520in%2520vivo%26jtitle%3DMol.%2520Cancer%2520Ther%26date%3D2009%26volume%3D8%26spage%3D3181%26epage%3D3190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Perera, T.; Lavrijssen, T.; Janssens, B.; Geerts, T.; King, P.; Mevellec, L.; Cummings, M. D.; Lu, T.; Johnson, D.; Page, M.</span><span> </span><span class="NLM_article-title">JNJ-38877605: A selective Met kinase inhibitor inducing regression of Met-driven tumor models</span>. Presented at the 99th AACR Annual Meeting,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">, </span>Apr 12–16, San Diego (CA), Abstr 4837.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=T.+Perera&author=T.+Lavrijssen&author=B.+Janssens&author=T.+Geerts&author=P.+King&author=L.+Mevellec&author=M.+D.+Cummings&author=T.+Lu&author=D.+Johnson&author=M.+Page&title=JNJ-38877605%3A+A+selective+Met+kinase+inhibitor+inducing+regression+of+Met-driven+tumor+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%26atitle%3DJNJ-38877605%253A%2520A%2520selective%2520Met%2520kinase%2520inhibitor%2520inducing%2520regression%2520of%2520Met-driven%2520tumor%2520models%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marando, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblish, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behshad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span> </span><span class="NLM_article-title">A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7127</span><span class="NLM_x">–</span> <span class="NLM_lpage">7138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1078-0432.CCR-11-1157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=21918175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7127-7138&author=X.+Liuauthor=Q.+Wangauthor=G.+Yangauthor=C.+Marandoauthor=H.+K.+Koblishauthor=L.+M.+Hallauthor=J.+S.+Fridmanauthor=E.+Behshadauthor=R.+Wynnauthor=Y.+Liauthor=J.+Boerauthor=S.+Diamondauthor=C.+Heauthor=M.+Xuauthor=J.+Zhuoauthor=W.+Yaoauthor=R.+C.+Newtonauthor=P.+A.+Scherle&title=A+novel+kinase+inhibitor%2C+INCB28060%2C+blocks+c-MET-dependent+signaling%2C+neoplastic+activities%2C+and+cross-talk+with+EGFR+and+HER-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3</span></div><div class="casAuthors">Liu, Xiangdong; Wang, Qian; Yang, Gengjie; Marando, Cindy; Koblish, Holly K.; Hall, Leslie M.; Fridman, Jordan S.; Behshad, Elham; Wynn, Richard; Li, Yu; Boer, Jason; Diamond, Sharon; He, Chunhong; Xu, Meizhong; Zhuo, Jincong; Yao, Wenqing; Newton, Robert C.; Scherle, Peggy A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7127-7138</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The c-MET receptor tyrosine kinase plays important roles in the formation, progression, and dissemination of human cancer and presents an attractive therapeutic target.  This study describes the preclin. characterization of INCB28060, a novel inhibitor of c-MET kinase.  Exptl. Design: Studies were conducted using a series of in vitro and in vivo biochem. and biol. expts.  RESULTS: INCB28060 exhibits picomolar enzymic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases.  This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines.  As a result, INCB28060 potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro.  Oral dosing of INCB28060 results in time- and dose-dependent inhibition of c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models, and the inhibitor is well tolerated at doses that achieve complete tumor inhibition.  In a further exploration of potential interactions between c-MET and other signaling pathways, we found that activated c-MET pos. regulates the activity of epidermal growth factor receptors (EGFR) and HER-3, as well as expression of their ligands.  These effects are reversed with INCB28060 treatment.  Finally, we confirmed that circulating hepatocyte growth factor levels are significantly elevated in patients with various cancers.  CONCLUSIONS: Activated c-MET has pleiotropic effects on multiple cancer-promoting signaling pathways and may play a crit. role in driving tumor cell growth and survival.  INCB28060 is a potent and selective c-MET kinase inhibitor that may have therapeutic potential in cancer treatment.  Clin Cancer Res; 17(22); 7127-38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqqT6dM1mGprVg90H21EOLACvtfcHk0lixc6wIn24DVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7nK&md5=c272514704702cb5cbcc9e405bea3c53</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1157%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMarando%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DHall%26aufirst%3DL.%2BM.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBehshad%26aufirst%3DE.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DZhuo%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520kinase%2520inhibitor%252C%2520INCB28060%252C%2520blocks%2520c-MET-dependent%2520signaling%252C%2520neoplastic%2520activities%252C%2520and%2520cross-talk%2520with%2520EGFR%2520and%2520HER-3%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7127%26epage%3D7138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Albrecht, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmange, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bode, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boezio, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dussault, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridrich, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan-Lefko, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jasmine Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rex, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegmund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimanovich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teffera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yajing Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellon, S. F.</span><span> </span><span class="NLM_article-title">Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2879</span><span class="NLM_x">–</span> <span class="NLM_lpage">2882</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800043g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvFShtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2879-2882&author=B.+K.+Albrechtauthor=J.-C.+Harmangeauthor=D.+Bauerauthor=L.+Berryauthor=C.+Bodeauthor=A.+A.+Boezioauthor=A.+Chenauthor=D.+Choquetteauthor=I.+Dussaultauthor=C.+Fridrichauthor=S.+Hiraiauthor=D.+Hoffmanauthor=J.+F.+Larrowauthor=P.+Kaplan-Lefkoauthor=J.+Jasmine+Linauthor=J.+Lohmanauthor=A.+M.+Longauthor=J.+Moriguchiauthor=A.+O%E2%80%99Connorauthor=M.+H.+Potashmanauthor=M.+Reeseauthor=K.+Rexauthor=A.+Siegmundauthor=K.+Shahauthor=R.+Shimanovichauthor=S.+K.+Springerauthor=Y.+Tefferaauthor=Y.+Yajing+Yangauthor=Y.+Zhangauthor=S.+F.+Bellon&title=Discovery+and+optimization+of+triazolopyridazines+as+potent+and+selective+inhibitors+of+the+c-Met+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met Kinase</span></div><div class="casAuthors">Albrecht, Brian K.; Harmange, Jean-Christophe; Bauer, David; Berry, Loren; Bode, Christiane; Boezio, Alessandro A.; Chen, April; Choquette, Deborah; Dussault, Isabelle; Fridrich, Cary; Hirai, Satoko; Hoffman, Doug; Larrow, Jay F.; Kaplan-Lefko, Paula; Lin, Jasmine; Lohman, Julia; Long, Alexander M.; Moriguchi, Jodi; O'Connor, Anne; Potashman, Michele H.; Reese, Monica; Rex, Karen; Siegmund, Aaron; Shah, Kavita; Shimanovich, Roman; Springer, Stephanie K.; Teffera, Yohannes; Yang, Yajing; Zhang, Yihong; Bellon, Steven F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2879-2882</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumorigenesis is a multistep process in which oncogenes play a key role in tumor formation, growth, and maintenance.  MET was discovered as an oncogene that is activated by its ligand, hepatocyte growth factor.  Deregulated signaling in the c-Met pathway has been obsd. in multiple tumor types.  Herein we report the discovery of potent and selective triazolopyridazine small mols. that inhibit c-Met activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVeQ8sYpasHLVg90H21EOLACvtfcHk0lixc6wIn24DVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvFShtLk%253D&md5=c0aec3ca102d90869884c139372f60a0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm800043g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800043g%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DBode%26aufirst%3DC.%26aulast%3DBoezio%26aufirst%3DA.%2BA.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DDussault%26aufirst%3DI.%26aulast%3DFridrich%26aufirst%3DC.%26aulast%3DHirai%26aufirst%3DS.%26aulast%3DHoffman%26aufirst%3DD.%26aulast%3DLarrow%26aufirst%3DJ.%2BF.%26aulast%3DKaplan-Lefko%26aufirst%3DP.%26aulast%3DJasmine%2BLin%26aufirst%3DJ.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DA.%2BM.%26aulast%3DMoriguchi%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DA.%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DReese%26aufirst%3DM.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSiegmund%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DK.%26aulast%3DShimanovich%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DS.%2BK.%26aulast%3DTeffera%26aufirst%3DY.%26aulast%3DYajing%2BYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520triazolopyridazines%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520c-Met%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2879%26epage%3D2882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Schiering, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marconi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flocco, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, Rita.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span> </span><span class="NLM_article-title">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET and its complex with the microbial alkaloid K-252a</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">12654</span><span class="NLM_x">–</span> <span class="NLM_lpage">12659</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1073%2Fpnas.1734128100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=14559966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=12654-12659&author=N.+Schieringauthor=S.+Knappauthor=M.+Marconiauthor=M.+M.+Floccoauthor=J.+Cuiauthor=Rita.+Peregoauthor=L.+Rusconiauthor=C.+Cristiani&title=Crystal+structure+of+the+tyrosine+kinase+domain+of+the+hepatocyte+growth+factor+receptor+c-MET+and+its+complex+with+the+microbial+alkaloid+K-252a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a</span></div><div class="casAuthors">Schiering, Nikolaus; Knapp, Stefan; Marconi, Marina; Flocco, Maria M.; Cui, Jean; Perego, Rita; Rusconi, Luisa; Cristiani, Cinzia</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">12654-12659</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The protooncogene c-met codes for the hepatocyte growth factor receptor tyrosine kinase.  Binding of its ligand, hepatocyte growth factor/scatter factor, stimulates receptor autophosphorylation, which leads to pleiotropic downstream signaling events in epithelial cells, including cell growth, motility, and invasion.  These events are mediated by interaction of cytoplasmic effectors, generally through Src homol. 2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  2 (SH2) domains, with two phosphotyrosine-contg. sequence motifs in the unique C-terminal tail of c-Met (supersite).  There is a strong link between aberrant c-Met activity and oncogenesis, which makes this kinase an important cancer drug target.  The furanosylated indolocarbazole K-252a belongs to a family of microbial alkaloids that also includes staurosporine.  It was recently shown to be a potent inhibitor of c-Met.  Here we report the crystal structures of an unphosphorylated c-Met kinase domain harboring a human cancer mutation and its complex with K-252a at 1.8-Å resoln.  The structure follows the well established architecture of protein kinases.  It adopts a unique, inhibitory conformation of the activation loop, a catalytically noncompetent orientation of helix αC, and reveals the complete C-terminal docking site.  The first SH2-binding motif (1349YVHV) adopts an extended conformation, whereas the second motif (1356YVNV), a binding site for Grb2-SH2, folds as a type II β-turn.  The intermediate portion of the supersite (1353NATY) assumes a type I β-turn conformation as in an Shc-phosphotyrosine binding domain peptide complex.  K-252a is bound in the adenosine pocket with an analogous binding mode to those obsd. in previously reported structures of protein kinases in complex with staurosporine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13Yf3cKB-ybVg90H21EOLACvtfcHk0li05ROv0y6TxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKnt74%253D&md5=d8cd3494f2583dfcb11efb6862aff607</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1734128100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1734128100%26sid%3Dliteratum%253Aachs%26aulast%3DSchiering%26aufirst%3DN.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMarconi%26aufirst%3DM.%26aulast%3DFlocco%26aufirst%3DM.%2BM.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DPerego%26aufirst%3DRita.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DCristiani%26aufirst%3DC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520tyrosine%2520kinase%2520domain%2520of%2520the%2520hepatocyte%2520growth%2520factor%2520receptor%2520c-MET%2520and%2520its%2520complex%2520with%2520the%2520microbial%2520alkaloid%2520K-252a%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A%26date%3D2003%26volume%3D100%26spage%3D12654%26epage%3D12659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1036</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1158%2F1535-7163.MCT-11-0839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22389468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1036-1047&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=K.+Burgessauthor=M.+Qiuauthor=L.+Engstromauthor=S.+Yamazakiauthor=M.+Parkerauthor=S.+Timofeevskiauthor=J.+J.+Cuiauthor=M.+McTigueauthor=M.+G.+Losauthor=S.+Benderauthor=T.+Smealauthor=J.+G.+Christensen&title=Sensitivity+of+Selected+Human+Tumor+Models+to+PF-04217903%2C+a+Novel+Selective+c-Met+Kinase+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; Burgess, Kristina; Qiu, Ming; Engstrom, Lars D.; Yamazaki, Shinji; Parker, Max; Timofeevski, Sergei; Cui, Jingrong Jean; McTigue, Michele; Los, Gerrit; Bender, Steven L.; Smeal, Tod; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1036-1047</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met pathway has been implicated in a variety of human cancers for its crit. role in tumor growth, invasion, and metastasis.  PF-04217903 is a novel ATP-competitive small-mol. inhibitor of c-Met kinase.  PF-04217903 showed more than 1,000-fold selectivity for c-Met compared with more than 150 kinases, making it one of the most selective c-Met inhibitors described to date.  PF-04217903 inhibited tumor cell proliferation, survival, migration/invasion in MET-amplified cell lines in vitro, and showed marked antitumor activity in tumor models harboring either MET gene amplification or a hepatocyte growth factor (HGF)/c-Met autocrine loop at well-tolerated dose levels in vivo.  Antitumor efficacy of PF-04217903 was dose-dependent and showed a strong correlation with inhibition of c-Met phosphorylation, downstream signaling, and tumor cell proliferation/survival.  In human xenograft models that express relatively high levels of c-Met, complete inhibition of c-Met activity by PF-04217903 only led to partial tumor growth inhibition (38%-46%) in vivo.  The combination of PF-04217903 with Recepteur d'origine nantais (RON) short hairpin RNA (shRNA) knockdown in the HT29 model that also expresses activated RON kinase-induced tumor cell apoptosis and resulted in enhanced antitumor efficacy (77%) compared with either PF-04217903 (38%) or RON shRNA alone (56%).  PF-04217903 also showed potent antiangiogenic properties in vitro and in vivo.  Furthermore, PF-04217903 strongly induced phospho-PDGFRβ (platelet-derived growth factor receptor) levels in U87MG xenograft tumors, indicating a possible oncogene switching mechanism in tumor cell signaling as a potential resistance mechanism that might compromise tumor responses to c-Met inhibitors.  Collectively, these results show the use of highly selective inhibition of c-Met and provide insight toward targeting tumors exhibiting different mechanisms of c-Met dysregulation.  Mol Cancer Ther; 11(4); 1036-47.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZrrZdx_x0SrVg90H21EOLACvtfcHk0li05ROv0y6TxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntLk%253D&md5=bd5d2896768e7ae6a65b9c5e2ec3ce15</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0839%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DBurgess%26aufirst%3DK.%26aulast%3DQiu%26aufirst%3DM.%26aulast%3DEngstrom%26aufirst%3DL.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DLos%26aufirst%3DM.%2BG.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DSensitivity%2520of%2520Selected%2520Human%2520Tumor%2520Models%2520to%2520PF-04217903%252C%2520a%2520Novel%2520Selective%2520c-Met%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1036%26epage%3D1047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Timofeevski, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Enzymatic characterization of c-MET receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5339</span><span class="NLM_x">–</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi900438w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=5339-5349&author=S.+L.+Timofeevskiauthor=M.+A.+McTigueauthor=K.+Ryanauthor=J.+Cuiauthor=H.+Y.+Zouauthor=J.+X.+Zhuauthor=F.+Chauauthor=G.+Altonauthor=S.+Karlicekauthor=J.+G.+Christensenauthor=B.+W.+Murray&title=Enzymatic+characterization+of+c-MET+receptor+tyrosine+kinase+oncogenic+mutants+and+kinetic+studies+with+aminopyridine+and+triazolopyrazine+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi900438w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi900438w%26sid%3Dliteratum%253Aachs%26aulast%3DTimofeevski%26aufirst%3DS.%2BL.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DZhu%26aufirst%3DJ.%2BX.%26aulast%3DChau%26aufirst%3DF.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DEnzymatic%2520characterization%2520of%2520c-MET%2520receptor%2520tyrosine%2520kinase%2520oncogenic%2520mutants%2520and%2520kinetic%2520studies%2520with%2520aminopyridine%2520and%2520triazolopyrazine%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26spage%3D5339%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Omori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotera, J.</span><span> </span><span class="NLM_article-title">Overview of PDEs and their regulation</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1161%2F01.RES.0000256354.95791.f1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=17307970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsF2kurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=309-327&author=K.+Omoriauthor=J.+Kotera&title=Overview+of+PDEs+and+their+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of PDEs and their regulation</span></div><div class="casAuthors">Omori, Kenji; Kotera, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-327</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Contraction and relaxation of vascular smooth muscle and cardiac myocytes are key physiol. events in the cardiovascular system.  These events are regulated by 2nd messengers, cAMP and cGMP, in response to extracellular stimulants.  The strength of signal transduction is controlled by intracellular cyclic nucleotide concns., which are detd. by a balance in the prodn. and degrdn. of cAMP and cGMP.  The degrdn. of cyclic nucleotides is catalyzed by 3',5'-cyclic nucleotide phosphodiesterases (PDEs), and therefore regulation of PDEs hydrolytic activity is important for modulation of cellular functions.  Mammalian PDEs are composed of 21 genes and are categorized into 11 families based on sequence homol., enzymic properties, and sensitivity to inhibitors.  PDE families contain many splice variants that mostly are unique in tissue-expression patterns, gene regulation, enzymic regulation by phosphorylation and regulatory proteins, subcellular localization, and interaction with assocn. proteins.  Each unique variant is closely related to the regulation of a specific cellular signaling.  Thus, multiple PDEs function as a particular modulator of each cardiovascular function and regulate physiol. homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrctQ0OjiRTE7Vg90H21EOLACvtfcHk0li05ROv0y6TxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsF2kurY%253D&md5=932f5158c5ebdd9a75a41317b0b12955</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000256354.95791.f1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000256354.95791.f1%26sid%3Dliteratum%253Aachs%26aulast%3DOmori%26aufirst%3DK.%26aulast%3DKotera%26aufirst%3DJ.%26atitle%3DOverview%2520of%2520PDEs%2520and%2520their%2520regulation%26jtitle%3DCirc.%2520Res.%26date%3D2007%26volume%3D100%26spage%3D309%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Aguirre, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collette, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bobrowski, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasi, E. R.</span><span> </span><span class="NLM_article-title">Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">416</span><span class="NLM_x">–</span> <span class="NLM_lpage">428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1177%2F0192623310364027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=20231546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXms1Ontbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=416-428&author=S.+A.+Aguirreauthor=J.+R.+Heyenauthor=W.+Colletteauthor=W.+Bobrowskiauthor=E.+R.+Blasi&title=Cardiovascular+effects+in+rats+following+exposure+to+a+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiovascular effects in rats following exposure to a receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Aguirre, Shirley A.; Heyen, Jonathan R.; Collette, Walter, III; Bobrowski, Walter; Blasi, Eileen R.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">416-428</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase receptor (RTK) signaling pathway, mesenchymal-epithelial transition factor (c-Met)/hepatocyte growth factor receptor (HGFR), has been implicated in oncogenesis and is a target of interest in cancer therapy.  PF-04254644 is a potent and selective inhibitor of c-Met/HGFR.  Wide ligand binding profiling of PF-04254644 revealed a potentially significant interaction with phosphodiesterase (PDE) 3, and follow-up PDE enzyme activity assays confirmed PF-04254644 as a potent inhibitor of PDE3 as well as other PDEs (1, 2, 5, 10, and 11).  Clin. observations, lab., and echocardiog. parameters were recorded in Sprague-Dawley (SD) rats that received PF-04254644 oral dosing for up to seven consecutive days.  Toxicol. evaluations revealed myocardial degeneration as an adverse event at all tested doses.  Echocardiog. evaluations revealed an increase in heart rate (HR) and contractility after the first dose with PF-04254644 and myocardial fibrosis correlated with decreased cardiac function after repeat dosing.  A study in telemetry-instrumented rats substantiated that PF-04254644 induced a sustained increased HR and decreased contractility after six days of treatment.  Data suggest that the decreased cardiac function and cardiotoxicity are likely due to inhibition of multiple PDEs by PF-04254644.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_6wrzHn8abVg90H21EOLACvtfcHk0lgKxe2Wuul2iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXms1Ontbc%253D&md5=59dc667b0b8436e87cb5b4ae1ec56778</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1177%2F0192623310364027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623310364027%26sid%3Dliteratum%253Aachs%26aulast%3DAguirre%26aufirst%3DS.%2BA.%26aulast%3DHeyen%26aufirst%3DJ.%2BR.%26aulast%3DCollette%26aufirst%3DW.%26aulast%3DBobrowski%26aufirst%3DW.%26aulast%3DBlasi%26aufirst%3DE.%2BR.%26atitle%3DCardiovascular%2520effects%2520in%2520rats%2520following%2520exposure%2520to%2520a%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DToxicol.%2520Pathol.%26date%3D2010%26volume%3D38%26spage%3D416%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirakawa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition</span> <span class="citation_source-journal">J. Appl. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1008</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1002%2Fjat.2801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22936366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yks7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=1008-1020&author=W.+Huauthor=B.+Hirakawaauthor=B.+Jessenauthor=M.+Leeauthor=S.+A.+Aguirre&title=Tyrosine+kinase+inhibitor-induced+myocardial+degeneration+in+rats+through+off-target+phosphodiesterase+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase inhibitor-induced myocardial degeneration in rats through off-target phosphodiesterase inhibition</span></div><div class="casAuthors">Hu, Wenyue; Hirakawa, Brad; Jessen, Bart; Lee, Michelle; Aguirre, Shirley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1008-1020</span>CODEN:
                <span class="NLM_cas:coden">JJATDK</span>;
        ISSN:<span class="NLM_cas:issn">0260-437X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">PF-04254644 is a selective kinase inhibitor of mesenchymal epithelial transition factor/hepatocyte growth factor receptor with known off-target inhibitory activity against the phosphodiesterase (PDE) family.  Rats given repeated oral doses of PF-04254644 developed a mild to moderate myocardial degeneration accompanied by sustained increase in heart rate and contractility.  Investigative studies were conducted to delineate the mechanisms of toxicity.  Microarray anal. of Sprague-Dawley rat hearts in a 6 day repeat dose study with PF-04254644 or milrinone, a selective PDE3 inhibitor, revealed similar perturbation of the cyclic adenosine monophosphate (c-AMP) pathway.  PDE inhibition and activation of c-AMP were further substantiated using PDE3B immunofluorescence staining and through a c-AMP response element reporter gene assay.  The intracellular calcium and oxidative stress signaling pathways were more perturbed by treatment with PF-04254644 than milrinone.  The rat cardiomyocytes calcium assay found a dose-dependent increase in intracellular calcium with PF-04254644 treatment.  These data suggest that cardiotoxicity of PF-04254644 was probably due to activation of c-AMP signaling, and possibly subsequent disruption of intracellular calcium and oxidative stress signaling pathways.  The greater response with PF-04254644 as compared with milrinone in gene expression and micro- and ultrastructural changes is probably due to the broader panel of PDEs inhibition.  Copyright © 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3XR4RRu0a4rVg90H21EOLACvtfcHk0lgKxe2Wuul2iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yks7bM&md5=5565a0333f18d96b4a9524f5decc6425</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fjat.2801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjat.2801%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DW.%26aulast%3DHirakawa%26aufirst%3DB.%26aulast%3DJessen%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DAguirre%26aufirst%3DS.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitor-induced%2520myocardial%2520degeneration%2520in%2520rats%2520through%2520off-target%2520phosphodiesterase%2520inhibition%26jtitle%3DJ.%2520Appl.%2520Toxicol.%26date%3D2012%26volume%3D32%26spage%3D1008%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">The discovery of receptor tyrosine kinases: Targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&issue=5&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=The+discovery+of+receptor+tyrosine+kinases%3A+Targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0lgKxe2Wuul2iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DThe%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520Targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26issue%3D5%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Scannell, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanckley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warrington, B.</span><span> </span><span class="NLM_article-title">Diagnosing the decline in pharmaceutical R&D efficiency</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">200</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.1038%2Fnrd3681" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=22378269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=191-200&author=J.+W.+Scannellauthor=A.+Blanckleyauthor=H.+Boldonauthor=B.+Warrington&title=Diagnosing+the+decline+in+pharmaceutical+R%26D+efficiency"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnosing the decline in pharmaceutical R&D efficiency</span></div><div class="casAuthors">Scannell, Jack W.; Blanckley, Alex; Boldon, Helen; Warrington, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-200</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past 60 years have seen huge advances in many of the scientific, technol. and managerial factors that should tend to raise the efficiency of com. drug research and development (RD).  Yet the no. of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms.  There have been many proposed solns. to the problem of declining RD efficiency.  However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the no. of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed.  Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias.  Our aim is to provoke a more systematic anal. of the causes of the decline in RD efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5e_81DC6r8LVg90H21EOLACvtfcHk0ljTmb6LtX-yHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhtrY%253D&md5=db3e4548260e55f47a9964e8d1b216fd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnrd3681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3681%26sid%3Dliteratum%253Aachs%26aulast%3DScannell%26aufirst%3DJ.%2BW.%26aulast%3DBlanckley%26aufirst%3DA.%26aulast%3DBoldon%26aufirst%3DH.%26aulast%3DWarrington%26aufirst%3DB.%26atitle%3DDiagnosing%2520the%2520decline%2520in%2520pharmaceutical%2520R%2526D%2520efficiency%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D191%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">McKim, J. M.,  Jr.</span><span> </span><span class="NLM_article-title">Building a tiered approach to in vitro predictive toxicity screening: A focus on assays with in vivo relevance</span> <span class="citation_source-journal">Comb. Chem. High Throughput Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm400926x&amp;key=10.2174%2F138620710790596736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm400926x&amp;key=20053163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400926x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtV2gsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=188-206&author=J.+M.+McKim&title=Building+a+tiered+approach+to+in+vitro+predictive+toxicity+screening%3A+A+focus+on+assays+with+in+vivo+relevance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance</span></div><div class="casAuthors">McKim, James M., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-206</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the greatest challenges facing the pharmaceutical industry today is the failure of promising new drug candidates due to unanticipated adverse effects discovered during preclin. animal safety studies and clin. trials.  Late stage attrition increases the time required to bring a new drug to market, inflates development costs, and represents a major source of inefficiency in the drug discovery/development process.  It is generally recognized that early evaluation of new drug candidates is necessary to improve the process.  Building in vitro data sets that can accurately predict adverse effects in vivo would allow compds. with high risk profiles to be deprioritized, while those that possess the requisite drug attributes and a lower risk profile are brought forward.  In vitro cytotoxicity assays were used for decades as a tool to understand hypotheses driven questions regarding mechanisms of toxicity.  However, when used in a prospective manner, they were not highly predictive of in vivo toxicity.  Therefore, the issue may not be how to collect in vitro toxicity data, but rather how to translate in vitro toxicity data into meaningful in vivo effects.  This review will focus on the development of an in vitro toxicity screening strategy that is based on a tiered approach to data collection combined with data interpretation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0IZCIjrA-XrVg90H21EOLACvtfcHk0ljTmb6LtX-yHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtV2gsbY%253D&md5=c1c9b2ec303d2df41df5c06b4b2a2d89</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F138620710790596736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138620710790596736%26sid%3Dliteratum%253Aachs%26aulast%3DMcKim%26aufirst%3DJ.%2BM.%26atitle%3DBuilding%2520a%2520tiered%2520approach%2520to%2520in%2520vitro%2520predictive%2520toxicity%2520screening%253A%2520A%2520focus%2520on%2520assays%2520with%2520in%2520vivo%2520relevance%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2010%26volume%3D13%26spage%3D188%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and lipophilic ligand efficiency (LipE or LLE) in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+lipophilic+ligand+efficiency+%28LipE+or+LLE%29+in+addressing+drug+safety+risks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520lipophilic%2520ligand%2520efficiency%2520%2528LipE%2520or%2520LLE%2529%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zze" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zze','PDB','3zze'); return false;">PDB: 3zze</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zbx" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zbx','PDB','3zbx'); return false;">PDB: 3zbx</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5','PDB','3zc5'); return false;">PDB: 3zc5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz','PDB','3zxz'); return false;">PDB: 3zxz</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zcl" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zcl','PDB','3zcl'); return false;">PDB: 3zcl</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i60"><a href="/doi/suppl/10.1021/jm400926x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_22575"></div></div></div></div></div><hr /></hr><p class="last">Metabolite profile of <b>8F</b> in human liver microsomes and profiles of <b>8</b> and <b>9</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400926x/suppl_file/jm400926x_si_001.pdf">jm400926x_si_001.pdf (145.59 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB accession codes are unphosphorylated c-Met kinase domain with <b>7</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zbx">3zbx</a>), <b>8</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zc5">3zc5</a>), <b>9</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zxz">3zxz</a>), and <b>28F</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3zcl">3zcl</a>).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400926x&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-17%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm400926x%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400926x" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679949bc1f553dca","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
